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ABSTRACT OF DISSERTATION

PRE-CLINICAL ADVANCEMENTS IN BIOMARKERS, TOOLS, AND THERAPEUTICS FOR A
METABOLIC NEURODEGENERATIVE DISEASE
Glycogen is the storage form of glucose and a highly important substrate for cellular
metabolism. Characterization of the enzymes and mechanisms of glycogen metabolism
began over 70 years ago and over the last 20 years, a previously unknown protein called
laforin has emerged as an important contributor to glycogen metabolism homeostasis.
Multiple labs demonstrated that laforin is a glycogen phosphatase and mutations in the
gene encoding laforin cause the formation of aberrant glycogen-like aggregates called
Lafora bodies (LBs). LBs are cytoplasmic, water-insoluble aggregates that drive
neurodegeneration and early death in Lafora disease (LD) patients. The direct
relationship between mutated laforin, LB formation, and LB neurotoxicity highlights the
importance of glycogen metabolism in the brain. To translate this knowledge into
effective LD therapeutics, a comprehensive analysis of pre-clinical biomarkers, a new set
of tools, and advancements in therapeutic strategies are needed.
Consistent with the clinical phenotype, the laforin KO mouse model possesses LBs
that drive neurodegeneration. A few studies have pointed to inflammatory responses in
both astrocytes and microglia. However, these data need to be considered thoroughly
to understand their relationship to LD. Two primary measures of pre-clinical LD
therapeutic efficacy are to ablate LBs and reverse astrocyte activation. In the present
work, we provide a longitudinal analysis of LBs and soluble glycogen and provide
physiological evidence of the propensity of LBs to aggregate. In this same study, we
provide evidence to suggest that microglia, not astrocytes, are drivers of an
inflammatory response in LD.
Another potential therapeutic target is glycogen metabolism, however, the exact
relationship between central carbon metabolism and laforin loss-of-function has yet to
be defined and is essential for exploring therapeutic options to target it. Herein, we
showcase a longitudinal discovery of changes to citric acid cycle intermediates specific
to the brain of the aging laforin KO and WT mouse model. We find that metabolite load
in adult mice is lower in laforin KOs compared to WT, however the metabolic signatures
of aged laforin KOs and WT mice overlap. Using a predictive biomarker analysis tool, we
find that a recently proposed driver of metabolic dysregulation in laforin KO mice,

glucosamine sequestration by PGBs, may also be driving aspects of metabolic disarray in
aging. These results have generated hypotheses regarding damaged metabolic pathways
in LD and aging that may be targeted for treatment.
These data are yet another indicator that laforin is critical for brain glycogen
metabolism. While laforin is known to remove phosphate from glycogen, how
phosphate impacts normal glycogen homeostasis or how hyperphosphorylation is
detrimental to glycogen homeostasis and LB formation remain under investigation.
Progress in this discovery could be accelerated with additional tools. The study
presented here showcases the generation and characterization of six laforin nanobodies
and their epitopes and demonstrates that one inhibits laforin’s phosphatase activity.
These laforin nanobodies could be useful tools for discovering the importance of
glycogen phosphate and its modulation by laforin, WT laforin crystallization, laforin
physical interactions, and laforin’s dynamic localization. Overall, these nanobodies
represent an important set of tools that will open new avenues to illuminate the
mechanism of laforin’s role in normal glycogen metabolism and LD.
Other applications of the laforin nanobodies are in vitro detection assays for preclinical/clinical assessment of laforin recovery treatments. Two theoretical therapeutic
options for laforin recovery include premature termination codon (PTC) readthrough
therapy and adeno-associated viral vector (AAV) therapy. Both these therapeutic
strategies aim to deliver corrected genetic information for proper translation of the
protein of interest. In the study we present here, we generate one sandwich ELISA with
two putative functions for either PTC readthrough or AAV pre-clinical/clinical
development using the laforin nanobodies.
This work has advanced pre-clinical biomarkers, tools, and therapeutics for LD, a
metabolic neurodegenerative disease. The results of which will be the basic framework
of effective therapeutic development for several possible treatment routs and
mechanistic insights into glycogen metabolism.
KEYWORDS: Lafora disease, biomarkers, nanobodies, drug screening, metabolomics,
neurodegeneration.
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The glycogen dysmetabolism hypothesis of neurodegenerative diseases:
convergent clues from neuropathology to biochemistry
1.1

Introduction

Despite several decades of profound progress in neurology and neuroscience, many
neurodegenerative disorders remain largely untreatable1. Considering that the primary
risk factor for neurodegenerative disorders is age and that by 2030 all baby boomers will
be at least 65, the proportion of people most prone to neurodegenerative diseases will
rise from the current ~15% (2020) to ~25% by 20602–4. By 2040, deaths by these
disorders are predicted to out-pace other prominent age-related fatalities due to lung
cancer, colon cancer, liver cirrhosis, multiple sclerosis, female breast cancer, and
malignant melanoma5. These statistics reflect the current and future US social and
economic burdens with respect to age-related diseases. Recent progress has made
significant contributions to identifying neurodegenerative hallmarks, including neuronal
cell loss, atrophy, astrogliosis, pathological protein inclusions, inflammation, oxidative
stress, mitochondrial dysfunction, ER stress, activation of microglia, hypoxia, and
neuronal dysfunction3,6,7. Unfortunately, these hallmarks have not yielded disease
altering therapies and treating neurodegeneration remains a futile battle8,9.
One emerging theory that may offer a new set of molecular targets is that metabolic
defects underlie many neurodegenerative pathologies1,7. Clinical investigations of
metabolic changes in neurodegenerative disorders identified 18Fluorodeoxyglucose
Positron Emission Tomography (18FDG PET) hypometabolism as a common, if not
universal, characteristic of these disorders10. While dysregulated glucose metabolism is
a clinical hallmark, the molecular underpinnings are still being defined. Additionally,
metabolic vulnerabilities of specific neuronal clusters often accompany
neurodegenerative disorders11.
Systemic glucose has been considered the primary fuel for the brain, but a growing
body of literature strongly implies that glycogen, the mammalian glucose storage cache,
plays an indispensable role in brain function12. The underappreciation of brain glycogen
comes from historic skepticism about its very existence that stymied advances in brain
glycogen metabolism until very recently when methodologies were developed to detect
it13. Earlier attempts to quantify brain glycogen were undermined by the fact that it
quickly degrades from the hypoxic brain14. This obstacle has been surmounted by rapid
preservation methods including either immediate flash freezing or microwave fixation
that are required to preserve it for robust and repeated quantification15. This
understanding led to the recent discovery that 25% of brain glycogen contains
glucosamine, a key building block for protein glycosylation16.
The basic architecture of glycogen and its metabolic enzymes are well-documented.
Glucose polymers are linked via α-1,4-glycosidic bonds via glycogen synthase (GS) that
are branched approximately every 13 glucose residues with α-1,6-glycosidic bonds via
1

glycogen branching enzyme (GBE). Glycogen is degraded by glycogen debranching
enzyme (GDE) that releases single branched glucose moieties and glycogen
phosphorylase (GP) that catalyzes the cleavage of two subunits of glucose13.
Glucosamine is incorporated into brain glycogen by GS and released by the concerted
efforts of GP and GDE16. Glycogen is also degraded in the lysosome by acid αglucosidase (GAA)17. As glycogen is the major glucose cache, its metabolism is tightly
regulated in a tissue-dependent manner18. Aberrant glycogen metabolism results in
glycogen storage disorders (GSDs), wherein glycogen is synthesized and accumulates yet
it is not broken down17. In the case of Pompe disease (GSD II), mutations in GAA result in
normal glycogen accumulating at a far greater rate than it can be broken down.
However, many GSDs feature an aberrant glycogen that cannot be broken down by
GAA, GDE, and/or GP19. Thus, aberrant glycogen is a diseased form that prevents cellular
use of the glucose that is stored in it20.
Aberrant glycogen deposits are called polyglucosan bodies (PGBs) that were first
identified in the aging brain by Purkinje21. The aging PGB, called corpora amylacea,
originates from astrocytes and contains cellular debris. Corpora amylacea have been
widely thought of as waste containers and recent work has proposed a rout of expulsion
from the brain to the cerebral spinal fluid and lymphatic meningeal system22. Another
subset of PGBs are intracellular PGBs that are a common feature of CNS GSDs that were
first identified in 1911 by Gonzalo Rodríguez-Lafora, a disciple of Alzheimer, Cajal, Vogt,
Minkowski, and Kraepelin23. Lafora’s discovery unmasked the pathophysiology of a GSD
that produced a rare, insidious, and quickly fatal childhood dementia later named
Lafora’s disease (LD)24. Lafora predicted that a metabolic disorder causes the formation
of the LD PGBs that drive LD progression. Greater than 100 years since Lafora’s
discovery, data from multiple laboratories support Lafora’s hypothesis25–28. Strikingly,
PGBs of varied physical morphologies have been identified in many other
neurodegenerative disorders, not currently classified as GSDs (Table 1.1A-F)29–35.
In this chapter, recent data is highlighted that demonstrates glycogen
dysmetabolism and PGBs as an integral factor of several neurodegenerative disorders,
including Pompe disease, LD, aging, temporal lobe epilepsy (TLE), amyotrophic lateral
sclerosis (ALS), and Alzheimer’s disease (AD). The differing histopathology and
anatomical locations of PGBs is described in each of these diseases and glycogen
dysmetabolism is a potential common metabolic phenotype. We frame the progression
of LD as an extreme phenotype of a metabolic imbalance that is driven by aberrant
glycogen. As such, recent success regarding LD basic research and clinical therapeutic
translation is a potential path for new therapeutics of common neurodegenerative
disorders. We aim to inspire investigation of the glycogen dysmetabolism hypothesis of
neurodegenerative diseases.
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1.2

Technological advances for quantifying and analyzing glycogen

Several quantitative biochemical and histological staining methods to quantify
glycogen have made large contributions to the investigation of brain glycogen but are
limited in specificity, spatial scale, and/or resolution13,15. Biochemical assays are
quantitative, requiring a large volume of sample that limits their ability to assess spatial
distribution36. Nuclear magnetic resonance spectroscopy (MRS) is quantitative and can
be performed on live subjects but is also limited in spatial resolution37. Electron
microscopy yields detailed observations within an area limited to several micrometers15.
Histological examination by light microscopy using PAS has been a historically preferred
method to determine regional, cellular, and subcellular glycogen distribution19.
However, PAS staining is not glycogen specific as it reacts with other carbohydrate
polymers like glycoproteins and proteoglycans38.
A series of method and tool advancements for accurate and sensitive glycogen
detection have recently emerged. The generation and development of two antiglycogen antibodies, IV58B6 and ESG1A9, have been important for mapping and
determining brain wide spatial arrangements and morphological characteristics of
glycogen with high specificity using immunohistochemistry (IHC) or
immunofluorescence (IF)15. IHC studies using either of the anti-glycogen antibodies
revealed glycogen stores in the hippocampus, cerebellum, and cortex (especially the
molecular layers) of the mouse and rat brain39. Studies utilizing these two antibodies has
detected a heterogeneous storage pattern of glycogen at multiple spatial scales, which
suggests that glycogen distribution and architecture may underlie local energy
requirements and metabolism. The addition of secondary and tertiary labeling has
allowed for the detection of glycogen at the subcellular level and has shown that
glycogen in mice is normally localized to the fine processes of astrocytes while trace
amounts are found in neurons15.
More recently, two significant advancements using mass spectrometry have been
pioneered for accurate glycogen quantification and distribution analysis. An analytical
method for quantifying carbohydrate polymers was developed using gas
chromatography-coupled mass spectrometry (GCMS) that provides robust analysis of
purified glycogen from tissue and quantification of the free glucose monomers40.
Another novel workflow was developed to quantify and spatially visualize glycogen in
situ using matrix-assisted laser desorption/ionization traveling-wave ion-mobility highresolution mass spectrometry (MALDI TW IMS)16. This novel MALDI workflow has
allowed exploration of the relationship between PGBs, glycogen, and protein N-linked
glycosylation in specific brain regions (see section 1.4.3 and 1.4.4).
While these advanced glycogen analysis methods have largely been performed on
mouse and rat samples, it is likely that the brain distribution, storage, and usage of
glycogen differ among other species as well15. Regional glycogen storage may also
depend on the metabolic state of the brain including the sleep cycle and circadian
rhythm. Limited studies have shown that aging also influences glycogen dynamics39.
3

These and other integral factors on brain glycogen dynamics require more in-depth
study especially with longitudinal dimensions to understand the extent of their influence
in health and disease and may be facilitated with these technological advances.
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1.3

Hypothesis: Aberrant glycogen metabolism is an underlying cause of
neurodegenerative disease

Although a range of shared therapeutic targets have been identified for
neurodegenerative disorders, current therapeutics are only symptom managing41.
Glucose hypometabolism, mitochondrial dysfunction, oxidative stress, hypoxia, and
glutamate dysregulation are widely correlated with neurodegeneration3,6,7. Recent
studies hypothesized that the causative pathology is metabolic failure, as several
neurodegenerative disorders contain metabolic defects in specific vulnerable neural
populations7,42. Thus, rescue of ‘brain energetics’ is an emerging therapeutic concept for
neurodegenerative disorders and aging. Tactics for ‘brain energy’ rescue in
neurodegenerative disorders include the rescue of brain glucose metabolism that
deteriorates in a progressive, disease and region specific manner7. Brain glucose and
glycogen metabolism is essential to cognitive function43. Glycogenolysis is necessary for
memory formation and retention and deficiencies in glycogen catabolism may be tied to
memory impairment associated with neurodegenerative dementias44,45. Glycogen is also
implicated in neural energetics as it regulates K+ and glutamate levels, which are known
to drive action potentials46. Hyperexcitability is found in early stages of AD when mild
cognitive impairments present and is a main feature of TLE47,48.
The pathological condition directly relating glycogen dysmetabolism to
neurodegeneration is LD. In LD, monogenetic linked glycogen metabolism failure is the
cause of PGB accumulation that drives a very severe childhood dementia accompanied
by severe epilepsy25–28. By knocking out or decreasing the activity of GS in LD mouse
models, LD mice no longer form PGBs and there is a rescue in neurodegeneration and
seizure susceptibility25,28,49. LD is also associated with the hallmark conditions of
neurodegenerative diseases like glucose transport, glutamate uptake, autophagy,
oxidative stress, and inflammation50. As such, data and conclusions from LD models
provide key insights for investigating the hypothesis that glycogen dysmetabolism
underlies other multifactored/sporadic neurodegenerative diseases, especially for those
in which PGBs are found, like in AD, TLE, and ALS.

1.3.1 Glycogen and cognitive function
Supporting evidence that glycogen dysmetabolism is an underlying cause of many
neurodegenerative diseases are the critical contributions that glycogen makes to brain
function. Glycogen is an obligatory substrate of long-term potentiation (LTP), synaptic
plasticity, learning, and memory51–55. This role is highlighted by the fact that CNS specific
GSKO animals have a significant deficit in their ability to learn an instrumental
conditioning task, a complete absence of LTP, and additional deficits in activities
indicative of synaptic strength like decreased neurotransmission at the pre-synaptic
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terminal55. Cognitive deficits in learning and memory are key prognostic indicators for
many neurodegenerative diseases, including LD42,56. In LD, severity of cognitive
symptoms at onset is the highest prognostic factor of decreased survival, where the
average survival time is eleven years after onset. Thus, cognitive decline may be the
most important factor associated with the fatal complications in LD that are related to
aspiration pneumonia, status epilepticus, or other common complications of chronic
neurodegenerative diseases50. These findings demonstrate the fundamental role of
brain glycogen in cognition, which is a primary clinical measure of all neurodegenerative
dementias57. Therefore, a potential avenue for discovering new molecular targets in
neurodegenerative diseases is brain glycogen metabolism as it plays an active role in
cognitive abilities and changes in synaptic strength underlying learning and memory
acquisition. LD mice have severe brain PGB accumulation, increased susceptibility to
induced seizures, and changes to synaptic transmission and LTP27. Strikingly, LD mice
exhibit episodic memory defects with age, providing additional evidence of a causal link
between glycogen dysmetabolism and cognitive challenges in neurodegenerative
diseases51. Thus, the basic science of LD and corresponding mouse models can be used
as templates to investigate the relationship of glycogen dysmetabolism and cognition in
other neurodegenerative diseases, where the cognitive deterioration is slower, survival
time is longer, and the driving pathology is less clearly defined.
1.3.2 Glycogen and neural energetics
The critical contribution of glycogen to neural energetics is rapidly emerging. The
majority of brain glycogen is stored in astrocytes, thus the influence of glycogen on
neurons is thought to be regulated through astrocytes58–60. Indeed, a well-known
neurotrophic feature of astrocytes is their influence on ion homeostasis and glutamate
clearance61. K+ efflux is a universally understood phenomenon of the action potential,
first studied on squids by Hodgkin and Huxley in 1953, and in the absence of K+ ion
clearance neuronal hypersynchronization burst firing and seizures occur62–64. Astrocytic
Na+/K+ pumps are sensitive to increases in extracellular K+ and consume energy during
increased axonal activity65–67. Inhibition of glycogenolysis in astrocytes, even in the
presence of glucose, impairs K+ uptake62. Therefore, energy that fuels fundamental
mechanisms of neural homeostasis is glycogen derived.
Glutamate is the dominant excitatory neurotransmitter and requires rapid removal
after synaptic transmission by cellular uptake61. Defects in glutamate transmission have
been linked to epileptic and neurodegenerative disorders and astrocytic glycogen
functions as a substrate for de novo synthesis of glutamate1,44,54. Conversely, glutamate
recycling triggers glycogenolysis to produce energy for Na+ restoration and for the
conversion of glutamate to glutamine68. As astrocytes are glycolytic, the energy required
for glutamate-glutamine cycling comes from the conversion of glucose to lactate12. Both
glutamine and lactate shuttle from astrocytes to neurons where glutamine is converted
to glutamate and lactate is thought to be used as an exogenous substrate of neuronal
oxidative metabolism69. The latter phenomenon is a controversial hypothesis known as
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the astrocyte-neuron lactate shuttle (ANLS) hypothesis postulating that lactate is the
primary fuel of neurons and it is produced by astrocytes53. An enticing hypothesis,
considering studies using mouse and rat olfactory neurons show that systemic glucose is
not sufficient to sustain neuronal energy consumption12.
The ANLS hypothesis suggests a critical utility for the metabolite mainly thought of
as a waste product of anaerobic metabolism70. In fact, lactate has recently been
suggested to be a major carbohydrate fuel across all cells and tissues71. The ANLS
hypothesis is based on the observation that cells with high rates of glycolysis or
glycogenolysis can form and shuttle lactate into diverse groups of cells whose ATP
demands are unmet72,73. Cells receiving lactate can convert it into glucose or feed it
directly into oxidative metabolism74. Systemic glucose or glycogen contained by neurons
is an insufficient fuel supply to meet their ATP demands74. Extracellular lactate can
support olfactory neuronal compound action potentials independent of glucose or other
monosaccharide availability12. A recent in vivo study found that arousal/startle response
in mice triggers a rapid lactate release from astrocytes that is followed by increased
lactate levels in neurons75. Further, glucose shuttling is improbable as astrocytes lack
glucose-6-phosphatase and they cannot release free glucose60. Therefore, oxidative
metabolism dependent neurons may receive astrocytic glycogen derived lactate for
direct entry into the TCA cycle. These data indicate that glycogen availability is an
important contributor to the maintenance of proper equilibrium between excitatory
and inhibitory neurotransmission, which is deficient in neurodegenerative diseases.
The extent to which glycogen supports brain neural activities remains to be seen.
Several reviews have classified glycogen as a key, even obligatory, fuel for the brain,
though more investigation is needed to understand the extent of its role12,15,43,76–78.
Current hypotheses based on cell culture studies pose that astrocytic glycogen is used to
support neuronal excitation during either hypoglycemia or compounded energy
demands76. A possible nuanced role of glycogen in neural energetics is highlighted by
the fact that CNS glycogen synthase knockouts (GSKOs) are more susceptible to
pharmacologically induced hippocampal seizures, but neuron specific GSKOs show less
susceptibility55,79. This suggests cell specific regulation of glycogen metabolism.
Interestingly, forebrain and neuron specific GSKOs do not show the same seizure
susceptibility but do show significant deficiencies in LTP and acquisition of instrument to
learning tasks79. These studies and brain glycogen mapping studies highlight how
regional, cellular, and subcellular spatial arrangements of glycogen may impose regional
and cell specific glycogen metabolism15. Moreover, glucose hypo-metabolic footprints
seen by 18FDG PET are regionally and disease specific and metabolic imbalances are
hypothesized to arise from specific regional and/or cellular neuronal populations1.
Neural energetics continue to emerge as a therapeutic target to which glycogen
metabolism is clearly linked. Further, regional and cellular locations of glycogen linked
metabolic perturbances are likely important. As such, the location of PGBs in
neurodegenerative diseases may provide important clues into their disease specific
metabolic pathologies.
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1.4

Lafora disease

1.4.1 LD PGBs drive disease pathogenesis
LD is an autosomal recessive childhood dementia and glycogen storage disorder that
severely affects the CNS resulting in death before age 3080. LD patients carry autosomal
recessive mutations in either Epm2a, which encodes the glycogen phosphatase laforin,
or Epm2b, which encodes the E3 ubiquitin ligase malin81–87. A hallmark of LD is
increasing numbers of cytoplasmic PGBs found throughout most tissues in LD patients
and mouse models80 (Figure 1.1A). These PGBs drive worsening bouts of generalized
myoclonic epilepsy and neurodegeneration25–28. Additionally, the original LB brain
biopsy performed by Lafora reported sclerosis of medium-sized pyramidal cells,
increased glia, and perivascular bleeding24. Laforin and malin KO mouse models have
been generated and replicate LB formation, increased susceptibility to induced seizures,
spontaneous myoclonus, neurodegeneration, and glial activation88,89.
Utilizing genetic models and pre-clinical treatments, multiple labs have
demonstrated that LD PGBs are both a diagnostic pathological feature and the drivers of
LD25–28. Laforin KO and malin KO mice lacking the GS activator Protein Targeting to
Glycogen (PTG) exhibit greatly reduced LB accumulation, resolved neurodegeneration,
myoclonus, and seizure susceptibility25,26. Malin KO mice lacking at least 50% of GSY1
activity do not exhibit LBs, neurodegeneration, or abnormal electrophysiological
properties27,28. Conversely, constitutively active GS in genetically modified mouse and fly
models results in neurodegeneration, as shown by progressive death of cerebellar
Purkinje neurons90. These results indicate that genetically decreasing glycogen load
results in disease rescue, while overaccumulation of glycogen can drive neuronal death.
The LD mouse models have also been key to defining additional pathways that are
perturbed, many being common to other neurodegenerative diseases, apoptotic
dysfunction, endoplasmic reticulum stress, reduced clearance of misfolded toxic
proteins through the ubiquitin proteasome system, and astrogliosis91–94. Multiple
genetic manipulations have been performed to establish that these effects are
important features of LD pathophysiology, though secondary to LD PGB accumulation.
For example, LD mouse models have an impairment of autophagy as measured by an
increase in p62. Rescue of p62 levels, as well as LTP, kainate induced seizures, and
neuroinflammation is genetically achieved by crossing a malin KO mice with mice lacking
one copy of GYS1, thereby decreasing GS activity by 50%. Moreover, mice with a
constitutively active brain specific GS or overexpressing PTG accumulate PGBs and
exhibit increased p62 levels, which are further increased when crossed with an LD
mouse. These results indicate that LB accumulation drives the autophagy and
neurological impairments in LD. Furthermore, they demonstrate that decreasing GS
activity to 50% ablates many of the clinical issues. In further support of these data,
administration of an inducer of autophagy partially restores autophagy defects,
neuroinflammation, endoplasmic reticulum stress, and seizure susceptibility in the
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absence of LB reduction95. Collectively, these data demonstrate that autophagy, seizure
activity, cognitive defects, endoplasmic reticulum stress, neurodegeneration, and
neuroinflammation are secondary to and driven by LB accumulation.
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1.4.2 Lafora body localization
LD PGBs were first described in a 1911 report on LD patient brain biopsies, where
Lafora observed them virtually exclusive to neurons in the cortical and spinal tissue24.
Patient biopsies reported PGBs in the ganglion cells of the second, third, and fourth
layers of the cerebral cortex, and in the cells of the quadrigeminal, visual, oblongata,
and posterior horns of the spinal cord. In LD mouse models, LBs are prevalent in
the hippocampus, cerebellum, cortex, and brainstem (Figure 1.2A)80. Since Lafora’s
initial sighting, LD PGBs were historically thought to mainly exist in neurons. Within the
last three years however, two independent investigations using a combination of
immunofluorescent techniques published the same conclusion that astrocytes harbor
the vast majority of PGBs in the brains of LD mouse models96,97. Only 4% of neurons
contained LD PGBs while they were found in 99% of astrocytes96. Further, astrocytic
PGBs have been described as more abundant in the astrocytic processes rather than the
soma96,97. Trace quantities of LD PGBs have been recently sighted in microglia, which is
consistent with the original work of Lafora24,97. Whether the microglia containing LD
PGBs had engulfed them or if the aggregates form inside them is not yet known.
Interestingly, microglia activation, a neuroinflammation marker of LD measured by
Iba1, is rescued in a malin KO model crossed with a mouse model unable to accumulate
glycogen in astrocytes98. In this double KO model, the LD PGBs are greatly diminished in
contrast to the malin KO model. These results further support the data indicating that
neuronal LBs represent a very small fraction of total LBs96,97. However, rescue of
astrocytic LBs do not rescue susceptibility to kainate-induced seizures, indicating that
LBs may drive secondary pathophysiology in a cell specific manner98. Interestingly,
astrocytic LD PGBs are less similar to neuronal LBs than they are to corpora amylacea in
terms of their distribution in the brain, size, clustering, and presence of neo-epitopes
recognized by IgMs96. Further, p62, a scaffold protein that can be bound by ubiquitin
and guide its binding partners to autophagosomes and autophagic processes, is
indicated to be a main feature of astrocytic, but not neuronal LD PGBs, and is also found
in corpora amylacea96,99,100. Further study is needed to determine if, like corpora
amylacea, astrocytic PGBs are being expelled to the CSF. If so, perhaps astrocytic PGBs
traversing the perivascular space promotes perivascular bleeding, as documented in
Lafora’s 1911 report.
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1.4.3 Lafora body architecture
By electron microscopy (EM) native LD PGBs range from 2-10+ μm and are formed
of clusters of ‘glycogen-like’ particles and fibrillar material (Figure 1.1A)80,101. LD PGBs,
like glycogen and starch, can be digested with -amylase that hydrolyzes -1-4glycosidic linkages102–104. Like brain glycogen, LD PGBs contain ~75% glucose and ~25%
glucosamine16. Multiple groups identified that LD PGBs stain similarly to plant starch
with iodine, Best’s carmine, methenamine-silver nitrate, and PAS-dimedone. However,
LD PGBs were metachromatically different than starch by Alcan and Toluidine blue
methods102,104. If native LD PGBs are boiled, mechanically agitated, or lintnerized and
viewed by light microscopy the polysaccharide forms into a network assembly in the
same way that starch disassembles with the same methods20. Since mammalian glucose
polymerization is performed exclusively by glycogen synthase, LD PGBs are aberrant
glycogen whose structural features are more comparable to starch105.
LD PGBs purified from brain and muscle have glucose chains dramatically longer
than normal glycogen that allows the chains to form helical structures making them
more resistant to degradation36,106,107. Long glucose polymers of starch, generally longer
than normal glycogen, form a clustered arrangement of branch points giving rise to
helical structures that expel water105,108. A confounding factor of LD PGBs is their
elevated phosphate content in comparison to starch and glycogen89. In starch, the role
of phosphate is to break up the tight helical associations. Therefore, the
phosphorylation and dephosphorylation of starch is a tightly regulated process critical
for controlled access of β-amylases and dispersal of glucose109,110. By keeping to the
starch analogy, the LD PGB hyperphosphorylation should increase the solubility of LD
PGBs, not decrease it. Thus, phosphorylation has been suggested to have little to do
with glycogen solubility and its role is poorly understood105,107. The normal biochemical
role of glycogen phosphate and the relationship of LD PGB hyperaccumulated
phosphate to LD is still unclear and continued investigation in this area will be highly
informative.
1.4.4 Aberrant glycogen metabolism in Lafora disease
LD PGBs form due to glycogen dysmetabolism caused by loss of function to the E3ubiquitin ligase malin or the glycogen phosphatase laforin with mutations in either gene
resulting in a similar histological phenotype25–28. While mutations in either gene result in
PGBs, the exact mechanism leading to PGBs has not been defined. Malin is an E3ubiquitin ligase that ubiquitinates several enzymes involved in glycogen metabolism,
glycogen debranching enzyme (AGL/GDE), protein targeting to glycogen (PTG/R5), a
regulatory subunit of protein phosphatase 1 (PP1), laforin, and glycogen
phosphorylase49,84,111–114. Malin-dependent ubiquitination of glycogen phosphorylase
results in nuclear localization of glycogen phosphorylase that impacts nuclear glycogen
metabolism and histone acetylation114. Laforin is the only human glycogen phosphatase
and interacts with a number of proteins involved in glycogen metabolism86,115–117.
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However, the exact mechanism(s) by which the loss of function of either laforin or malin
create aberrant hyperphosphorylated glycogen still needs to be resolved. Additionally,
many unanswered questions about the role of nuclear glycogen metabolism and how
brain glycogen metabolism is regulated remain.
This is of clinical interest considering that LD patients die of neurological
complications although PGBs are also abundant in the skeletal muscle and heart82.
Tissue specific regulation of glycogen metabolism is well studied105. Interestingly, the LD
PGBs architecture is also tissue specific, showing the longest and most starch-like chain
length distribution in the brain, followed by those from heart, and then skeletal
muscle20. A positive correlation between PGB chain length and degree of tissue
deterioration has been suggested as neuronal tissue is the first to degenerate in LD20.
Therefore, tissue regulated glycogen metabolism may influence the pathogenic features
of LD PGBs that promote more mild or severe cellular dysregulation.
Cellular metabolism is rescued by LD PGB breakdown using an amylase fusion
protein that can enter mouse brain tissue and break up LD PGBs118. Moreover, depletion
of astrocytic LBs, which are the predominant form of LBs, in a malin KO mouse results in
the partial rescue of central carbon, amino acid, and lipid metabolic pathways98. In many
nervous system diseases, glycosylation is severely depleted119. In laforin KO mice and
GSD III mouse models, glycogen derived glucosamine were determined to be higher
than age matched controls16. Further, N-linked glycosylation defects were linked to
brain regions where PGBs are most abundant. Impressively, the aberrant glycosylation
footprint of LD mice resemble normal conditions after treatment with the amylase
fusion protein16,118. These data suggest that PGB formation likely sequesters
glucosamine, leading to metabolic disarray in the mouse. Furthermore, they emphasize
that glycogen is needed to support the brains normal metabolic functions.
1.4.5 Clinical evidence of brain metabolic defects in LD
A recent retrospective study and review focused on eight Italian patients genetically
confirmed for LD that underwent 18F-FDG-PET120. Though the patient ages, genders,
genotypes, and disease severity were mixed in this analysis, a bilateral hypometabolic
phenotype was observed in all patients that was more pronounced in advanced disease
states. Interestingly, regions with high PGB loads, brainstem, cerebellum, hippocampus,
and cerebral cortex, did not directly overlap with the hypometabolic regions that were
the temporal (8/8), parietal (7/8), and frontal lobes (7/8), as well as the thalamus (6/8)
(Figure 1.2A). Further, temporoparietal hypometabolism in patients was worsened in
correlation to impaired visual symptoms. In nine additional cases identified from eight
publications, 18F-FDG-PET showed heterogeneous findings, ranging from diffusely
decreased cerebral glucose metabolism to unremarkable examinations in two cases.
Prospective longitudinal studies are needed to clarify these data, but a regionally
specific hypometabolism hallmark is emerging. While these studies are difficult for rare
diseases, there is an ongoing natural history study assessing 30 LD patients for two years
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at four clinical sites121. This study, and others like it, will provide key clinical baselines to
assess common features between LD and other neurodegenerative diseases.
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1.5

Pompe disease - glycogen storage disease type II

1.5.1 Aberrant glycogen in Pompe disease - glycogen storage disease type II (GSD II)
Pompe disease (GSD II) is a lysosomal storage disorder caused by deficiency of the
lysosomal enzyme acid alpha-glucosidase (GAA, alglucosidase alpha). Mutations in the
GAA gene lead to excessive accumulation of lysosomal glycogen primarily in the cardiac,
skeletal, and smooth muscles. The availability of enzyme replacement therapies (ERTs)
for Pompe patients are increasing their lifespans, revealing neurological components
initially overshadowed by myopathies. Thus, a CNS phenotype is emerging in Pompe
disease provoking a reclassification of the GSD to be attributed to both muscle and
nervous system122.
The ultimate involvement of the CNS in Pompe disease is not yet clear. However,
several observations by EM and PAS indicate that full characterization of Pompe
neuropathology is critical to understanding and treating this disease. In the infantile
form, glycogen accumulation is seen in neurons of the cortex, midbrain, pons, medulla,
and cranial nerve nuclei (Figure 1.1B)123. Glycogen accumulation is also detected
throughout nuclei of the brainstem and cerebellum (Figure 1.2B)124. Neuronal swelling,
or ballooning, is observed in the substantia nigra, dorsal raphae nuclei, pontine nuclei,
inferior olivary nuclei, and dentate nucleus122. Additionally, Schwann cells of nerve
sheaths in the cortex, glial cells and astrocytes of white matter, but rarely Purkinje cells,
all accumulate glycogen. Failure to meet myelination milestones at a median age of 6
months in Pompe patients has been suggested to be related to the involvement
glycogen accumulation in the CNS125. Some studies have indicated that glycogen
accumulation in the cerebral cortex is associated with learning difficulties and
intellectual disability in type II glycogen storage diseases126–129.
Interestingly, glycogen accumulation is more prominent in the infantile onset
version of Pompe disease, while late onset Pompe disease glycogen accumulation is
observed more rarely122. In late onset, the CNS involvement of glycogen has been
observed in Schwann cells of the nerve sheaths in the cerebral cortex and spinal cord.
Lysosomal glycogen as also been detected in neuronal cell bodies spheroid-shaped
structures resembling corpora amylacea are reported in the spinal cord130. In large
Pompe diseased mammals and birds including cattle, dogs, quails, sheep, and cats,
glycogen deposits are shown within brain and spinal cord accumulating in neurons and
glial cells131. The extent of the CNS involvement in Pompe disease may be elucidated
using Pompe disease mouse models with targeted disruption of GAA. Three mouse
models with targeted disruption to GAA provide evidence of PAS positive glycogen
accumulation in the brain and spinal cord including the cerebral cortex, olfactory bulb,
thalamus, hippocampus, hindbrain, cerebellum, and medulla132. AAV-mediated gene
therapy in GAAKO mice improves neurological defects, but additional research is
necessary to understand the clinical translation of these findings133.
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1.5.2 Aberrant metabolism in Pompe disease
Mutations in the gene encoding the lysosomal enzyme GAA prevent Pompe patients
from breaking down lysosomal glycogen in the muscle, heart, and CNS131. Glycogen
accumulates initially in the lysosome and then in the cytoplasm and becomes
pathogenic134. Subsequently, swelling and rupture of lysosomal membranes releases
hydrolytic material causing cellular damage17. Clinical severity is predicted based on
residual activity of GAA135. In the most severe cases, patients undergo progressive
myopathy and hypertrophic cardiomyopathy with the main cause of fatality being
respiratory failure131.
GAA replacement therapy has been useful as both a proof-of-concept for ERTs and
in the clinic with two that are currently approved. The current standard ERT (Myozyme
and Lumizyme) utilizes a recombinant human GAA (rhGAA) analog that enters cells and
lysosomes by the mannose-6-phosphate (M6P) receptor135. Both ERTs are created using
recombinant DNA technology to produce the human GAA enzyme in Chinese hamster
ovary (CHO) cells and are biologically comparable. Myozyme and Lumizyme have been
shown to improve patient survival rates, however, manufacturing differences result in
differing clinical attributes. Therefore, Myozyme is indicated for infantile-onset Pompe
disease while Lumizyme is indicated for patients aged ≥8 years136.
Unfortunately, because rhGAA is exclusively targeted to the lysosome, cytoplasmic
glycogen is left to accumulate135,137. A newer delivery platform, tested in Pompe mouse
models, utilizes an antibody fragment (Fab) fused to GAA called VAL-1221 that allows
entry into the lysosome and cytoplasm137. This antibody-enzyme fusion (AEF) protein is
comprised of the Fab fused to GAA and gains entrance into cells by either the M6P
receptor the equilibrative nucleoside transporter 2 (ENT2) receptor and allows for
clearance of lysosomal and cytoplasmic glycogen. VAL-1221 completed a Phase I/II
clinical trial with promising safety profiles and offers greater potential for clearing both
cytoplasmic and lysosomal glycogen.
A pre-clinical study on LD mice has tested an AEF platform, VAL-0417, to deliver
amylase to cells in order to degrade pathogenic LBs, rather than replacing an enzyme118.
The AEF is comprised of the humanized 3E10 Fab fragment and pancreatic α-amylase.
VAL-0417 degrades LBs and reduces LB load in vitro and degrades glycogen and
polyglucosan in vivo. Using VAL-1221 to test LD PGB clearance from the brains of LD
mouse models would be useful for discovering if the AEF could enter cells of the CNS as
well as fibroblasts. If so, VAL-1221 may have the potential therapeutic application for
any of the 17 GSDs (Table 1.1). Further, the utility of VAL-1221 within the CNS of Pompe
patients would be a useful investigation to further understand the involvement of the
CNS and the aberrant glycogen therein to the clinical progression of Pompe disease.
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1.6

Aging

1.6.1 Aberrant glycogen in aging
Age-dependent brain PGBs called corpora amylacea were first described in 1837 yet
they are an understudied aggregate21. Corpora amylacea are PAS+ aggregates that were
historically defined as histological features that increased in abundance with age and
even more with neurological disease29. Corpora amylacea are found largely in glia
throughout the brain (Figure 2C)19. Neurodegenerative diseases in which
hyperabundant corpora amylacea have been described include Parkinson’s disease,
diabetes, vascular dementia, multiple sclerosis, Huntington’s disease, Pick’s disease,
diabetic neuropathy, peripheral neuropathy, motor neuron disease19,138. Thus, as aging
is inextricably linked with neurodegeneration there is also increased corpora amylacea
accumulation. While corpora amylacea are increased in some diseases, it is currently
unclear how similar or different diseased corpora amylacea are from disease specific
PGBs.
The age-dependent existence of corpora amylacea has been re-confirmed recently in
fly models and multiple mouse models, including wildtype C57BL/J6 and the accelerated
aging mouse model, senescence accelerated mouse prone 8 (SAMP8)99. SAMP8 mice
also exhibit reduced lifespan, lordosis, hair loss, and reduced physical activity, similar to
human aging139,140. Like LD PGBs, corpora amylacea are observed widely in astrocytes
and less often in neurons29. Corpora amylacea ultrastructure is a spherical body ranging
from 2-30 m that appears as clustered 8-12 nm fibrils that are aggregated or tangled
and can be decorated with cell debris29,100,141. The fibrils are comprised of glucose
polymers as are PAS+ and diastase-resistant and are dependent on the activity of GS in
fly and mouse models99. Corpora amylacea appear to contain a dense core ranging 50100 nm in diameter surrounded by concentric rings (Figure 1C)29.
For nearly 180 years, corpora amylacea were largely ignored and considered benign
and/or innocuous aging aggregates31. Yet repeated findings by electron microscopy
depicted cellular debris, including organelles from neurons, astrocytes, and
oligodendrocytes, to be harbored within corpora amylacea29,100. Additionally, the
presence of the proteasome targeting protein ubiquitin has been an identifying feature
of corpora amylacea100. Together, these studies implicated corpora amylacea in cellular
waste removal and suggested that corpora amylacea may be a vessel in which cell
debris could be removed from the cell and eventually degraded. Recent reports
corroborate the hypothesis that corpora amylacea may be an integral component of
brain waste disposal with corpora amylacea acting as waste containers to protect the
cell from damaging residual products21,31,142. Naturally occurring IgM antibodies were
discovered against corpora amylacea neo-epitopes that detect corpora amylacea and
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direct macrophages to phagocytize them21,31. Further, data indicating that corpora
amylacea exist predominantly in periventricular and subpial regions were intriguing, but
no reports identified their existence in the CNS, suggesting that they simply
accumulated and remained trapped19. Improved methods, which had previously failed
to identify corpora amylacea in the cerebral spinal fluid (CSF), were elegantly employed
to discover that corpora amylacea are transported through the blood brain barrier,
entering the CSF, and are present in lymph nodes22. Moreover, these data demonstrate
that corpora amylacea can be phagocytosed by macrophages22. Thus, corpora amylacea
are likely involved in a cellular clearance mechanism.

1.6.2 Aberrant metabolism in aging
Aging is intimately associated with neurological deterioration and is the greatest risk
factor for it143. There are multiple biomarkers that overlap between aging and
neurodegenerative diseases, including the production of cognitive defects like memory
loss and learning impairments along with molecular perturbations like reactive oxygen
species and mitochondrial defects3. 18F-FDG-PET imaging of age-influenced brain
metabolism indicates that the frontal lobes as well as regions within the default mode
network, including the temporal and parietal lobes, and prefrontal and posterior
cingulate cortex show a strong age-related glucose hypometabolism trend144. These
data suggest that aging alone could cause a widespread reduction in brain matter and
glucose metabolism.
Only a few studies have begun to examine brain metabolism to characterize the role
it plays in the CNS during aging. One 2016 study examined the aging metabolic profile of
the cortex, hippocampus, and caudoputamen at 12-, 18-, and 24-months of age for
normal male C57BL/6 mice using HILIC ESI-Q-TOF/MS145. This global-untargeted
metabolomics study suggested aging is associated with a significant imbalance of core
metabolite levels. Specifically, NAD levels decline, AMP/ATP levels increase,
purine/pyrimidine accumulate and there are significantly altered oxidative
phosphorylation and nucleotide biosynthesis and degradation. A more recent study
determined metabolic fingerprints of brain samples in young (~2-months) and aged
(~24-months) normal female C57BL/6J mice using 1H-NMR spectroscopy146. The NMR
spectra showed age-dependent changes revealed decreased concentrations of lactate,
methionine, N-acetylaspartate, uridine, and inosine. In contrast, concentrations of
leucine, isoleucine, valine, glutamine, allantoin, uracil, tyrosine, and phenylalanine were
increased in the aged mice. These untargeted global analyses of wildtype aged mice
demonstrate that aging is associated with increased metabolite diversity. Several
pathways may be involved in these changes as aging metabolic signatures have been
associated with carbohydrate, lipids, amino acids, and redox metabolism147. Much more
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analyses, especially on a longitudinal time frame, is needed to understand the
mechanisms that drive metabolic defects in aging.
Understanding the mechanism by which metabolites are dysregulated in the aging
brain may uncover the inextricable link between aging and neurodegeneration. A
potential link between aging and aberrant brain metabolism are the aging corpora
amylacea, which are even more abundant in neurodegenerative diseases148. Similarly,
the abundance of other neurodegenerative markers like Heat Shock Protein 70 (HSP70),
advanced glycation end products (AGEP), and alpha-synuclein increase with age149–152.
Strikingly, mice lacking GS also lack these markers in all brain regions99. While corpora
amylacea accumulation disrupts neurological function in aged mice, mice lacking GS
exhibit decreased corpora amylacea and increased maximum climbing speeds99.
Conversely, increased GS activity promotes increased corpora amylacea and progressive
degeneration of Purkinje neurons in mice and flies99. Thus, neuronal glycogen synthesis
contributes to age-related functional decline. These data provide a direct link between
glycogen synthesis and the formation of corpora amylacea to age-dependent proteinbased aggregates that are well known hallmarks of many neurodegenerative diseases of
aging. Furthermore, they indicate that the equilibrium of brain glycogen is critical, and
imbalance creates neurodegeneration.
Unfortunately, a direct physiological relationship of glycogen and corpora amylacea
to the aging metabolome is not well-defined at this time. The historical assumptions
that corpora amylacea are innocuous resulted in limited examination of the relationship
between aberrant glycogen metabolism in aging. Data from the recent resurgence in
corpora amylacea suggests that progressive accumulation of aberrant glycogen in the
brain may contribute to aging-based neurological decline. If so, then interventions that
slow this process could be protective against neurological deficits of aging. Glycogen
synthesis could be a target to tackle the age-related deterioration of the nervous
system.
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1.7

Temporal lobe epilepsy

1.7.1 Aberrant glycogen in temporal lobe epilepsy
Greater than 3 million in the US and over 70 million globally suffer from
epilepsy153,154. Several factors can cause epilepsy including stroke, prenatal damage, CNS
infection, head injury, genetics, and brain tumors155. For most epileptic patients, the
cause is unknown. Seizures are typically diagnosed with electroencephalography (EEG)
where “spike and wave” formations coming from specific electrodes map seizure
activity to the surface of the brain156. These signals can discriminate a focal epilepsy
from a generalized one. The chaotic neuronal discharge that defines epilepsy can be
dampened with anti-seizure medications, and cocktails of these medications yield
diminishing returns with the addition of each one157. Available epilepsy medications fail
to control seizures in one third of patients including those with the most common focal
refractory epilepsy, temporal lobe epilepsy (TLE)157,158. Although use of many new
antiepileptic drugs with new mechanisms of action has increased, the ability to achieve
seizure freedom has not157. Therefore, a paradigm shift in research strategies and
therapeutic avenues is needed.
For TLE, several different neurological phenotypes are identified, which divide the
disease into pathological subgroups. About 30% of TLE patients have identifiable MRI
lesions such as tumor, cortical dysplasia, or cavernous hemangioma159. Approximately
50% of TLE patients, fall into a pathological subgroup called mesial temporal lobe
epilepsy (MTLE) that is classically characterized by hippocampal sclerosis (HS positive) by
MRI. Patients with MTLE can suffer from spontaneous recurrent seizures and neuronal
loss that originate from mesial temporal lobe structures, such as the hippocampus,
parahippocampus, amygdala, entorhinal cortex temporal pole, and the 2 rostral thirds
of the superior middle and inferior temporal gyri of the right hemisphere160–162. For the
remaining portion of TLE patients, MRI cannot identify the brain pathology.
MTLE is particularly interesting with respect to PGBs as they are observed in the
temporal regions that are commonly biopsied, and these surgical resections create
dramatic reduction in seizure activity (Figures 1.1D and 1.2D)163. Clinical reports of PGBs
in biopsied temporal lobes from patients with TLE began to appear in the early 1990’s
and have now become a marker for MTLE34,163,164. For MTLE patients, temporal
lobectomies are frequently performed for those with partial complex intractable
seizures163. In most of these resections, the hippocampus reveals neuronal loss
especially of the CA1, CA3, and endofolium sectors161. These findings overlap with
electron microscopy images, as well as PAS+ staining that show a strong presence of
PGBs in the pyramidal layer of the hippocampus, primarily the CA1, CA3, CA4,
endofolium, and fascia dentata sectors165,166. Interestingly, PGBs also appear in the
parahippocampal region and the amygdala (Figure 1.2D). Within the temporal lobe,
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PGBs appear filamentous and amorphous, dominating the white matter and
perivascular area, and showing up inside astrocytes and axons34. The localized nature of
MTLE PGBs has provoked the intriguing possibility that MTLE may be a localized form of
a glycogen storage disorder. Now, this concept is gaining traction as studies are
demonstrating metabolic links between aberrant glycogen and MTLE167–169.

1.7.2 Aberrant metabolism in temporal lobe epilepsy
Epileptic foci in TLE have been correlated with hypometabolic activity using 18F-FDGPET. TLE hypometabolic zones include the contralateral temporal lobe, ipsilateral
temporal neocortex, the ipsilateral basal ganglia and thalamus159. Interictal glucose
hypometabolism is reported in 80% of patients with mesial TLE. Interestingly, even in
patients without evidence of hippocampal sclerosis on MRI, the localization of 18F-FDG
PET hypometabolism corresponds to the ictal EEG region. 18F-FDG-PET can also provide
prognostic data based on the extent of initial hypometabolism present167,170. A more
extensive hypometabolic region can indicate a poor prognosis and a longer duration of
epilepsy. Therefore, hypo-glucose metabolism is a clinical biomarker for TLE that is used
to determine patient management and surgical decisions. A recent study demonstrated
the utility of 18F-FDG PET in localizing an ictal focus in TLE patients even in those with
normal MRI159. This study demonstrated that moderate to severe temporal lobe
hypometabolism was noted in cases of lesional MRI. Thalamic hypometabolism was
associated with moderate to severe rather than mild temporal lobe hypometabolism,
suggesting that a hypometabolic thalamus is a marker of temporal dysfunction.
Extratemporal hypometabolism was a predictor of poor postsurgical seizure outcome
while localized temporal hypometabolism predicted a good outcome170. Thus, a
hypometabolic assessment is a clinically useful diagnostic and prognostic indicator of
TLE.
A hypothesis is emerging that neuronal action potentials are supported by systemic
glucose and brain glycogen. Glucose alone is insufficient to support compound action
potentials and is supplemented by glycogen12. The ANLS hypothesis (see section 1.3.2)
suggests that lactate derived from astrocytic glycogen is a major carbohydrate fuel
supporting neuronal energetics. Depleting glycogen or interfering with lactate transport
results in the loss of the compound action potential171. Moreover, glycogen homeostasis
is required to control hyperexcitability and seizures68,79.
In TLE, K+ buffering is clearly dysregulated in specimens from TLE patients172. One
study found that astrocytic K[ir] channels are dysfunctional in sclerotic CA1 hippocampal
regions of MTS patients173. Using patch clamp, a reduction in astroglial K[ir] currents was
observed in sclerotic compared with nonsclerotic hippocampi. These data indicate that
dysfunction of astroglial K[ir] channels could underlie impaired K+ buffering and
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contribute to hyperexcitability in epileptic tissue. When and how this dysfunction
develops during epileptogenesis is not yet clear. Considering the critical role of
astrocytes to maintain interstitial K+ homeostasis and the connections between
astrocytic K+ buffering and astrocytic glycogen, impairment of astrocyte K+ uptake
should be proconvulsant. Thus, PGB laden sclerotic tissue may be connected to a
dysfunction of astrocytic K+ transporters and K+ buffering.
Astrocytic K+ homeostasis and glycogen metabolism are also coupled to glutamate
uptake (see section 1.3.2), which is dysregulated in TLE. In TLE patients and in rodent
epilepsy models, regions of the hippocampus affected by cell death exhibit a
downregulation of glutamine synthetase and an increase in extracellular glutamate
concentration, ultimately resulting in neural hyperexcitability, excitotoxicity, and
neurodegeneration168,174. While glutamate levels are increased, glutamine levels are
decreased, and the process of cycling is slower as observed my magnetic resonance
spectroscopy169. These data pose another rout by which the glycogen dysmetabolism
and PGBs could upend the foundations of neural homeostasis promoting seizure
activity. Glycogenolysis is suggested to yield the ATP supply that maintains the Na+
gradient that drives glutamate transport172. Inhibition of glycogenolysis can rase
extracellular glutamate levels79. Glutamate transport requires the cotransport of Na+
and H+ and the counter transport of K+. While, glutamate transporters are expressed on
multiple cell types, astrocytes are primarily responsible for glutamate uptake175. Thus,
suppression of glycogenolysis by PGB accumulation could disrupt the ion gradients
required for glutamate uptake by astrocytes. Future studies are needed to clarify the
potential mechanism of glycogen dysmetabolism in TLE.
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1.8

Amyotrophic lateral sclerosis

1.8.1 Aberrant glycogen in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disorder176.
Motor neurons of the corticospinal tract, motor cortex, and motor neurons of the lower
brainstem and spinal cord are affected. ALS onset occurs around age 50 with a fatal
prognosis in only 3-5 years. Several mechanisms are correlated to ALS onset and
progression, including excitotoxicity, oxidative stress, mitochondrial dysfunction, protein
aggregation, diminishment in axonal transport, defects in RNA metabolism, and
neuroinflammation. Mutant forms of more than 40 genes have been clinically
implicated in ALS, including superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43
(TDP-43), and fused in sarcoma (FUS), although most cases are sporadic177. Without
effective treatment, ALS remains a fatal diagnosis and new hypotheses regarding
therapeutic targets are focused on glucose metabolism.
CNS protein misfolding and aggregation is commonly associated with
neurodegeneration in ALS. For example, inclusions of human mutant or wild type SOD1
are found at autopsy and in SOD1 overexpressing transgenic mouse models. Recently,
glycogen accumulations in ALS and ALS SOD1G93A transgenic mice were detected.
Strikingly, large PAS+ PGB-like aggregates were observed in cervical spinal cord sections
from ALS patients that were absent in age and gender matched donors (Figure 1.1E and
1.2E)32. ALS PGBs occupied both neurons and glia in the gray matter and only astrocytes
in white matter. Biochemical analysis of tissue homogenates confirmed the elevated
glycogen in both gray and white matter, yet glucose was only elevated in the gray
matter. Glycogen levels were also higher in the brainstem and lumbar spinal cord as well
as in the liver and skeletal muscle prior to disease symptom onset.
1.8.2 Aberrant glycogen metabolism in amyotrophic lateral sclerosis
Altered energy metabolism in ALS correlates to disease progression, suggesting a
pathogenic role for energy metabolism in ALS178. Nearly two dozen studies have
examined ALS patients using 18F-FDG-PET that has uncovered a diffuse cortical
hypometabolic phenotype179–181. Therefore, reduced cortical glucose uptake has
become a robust early indicator of ALS. Recent studies have described a regional
hypermetabolic phenotype localized to the brainstem and both the cortical and dorsal
spinal cord. In SOD1G93A mice, spinal cord glucose uptake initially increased before
symptom onset and subsequently declined during disease progression182. Additionally,
proteins involved in glycolysis, β-oxidation, and mitochondrial metabolism are altered
before disease onset183. ALS patients placed on high carbohydrate hypercaloric diets
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have displayed increased survival and decreased life-threatening events and
hospitalization184. Additionally, an ALS fruit fly model overexpressing TDP-43 and
phosphofructokinase (PFK), the rate limiting enzyme of glycolysis, in the CNS displayed
increased locomotor activity and lifespan185. Thus, increased glucose availability may be
protective, and the early hypermetabolic activity may be an initial mechanism to
compensate for metabolic perturbations.
Recent metabolic observations suggest links between glycogen accumulation and
metabolic deficiencies in ALS. In the spinal cords of ALS patients, alpha-glucosidase, the
deficient enzyme in Pompe disease, is decreased at the mRNA and protein levels32,186.
ALS SOD1G93A transgenic mice also show a reduction in alpha-glucosidase in the spinal
cord, as well as liver and skeletal muscle32. In several neuromuscular diseases including
ALS, genetic evidence suggests that aberrant metabolism of glycosphingolipids, a
subgroup of glycolipids, plays an important role. Glycolipids are lipids attached to a
carbohydrate polymer by a glycosidic bond. They are found on the surface of all
eukaryotic membranes extending from the cell membrane to the extracellular
environment. Glycosphingolipids are formed through the covalent linkage of a glycan
moiety to ceramide, a lipid prominently found in the myelin sheath that surrounds
axons. In the SOD1G93A mouse model, inhibition of glycosphingolipid synthesis
exacerbated disease progression, whereas administration of GM3, a subtype of
glycosphingolipids, slowed it187. Thus, glycosphingolipids may be important players in
ALS and their aberrant metabolism may be related to glycogen accumulation. Further
investigations are needed to discern the type of glycogen or PGBs that were observed in
ALS patients and mice. Crossing ALS mice with a GSKO line would aid in defining the
relationship of glycogen accumulation to pathogenesis in ALS.
To further understand the underpinnings of glucose hypometabolism in ALS, polar
metabolite changes in ALS in important field of investigation, yet largely
unstudied178. Though clinical meta-analysis suggests that metabolism does impact ALS,
there is not an assertive study to establish any direct link between changes in metabolic
parameters and the progression and survival of ALS176. Therefore, some pathways may
be affected and modulate ALS outcome, but they are not defined. One study has
analyzed FUS mutated human derived ALS motor neurons in vitro and did not identify
alterations to glycolysis or TCA cycle intermediates188. Given the recent discovery of
glycogen accumulation in the spinal cord, further investigation into the neural and/or
glial cell origins may elucidate cell specific metabolic deficiencies. Interestingly, the
lactate shuttle has been shown to exist beyond axons and astrocytes in
oligodendrocytes and their myelinated axons. Oligodendrocytes have been proposed to
perform aerobic glycolysis and give lactate to the myelinated compartments. Though
glycogen’s role in this process has not been defined, alterations in metabolic support by
oligodendrocytes is now expected to underlie various diseases that are psychiatric or
physiological like ALS. Further investigation in these areas may provide a clearer
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understanding of how different cell types in the CNS contribute to reduced
carbohydrate catabolism and new therapeutic opportunities for ALS.
1.9

Alzheimer’s disease

1.9.1 Aberrant glycogen in Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia. In 2021, 6.2 million
Americans (11.3%) 65 and older are living with AD189. Adults younger than 65 can also
develop AD, but this prevalence is rarer and number less certain. Like many chronic
diseases, AD develops from multiple factors. The greatest risk factor for AD is age and
genetics, especially the E4 APOE variant, and having a family history of AD190. Hallmark
clinical symptoms of memory loss and brain atrophy are believed to be driven by senile
plaques of β-amyloid and neurofibrillary tangles of hyperphosphorylated-tau191. Due to
these misfolded aggregates, AD is a proteinopathy192. In both sporadic and familial AD,
amyloid-β oligomers are observed in the cerebral cortex and hippocampus and
neurofibrillary tangles of hyperphosphorylated-tau are deposited in soma and processes
of neurons193,194. Neurofibrillary tangles first develop in the transentorhinal cortex and
spread to the entorhinal cortex and hippocampus prior before showing in neocortical
regions193. A cascade of other symptoms that define AD include, innate immune
activation and inflammation, ER stress, ROS, mitochondrial dysfunction, synaptic
toxicity, and cell death192. Ultimately a combination of some or all of these
perturbations cascade to drive neurodegeneration that leads to atrophy of the
neocortex, hippocampus, amygdala, basal forebrain, and brainstem. Clearing the
plaques or tangles do not prevent or rescue the disease, and the cascade of effects are
still undefined as cause or consequence of the proteinopathy. Thus, a new framing of
the underlying mechanisms or causes of AD is welcomed195.
AD glycogen-like aggregates were first described using light and electron
microscopy in 1985 from post-mortem brain and called granular glycogen bodies (Figure
1.1F)148. While termed granular glycogen bodies, the exact composition and architecture
of these aggregates are unknown. EM observations distinguish these glycogen bodies
from PGBs in that their ultrastructure appears granular rather than fibrillar as seen in LD
and aging (Figure 1.1A, C, F). Further, toluidine blue stains these deposits an even dark
blue, as opposed to the light blue periphery of CA. Thus, the AD granular glycogen
bodies were distinct from visible corpora amylacea yet also observed in proximity to
corpora amylacea in AD brains. The AD granular glycogen bodies range 5-50 m and are
found non-membrane bound in the cytoplasm of cellular processes in both gray and
white brain matter. While primary neuronal atrophy is observed in the hippocampal and
cortical regions, AD glycogen-like aggregates are found more broadly throughout the
brain, including the medial frontal, anterior and posterior central, medial temporal, and
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lateral occipital gyri (Figure 1.2F). Further investigation of the structure of AD granular
glycogen and cellular origins is needed.
1.9.2 Glycogen metabolism in Alzheimer’s disease
Though direct links between glycogen and AD are currently under investigation,
glucose hypometabolism is an established clinical AD hallmark that is especially
prominent in E4 APOE carriers196–199. Another emerging metabolic connection is that
astrocyte energetics and metabolism may be a critical factor200. In healthy aging,
astrocytes support neurons by maintaining neuron homeostasis, maintaining ion
gradients and removing excess extracellular glutamate as well as Aβ, the main
component of the amyloid plaques found in AD brains201.
In the diseased stage, astrocytes show decreased glycolysis202,203. The resulting
glucose hypometabolism represents a misregulation of nutrient transporters, metabolic
enzymes and mitochondrial complexes200. This is connected to levels of
hyperphosphorylated tau in cerebrospinal fluid (CSF) and impaired cerebral
metabolism204. The metabolic changes create a cascade of pathological events, leading
to oxidative stress and astrogliosis. Reactive astrocytes produce proinflammatory
cytokines that activate microglia and amplify neuroinflammation in the brain205,206. They
produce more reactive oxygen species and their support functions decline200. There is a
reduction in glutathione, which prevents damage by reactive oxygen species, glutamate
uptake, and Aβ clearance, with a concomitant increase in Aβ production. This ultimately
results in Aβ deposition in the brain and synaptic dysfunction, causing dementia.
What promotes abnormal glucose metabolism in AD is not known. One hypothesis is
that the observed overactivity of glycogen synthase kinase 3 beta (GSK3B) could have
the effect of inhibiting GS and starving the cell of glycogen207. Another is that soluble
glycogen is in limited supply due to the progressive formation of AD granular glycogen.
Glycogen breakdown is key to many aspects of brain function, and its tie to learning and
memory formation as well as long term memory consolidation (see section 3.1) are
particularly interesting in the case of AD. Genetically engineered mice that cannot form
glycogen in the brain (GSKO) have defects in long-term potentiation (LTP), which is
consistent with their deficits in short-term memory formation and long-term memory
consolidation27. Also consistent with this hypothesis, feeding AD mice a diet
supplemented with pyruvate facilitates increased soluble glycogen stores and improves
spatial learning208.
Interestingly, cerebral glucose hypometabolism as measured by 18F-FDG-PET has
emerged as a clinical hallmark for AD196–199. The degree of glucose hypometabolism has
an intimate relationship with AD clinical symptoms and severity. There are multiple
clinical and animal studies focused on whether AD cerebral hypometabolism implies
general impairment of glucose utilization, i.e., transport deficiencies, or another
mechanism specific to glucose. Further, a body of work validating the predictive power
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of cerebral hypometabolism, especially in carriers of E4 APOE, has raised a “chicken-oregg” narrative with respect to impaired glucose utilization causing neurodegenerative
processes and vice versa10.
Cerebral hypometabolism could be part of a vicious cycle, both cause and
consequence of AD neurodegeneration10. A glycogen dysmetabolism centric view poses
the concept that glucose sequestration is a function of glycogen dysmetabolism yielding
AD granular glycogen and consequently brain hypometabolism. The creation of AD
granular glycogen likely precedes neurodegeneration, however that does not preclude
the possibility that it ignites a positive feedback loop wherein the neurodegenerative
processes further impose glycogen and/or glucose dysmetabolism.

1.10 Conclusions and future directions

Searching for effective treatments of neurodegenerative diseases is one of the more
challenging aspects of neuroscience. Scientists have made significant advancements
understanding the range of molecular and cellular pathologies that contribute to
neurodegeneration, including protein aggregation, mitochondrial dysfunction,
glutamate toxicity, calcium load, proteolytic stress, oxidative stress, neuroinflammation,
and aging. Efforts to treat neurodegenerative diseases are often limited by the fact that
they tend to address any one of the above pathological changes while ignoring
others. Lack of clarity regarding a possible root cause that underlies all the above
pathologies poses a significant challenge to the crusade of curing neurodegenerative
disease.
Glucose hypometabolism underlies virtually all neurodegenerative diseases.
Evidence of glycogen metabolism disruption is a striking similarity between LD and
Pompe disease, aging, TLE, AD, and ALS. In this respect, Lafora’s disease offers a helpful
model. LD is a fatal neurodegenerative disease, with traditional neurodegenerative
disease biomarkers of ROS, inflammation, astrogliosis, hypoxia, and neuronal
dysfunction, exacerbated by defined metabolic targets involved in glycogen metabolism.
LD is a glycogen storage disorder, defined by PGB aggregation all over the body, driving
metabolic defects, CNS deterioration, and fatality. While similar aberrant glycogen
accumulation is found in the CNS of Pompe, aging, TLE, AD, and ALS patients, it has not
been as well characterized as in LD.
A standard approach to classifying the structure and identity of PGBs will be useful
to determine the classifications of these PGBs. Using a published pipeline of methods
used to examine the structure and localization of LD PGBs, similar experiments should
be performed to understand structural aspects in Pompe disease, aging, TLE, AD, and
ALS15,40,209. With this knowledge, we may re-group classifications of GSDs and challenge
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the classification of neurodegenerative diseases that are not traditionally defined GSDs
but diagnosable by glycogen deposits/PGB accumulation. Moreover, due to increased
technological advances in glycogen detection, many classical GSDs where a neurological
component may be missed should be re-investigated for the influence of CNS PGBs.
There are other neurodegenerative diseases in which to our current understanding,
do not develop disease specific PGBs but are afflicted with a gross accumulation of the
aging PGB, CA. Exact differences between corpora amylacea and disease PGBs have yet
to be extracted beyond aspects observable by microscopy. Astrocytic LD PGBs for
example, appear immunologically like corpora amylacea. Molecular and structural
differences between corpora amylacea that hyperaccumulates with neurological disease
and aging PGBs need to be examined.
Ultimately, the relationship of glycogen deposits/PGBs to upstream and downstream
metabolic defects is of interest. Current advances in metabolomics and MALDI to
measure glycogen and related metabolic changes may facilitate an understanding of the
dysregulated brain energy metabolism underlying neurodegenerative diseases. The
possibility of using newly developed methods and technologies to find translational
molecular targets is exciting. Given the importance of glycogen synthesis to brain
energetics and the succession of multifaceted events detrimental to health that follow
its dysmetabolism, glycogen in disease research will be a critical area neuroscience in
the years to come.
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Table 1.1 Glycogen storage diseases.
Disease Name(s)
GSD 0a
GSD 0b
GSD 1a, von Gierke

Gene
GYS2
GYS1
G6PC

GSD 1b, von Gierke

SLC37A4

GSD 2, Pompe disease
GSD 3, Cori/Forbes
GSD 4, Anderson,
Adult polyglucosan body
disease (ABPD)
GSD 5, McArdle
GSD 6, Hers
GSD 7, Tauri
GSD 9a

PHKA2

GSD 9b

PHKB

GSD 9c

PHKG2

GSD 9d

PHKA1

GSD 10

PGAM2

GSD 11, Fanconi-Bickel
GSD 12
GSD 13
GSD 14
GSD 15

SLC2A2
ALDOA
ENO3
PGM1
GYG1

Danon disease

LAMP2

Lafora disease, 2A

EPM2A
NHLRC1
(EPM2B)

Lafora disease, 2B

OMIM
240600
611556
232200

GAA
AGL

Affected enzyme
Liver glycogen synthase
Muscle glycogen synthase
Glucose-6-phosphatase α
Glucose-6-phosphatase
transporter
Alpha α-glucosidase
Glycogen debranching enzyme

GBE1

Glycogen branching enzyme

232500

PYGM
PYGL
PFKM

Muscle phosphorylase
Liver phosphorylase kinase
Muscle phosphofructokinase
Phosphorylase b kinase (α2
subunit)
Phosphorylase b kinase (β
subunit)
Phosphorylase b kinase (𝛾
subunit)
Phosphorylase b kinase (α1
subunit)
Muscle phosphoglycerate
mutase
Glucose transporter 2*
Aldolase A
β-Enolase
Phosphoglucomutase 1
Glycogenin-1
Lysosomal-associated
membrane protein 2
Laforin

232600
232700
232800

Malin

254780
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232220
232300
232400

236000
261750
613027
300559
261670
277810
611881
612932
614921
603942
300257
254780

Figure 1.1 Electron microscopy (EM) and Periodic Acid Schiff stain (PAS) of glycogen
deposits/PGBs.
A) Lafora disease (LD) B) Pompe disease – glycogen storage disorder type II (GSD II) C)
Aging D) Temporal lobe epilepsy (TLE) E) Amyotrophic lateral sclerosis F) Alzheimer’s
disease (AD)
Multiple images in C, E, and F represent different donors.
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Figure 1.2 Diagram of glycogen deposits/PGBs in neurodegenerative diseases.
Black dots/circles represent aberrant glycogen accumulations. A) Lafora disease (LD) B)
Pompe disease – glycogen storage disorder type II (GSD II). Black dots represent PGB
accumulation in EOPD and black circles represent PGB accumulation in LOPD. C) Aging
D) Temporal lobe epilepsy (TLE) E) Amyotrophic lateral sclerosis F) Alzheimer’s disease
(AD).
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Pathological biomarkers of a glycogen metabolism disorder in the aging
brain
2.1

Introduction

Brain metabolism is the biochemical engine of cognition, memory, and behavior and
is ignited and fueled by glucose. The brain accounts for 2% of body mass and 25-40% of
total glucose utilization in the resting state and glucose is the pivotal molecule driving
brain central carbon metabolism210–212. Glucose not only provides bioenergetics for ATP,
but also supports nucleotide and neurotransmitter biosynthesis that is important for
synaptic communications and normal brain homeostasis. Glucose is stored as the
macro-biomolecule glycogen, the majority of which is found in the liver and skeletal
muscle. Until recently, glycogen could not be detected in the brain because previous
methods were not sensitive enough and failed to preserve glycogen from degradation
after euthanasia. Recently improved detection methods and rapid preservation
methods have proven successful at preventing glycogen degradation post-euthanasia.
These advances led to discoveries of an emerging role for glycogen in synaptic plasticity
and memory consolidation45,52,54.
Glycogen is comprised of glucose monomers that are linked by -1,4-glycosidic
linkages into polymers by glycogen synthase (GS). These glycose polymers are branched
every ~13 glucose residues by glycogen branching enzyme that generates -1,6glycosidic linkages. Glucose-1-phosphate is released by degrading cytoplasmic glycogen
by glycogen debranching enzyme and glycogen phosphorylase. Static analysis of brain
glycogen using immunohistochemistry (IHC) reveals region specific and heterogeneous
storage patterns39,213. However, a dynamic analysis of glycogen in aging and disease is
lacking. Mutations in genes encoding glycogen metabolism enzymes cause glycogen
storage diseases (GSDs) with severe tissue specific pathogenesis214. A hallmark of most
GSDs are insoluble glycogen-like aggregates called polyglucosan bodies (PGBs), which
vary in cellular location and morphology depending on the molecular defect.
The pathogenicity of brain PGBs is highlighted by the GSD Lafora disease (LD) that
also presents as a fatal childhood dementia and progressive myoclonus epilepsy, where
LBs are known drivers of the severe disease course. Multiple laboratories using
numerous pre-clinical models have demonstrated that LBs drive LD inflammation,
neurodegeneration, and epilepsy25,27,51,92,215–221. LD patients develop seemingly normal
during their first decade of life with epilepsy and myoclonus emerging during
adolescence80. Patients then experience rapid neurodegeneration, ataxia, dysarthria,
and amaurosis that leads to a vegetative state prior death typically within 10 years of
onset. LD is an autosomal recessive childhood dementia caused by mutations in either
the Epilepsy Progressive Myoclonus type 2a or 2b (Epm2a or Epm2bB) gene each
accounting for ~50% of cases46,81–83. The proteins encoded by Epm2a and Epm2b are the
glycogen phosphatase laforin and the E3 ubiquitin ligase malin, respectively. Loss of
function of either protein promotes the generation of aberrantly branched, hyperphosphorylated, cytoplasmic PGBs called Lafora bodies (LBs) throughout the body and
most extensively observed in the skeletal muscle, heart, brain where they are
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neurotoxic78,222. In the brain, LBs are found in 99% of astrocytes, and <10% of neurons96.
Multiple independent studies have established that decreasing LB formation or ablating
previously established LBs prevents neurodegeneration and epilepsy in LD mouse
models while restoring normal brain metabolism25–28,118,223. Conversely, overexpression
of constitutively active glycogen synthase promotes the accumulation of a PGB that
drives neurodegeneration in flies and mice90. These studies have elucidated the
molecular etiology of LD and established the importance of proper glycogen metabolism
in the brain.
Visualizing glycogen is often achieved by using Periodic Acid Shiff staining that was
developed in the 1940’s224. PAS reacts with 1,2-glycol linkages and stains multiple
carbohydrate polymers, including glycogen, PGBs, glycoproteins, and proteoglycans38.
PAS stain is a standard technique for identifying glucose polymers in paraffin embedded
tissue, but PAS is limited in both specificity and sensitivity. A more accurate method for
quantitation of glucose polymers has been recently established using gaschromatography coupled mass spectrometry (GCMS)40. There are many sources of
glucose polymers in tissues beyond glycogen like glycoproteins and proteoglycans,
which PAS and GCMS can detect.
LBs can also be detected by an IgM antibody purified from the antisera of rabbits
inoculated with the myocardium of a LD patient, designated KM279217,225,226. KM279
detects LBs from human brain, skeletal muscle, heart, and liver as well as LBs from other
mammals like dogs and mice225–231. KM279 also detects other PGBs like those found in
GSD IV, hepatocyte “ground-glass” inclusions in livers of alcohol abuse patients,
aggregates in a patient with alpha-thalassemia major receiving iron chelation therapy,
and aggregates in a patient with trisomy 21 who had undergone a bone marrow
transplant for acute myeloid leukemia232,233. Importantly, KM279 also detects a PGB
found in the aging brain called corpora amylacea, a polyglucosan structure catalyzed by
glycogen synthase that accumulates with advancing age90,225,226,234. A recent detailed
analysis defined that KM279 recognizes aberrant PGBs but does not detect normal
glycogen225.
An additional anti-carbohydrate antibody is IV58B6. IV58B6 is a robust anti-glycogen
antibody that was raised against the mandibular cartilage of a rat38,225,235,236. IV58B6 can
detect both soluble and insoluble glycogen molecules, like PGBs, as well as
mycobacterial polysaccharides and α-glucans39,213,226,237–245. Interestingly, glycogen
synthesized in vitro either enzymatically or synthetically is not detected by IV58B6 but
can be detected by the anti-glycogen antibody ESG1A9, providing a clue that the
epitope may be related to branching structure39. Several groups have reported that
IV58B6 and ESG1A9 have different affinities for varied sizes of glycogen particles39.
Although the exact epitopes of KM279, IV58B6, and ESG1A9 still need to be defined,
these antibodies are powerful tools to visualize and quantify glycogen and glycogen-like
aggregates while maintaining spatial information that is lost when glycogen is purified,
hydrolyzed, and quantified. The IV58B6 and KM279 antibodies have been used to study
healthy and diseased glycogen in the WT and Epm2a-/- (LKO) mouse brain15,217.
In this study, four methods were applied to define the longitudinal patterns of
soluble glycogen, corpora amylacea, and LBs in WT and LKO mice. PAS stain, KM279, and
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IV58B6 IHC analysis of WT mouse brains, skeletal muscle, and hearts are supported by a
recently established and highly robust method for quantifying hydrolyzed glycogen
using GCMS. These methods were also used to examine laforin heterozygote mice, a
model of healthy carries of an LD locus.
These methods were used to define a longitudinal analysis of glycogen dynamics in
mice with healthy and diseased glycogen metabolism. In doing so, this study contributes
to the characterization of the detection specificity of PAS and the glucose polymer
detection method by GCMS and the epitopes of IV58B6 and KM279. For sake of clarity,
we discuss these techniques with respect to their known specificities for soluble
glycogen and/or PGBs. Thus, this longitudinal study is a comprehensive biomarker
analysis of the dynamics of glycogen and PGBs. Brain glycogen and LBs are largely found
in astrocytes, and glia have been proposed to be involved in an inflammatory response
in LD25,27,118,215,221,223. Using traditional markers of astrogliosis, Gfap, and microgliosis,
Iba1, we also include analyses of glial activation over time. Our analyses collectively
describe a plateau effect of total LB accumulation and provide physiological evidence to
strongly suggest their propensity to aggregate. We further show that microglia are
significantly activated in LKOs compared to laforin heterozygotes, whose microglia
activation is the same as in WT mice. These main findings act as a particularly important
set of biomarkers highly useful for current and future pre-clinical development of LD
therapeutics118,223.
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2.2

Methods

2.2.1 Mouse models and tissue preparation
Laforin KO (LKO) mice have been described previously and were generated
by removing the DSPD exon of Epm2a, producing an Epm2a-null mutant217. Male
C57BL/6J LKO, and WT mice were bred to create laforin heterozygotes. The mice were
housed in a climate-controlled environment with a 14/10 h light/dark cycle (lights on at
0600 h) with water and solid diet provided ad libitum throughout the study. The animal
procedures used in this study were approved by the Institutional Animal Care and Use
Committee (IACUC) at as specified by the 1985 revision of the Animal Welfare Act. WT,
LKO, or laforin heterozygous mice were sacrificed at 1-, 3-, 6-, 9-, 12-months. WT and
LKO mice were also sacrificed at 24-months. Mice were sacrificed by cervical dislocation,
and decapitation, and tissues were rapidly dissected. One half of the heart, half the
quantity of dissected skeletal muscle, and one hemisphere of the brain was fixed with
formalin (10% formaldehyde in PBS) for 24 h and exchanged for 70% ethanol after 24 h
for immunohistochemistry. The remaining tissue was flash-frozen in liquid nitrogen.
2.2.2 Histology
Periodic Acid Schiff (PAS) staining was performed per standard protocol on 4 m
sections of formalin fixed brain, skeletal muscle, or heart embedded in paraffin234.
IHC was performed on 4 m sections of brain, heart, or skeletal muscle using
IV58B6, Gfap, or Iba1 were de-waxed, rehydrated, and warmed to 37˚C for 1 h in
Ventana CC2 Standard buffer for antigen retrieval. The antigen retrieval method specific
to sections receiving KM279 were [Dako Low pH, 110C, 20', 1 h RT]. The generation of
KM279 and IV58B6 primary antibodies has been previously described225,226,235.
Concentrations of antibodies were as follows: KM279 1:50, IV58B6 1:50, Gfap (Ab7260)
1:2000, Iba1 (ab5076) 1:300. Detection kits used: KM279 Vector MOM (MP-2400),
IV58B6 Vector MOM (MP-2400), Gfap Ventana OmniMap Rabbit-HRP (760-4311), Iba1
Ventana OmniMap Goat-HRP (760-182).
2.2.3 Gas-chromatography mass spectrometry (GCMS) analysis of glycogen
One hemisphere of the brain, half the quantity of dissected skeletal muscle, and one
half of the heart was flash-frozen in liquid nitrogen and pulverized into powder (5 m
particles) using a liquid nitrogen Freezer/Mill Cryogenic Grinder (SPEX SamplePrep).
Glycogen purification, hydrolysis, derivatization, and quantitation of glycogen by GCMS
was performed as described previously40. 20 mg of each pulverized tissue was extracted
in 1 mL of 50% methanol and separated into polar (aqueous layer) and insoluble
fractions containing glycogen/DNA/RNA/protein by centrifugation at 4C 15,000 rpm for
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10 min. The pellet was subsequently washed three times with 50% methanol and once
with 100% methanol to remove polar contaminants. The polar fraction was saved for
future experiments. The pellet was hydrolyzed by resuspension in 100 μL of deionized
water followed by addition of an equal part of 6 N HCl. The samples were vortexed
thoroughly and incubated at 95 °C for 2 h. The hydrolysis was quenched by adding 100%
methanol after which, the samples were incubated on ice for 30 min. The supernatant
was collected after centrifugation at 15,000 rpm at 4°C for 10 min and subsequently
dried by SpeedVac (Thermo). Derivatization of dried polar samples began with the
addition of 70 μL of 20 mg/mL methoxylamine hydrochloride in pyridine followed by a
30 oC incubation for 1.5 hr. Then, 50 μL was transferred to a V-shaped amber glass
chromatography vial and 80 μL of trimethylsilylating agent N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was added. This step was followed by a 30 min incubation
at 37 oC. After cooling, the derivatized mixture was analyzed by GCMS. An Agilent 7800B
GC coupled to a 5977B MS detector was used in this study. GCMS protocols were similar
to those described previously except for a modified source temperature of 280 °C209.
MassHunter Unknowns Analysis (B.09.00, Agilent Technologies, Santa Clara, CA, USA)
software matched to the FiehnLib metabolomics library was utilized for curation of the
MS data set with retention time and fragmentation pattern matching. Mass spectra
were translated to relative metabolite abundance using MassHunter Quantitative
Analysis (TOF) (B08, Agilent Technologies, Santa Clara, CA, USA). Relative abundances
were adjusted to protein input.
2.2.4 Quantification and statistical analysis
PAS staining and IHC quantitation was achieved using HALO analysis software by
Indica Labs. PAS, KM279, and IV58B6 analysis (total glycogen) were based on the “Area
Quantification” v2.1.11 algorithm. Analysis of IV58B6 regarding nuclear and cytoplasmic
glycogen, Gfap, and Iba1 were based on the Multiplex IHC v2.3.4 algorithm. Activated
microglia analysis was based on the “Microglial Activation” v1.4 algorithm. Multiple
comparison two-way Anova and descriptive statistics were performed using GraphPad
Prism software.
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2.3

Results

2.3.1 Longitudinal analysis of glycogen and PGBs in the brain, skeletal muscle, and
heart
PAS stain is a historically standard technique for identifying PGBs and glycogen in
paraffin embedded tissue38,142. A more accurate method for quantitation of glucose
polymers has been recently established using GCMS40. Using both methods, we
analyzed whole brains of 1-, 3-, 6-, 9-, 12-, and 24-month-old WT and laforin knockout
(LKO) male mice. To achieve minimal glycogen degradation post-mortem, mice were
euthanized by cervical dislocation followed by decapitation and rapid dissected with
tissues submerged in liquid nitrogen or formalin. PAS-stained slides were digitally
captured using a ZEISS Axio Scan.Z1 slide scanner and analyzed using the HALO image
analysis platform. PAS staining (Figures 2.1 and 2.2) and respective area quantitation
(Figure 2.1B) revealed that the quantity of PAS+ signals in the brain of LKO mice sharply
increases between the ages of 1- and 6-months and then plateaus 8-fold higher than
WT. Conversely, WT PGBs steadily increased over time though at a dramatically lower
level than LKO mice (Figure 2.1B).
While PAS reacts with glycogen, glycoproteins and proteoglycans, the GCMS-based
method specifically quantifies glucose. Therefore, the GCMS method was utilized to test
if the PAS+ quantification was reporting levels of glucose-based polymers. Tissues frozen
in liquid nitrogen were pulverized to 5 μm particles using a magnetic assisted tissuegrinding mill while submerged in liquid nitrogen. The free lipids and polar metabolites
were removed by the addition of 50% methanol:chloroform (1:1). Glycogen and PGBs
were extracted with subsequent methanol and trichloroacetic acid treatment and,
resuspended in H2O, hydrolyzed to glucose monomers by HCl, derivatized, and analyzed
by GCMS40. LKO GCMS quantitation revealed a dramatic increase between 1- and 3months that plateaus after 6-months and is 5-fold higher than WT (Figure 2.1C).
Adjacent slices from the same animals were analyzed by immunohistochemistry
(IHC) using the IV58B6 antibody that has been demonstrated to detect both glycogen
and PGBs and the KM279 antibody that detects PGBs (Figure 2.3A)225,226,235. By 12months, LKO whole brain KM279 detection signals reached an amplitude that is higher
than WT by 15-fold (Figures 2.3B-C and 2.4). Importantly, WT whole brain KM279
detection is identical to that seen in laforin heterozygotes suggesting that healthy LD
carriers do not accumulate LBs (Figures 2.27A-B and 2.4). Analysis and quantitation of
IV58B6 detection closely match the total glucose polymers detected by GCMS (Figures
2.3D-E, 2.5 and 2.1B). IV58B6 detection signals dramatically increased between 1- and
3-months and plateaued after 6-months 2-fold higher than WT. Conversely, there is no
statistical difference in IV58B6 glycogen levels in aged WT mice. Interestingly, a study
examining glycogen in young versus old mice using IV58B6 IHC demonstrated patchy
glycogen that diminished over time as corpora amylacea accumulate, resulting in
glycogen intensity levels remaining the same39. The same change in glycogen
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morphology is observed and quantified by IV58B6 and GCMS in the WT and laforin
heterozygous mice (Figures 2.3D-E and 2.28A-C).
On the corresponding WT and LKO skeletal muscle and heart tissues, we performed
a similar longitudinal PAS stain, KM279 IHC, and GCMS analysis. Unlike the rapid
accumulation and plateau with PAS+ and KM279 staining observed in the LKO brain, a
continuous increase was observed from 1-month to 24-months for both signals in the
LKO skeletal muscle and heart (Figures 2.6A-F, 2.7, 2.8, 2.9, and 2.10). WT KM279
signals increased in skeletal muscle and heart tissues over time, but the increase was
dramatically more blunted than in the age-matched LKO tissues (Figures 2.6A-C, 2.7,
2.8, 2.9, and 2.10). These data illustrate that the rate of LB accumulation in skeletal
muscle and heart is constant and is not like the rapid and then plateaued accumulation
in the brain. GCMS analysis on LKO skeletal muscle supported the KM279 detection
findings exhibiting an increase in glucose polymers over time and reaching a level 5-fold
higher than WT by 12-months (Figure 2.29A). The same analyses performed on LKO
hearts indicates that glucose polymers are 8-fold higher than WT by 12-months (Figure
2.29B). GCMS analysis of WT and laforin heterozygous skeletal muscle shows that
glycogen levels remain constant between 1- and 12-months while increasing in heart
(Figure 2.29C-D). Interestingly, KM279 detection is also observed to increase in the
heart of laforin heterozygotes but not in WT (Figure 2.10). These results contribute to
the characterization of tissue specific glucose polymer dynamics.
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2.3.2 Longitudinal analysis of glycogen and PGBs in the hippocampus, cerebellum,
and brainstem
In LD patients and mice, PGBs are predominately observed in the hippocampus,
brainstem, and cerebellum218. Therefore, we defined these regions-of-interest (ROIs)
and performed regional “Area Quantification” analysis of the KM279 detection signal by
using the HALO image analysis platform. In each of the ROIs, the LKO KM279 detection
signal increases rapidly before 6-months and plateaus after 6-months of age (Figures
2.11A-C, 2.12, 2.13, and 2.14), which is the same pattern observed in whole brain
analysis (Figure 2.3B-C). During the plateau, hippocampus and cerebellum LKO KM279
detection signals are each 30-times higher than WT (Figure 2.11A, C). The brainstem
LKO KM279 detection signal is 15-times higher than WT (Figure 2.11B). Therefore, LBs
are highest in the hippocampus and cerebellum. The WT KM279 detection signal shows
an expected age dependent upward trend that is matched by laforin heterozygotes,
suggesting that healthy carriers of an LD locus do not have LBs (Figures 2.11A-C, 2.12,
2.13, 2.14, and 2.27C).
Between 1- and 6-months, the rate of KM279 detection signal increases most rapidly
in the cerebellum, with a rate of increase that is 10-times faster than in the
hippocampus and 5-times faster than in the brainstem (Figure 2.11A-C). Within this
same time frame, KM279 detection in the brainstem increases 2-times faster than in the
hippocampus (Figure 2.11A, C). Taken together, these results suggest that LB onset and
accumulation rate is highest in the cerebellum, followed by brainstem, and lastly in the
hippocampus.
A similar ROI analysis was performed to quantitate the IV58B6 detection signal. Like
whole brain analysis, regional IV58B6 detection on LKO mice indicates that the IV58B6
detection signal increases steeply between 1- and 6-months and then plateaus (Figures
2.11D-F, 2.15, 2.16, 2.17). The LKO IV58B6 detection signal is highest in the
hippocampus followed by the cerebellum and the brainstem, where total glycogen is 5times, 3-times, and 2-2.5-times higher, respectively, than in WT mice (Figure 2.11D-F).
The WT IV58B6 detection signal is approximately equal between the hippocampus and
cerebellum and does not increase with age, which agrees with previous reports (Figure
2.11D, F)15. The IV58B6 detection signal in the brainstem is less than in the hippocampus
or cerebellum and shows an increasing trend over time (Figure 2.11E). The laforin
heterozygote hippocampus IV58B6 detection signal is almost 2-times as much as WT
and decreases overtime (Figure 2.12D-F). This finding may be suggestive of a region
dependent regulation of laforin expression. Observational analysis of the WT and laforin
heterozygote hippocampus exhibits a morphological change in IV58B6 detection
patterns between the two genotypes over time, moving from a disperse to clustered
arrangement (Figure 2.12A). These data emphasize results from the whole brain
analysis in which IV58B6 detection and GCMS detection of carbohydrate polymers
remains constant over time while changes in IV58B6 detection patterns are observed
(Figures 2.1C, 2.3D-E, 2.5, 2.15, 2.16, and 2.17).
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2.3.3 Average size and size variation of LD and aging PGBs in the hippocampus
Both PAS staining and KM279 IHC detect PGBs. Interestingly, PAS staining yields
uniform signals while KM279 IHC yields light and dark staining as well as uniform versus
punctate patterns. Therefore, we studied these signal attributes to characterize LBs and
corpora amylacea. We first measured the diameters and calculated descriptive statistics
of PAS+ signals from the hippocampus of WT and LKO mice during 6-, 9-, 12-, and 24months, i.e., the age range where the PAS+ signal “Area Quantification” plateaus. The
PAS+ signal coefficient of variation increases in LKO mice from 42% to 61% between 6and 12-months, while in WT mice it does not change over time and is on average 43%
(Table 2.1). These statistical measures indicate that PAS+ signal diameters vary
significantly in both LKO and WT and that the variation increases with age in LKO mice.
The average diameters of LKO PAS+ signals increase from 1.4-3.2 μm, and range from
4.5-14.6 μm, while neither the average diameter nor range of WT PAS+ signals change
with age (Figure 2.1D and Table 2.1). Importantly, the LKO PAS+ signals described in the
75th percentile increase more dramatically over time than those within the 25th
percentile, while neither value changes over time in WT mice (Table 2.1). These data
indicate that the size of PAS+ signals become larger with time while PAS+ “Area
Quantification” stays the same. Furthermore, the increase in LB size variation is driven
by the higher abundance of larger signals. Collectively, these data strongly suggest that
LBs aggregate.
A similar analysis was performed on KM279 detection signals using adjacent brain
slices. The KM279 detection signal reveals two structures in the brains of WT and LKO
mice. One structure appears uniform, looking dense, dark brown, and circular (Figure
2.30A, B). The other is a non-uniform structure, appearing uncondensed and light brown
and encircling the uniform structure (Figure 2.30A-D). These structures were separately
quantified using the “Area Quantification” analysis tool (Figure 2.30C, D). Between 1and 24-months, the accumulation of the “uncondensed” material paralleled the
accumulation of the uniform dark brown circular aggregates with almost 2-times the
abundance (Figure 2.30C). To measure the diameters of KM279 detection signals we
measured the uniformly detected structures because the boundaries are clearly defined
and excluded the non-uniform appearing material (Figure 2.30A-B). The calculated
coefficient of variation of the of WT uniform KM279 detection signals does not change
over time and is on average 52%. In LKO mice, an increase in the coefficient of variation
of the uniform KM279 signals is only significant between 12- and 24-months and is on
average 33%. Thus, the average variation of uniform KM279 detection signals in WT
mice is significantly higher than in LKOs (Table 2.1 and Figure 2.30E). Further, the WT
KM279 detection signal variation is the same in laforin heterozygote mice (Figure
2.11C). In contrast to the PAS+ signals, the average diameters of the LKO 6-, 9-, 12-, and
24-month-old uniform KM279 signals did not change with age, which is also seen in WT
mice (Table 2.1). However, the average diameter of the uniform KM279 signals in LKOs
is larger than in WT, averaging 3.7 μm versus 2.9 μm (Table 2.1). These collective
findings indicate that the average diameter of the LKO uniform KM279 signals is larger
than WT, while WT uniform KM279 signals exhibit larger diameter variation than LKOs.
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Further, in both WT and LKO mice, the average diameter of the uniform KM279 signals
is larger on average than PAS+ signals (Figure 2.1D, 2.30E, and Table 2.1). Thus, analysis
of PAS+ and KM279 detection signals indicate diverging characteristics between the LKO
and aging PGB. Furthermore, PAS+ and KM279 detection signals exhibit a divergence in
PGB detection specificity.
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2.3.4 Longitudinal analysis of Gfap and Iba1 inflammatory markers
Astrocytes and microglia play complementary roles in building and maintaining the
brain, especially with respect to their proinflammatory reactions to
neurodegeneration246. These glial cells also have an emerging relationship to glycogen
and aberrant PGBs. Astrocytes are the main cells that accumulate glycogen in the brain
and two recent independent studies demonstrated that glycogen inclusions within LKO
or malin knockout (MKO) mouse brains were found in 99% of astrocytes and only 4% of
neurons96. Glycogen inclusions were also found within microglia, suggesting a role for
both astrocytes and microglia in LD96. Further, some recent studies have pointed to the
possibility that the glycogen inclusions that accumulate in glia may promote irregular
functionality of their inflammatory responses, which may be an important biomarker of
LD96,97. Gfap-immunoreactive astrocytes and Iba1-immunoreactive microglia have
previously been quantified at 3-4-months and 12-months in LKO and MKO mice showing
increased cell count or activation at the latter time point25,28,221,247,248. For a more
complete assessment of the inflammatory response in LD we performed a longitudinal
analysis of Gfap expressing astrocyte and Iba1 expressing microglia activation in the LKO
mouse brains and compared them to WT and laforin heterozygous aging mouse brains.
Using “Multiplex IHC” analysis of Gfap reactive astrocytes, we first quantitated the
number of these glial cells over time. Whole brain quantitation indicates that the
number of Gfap positive astrocytes in LKO mice is the same as WT animals until 12months (Figure 2.31A). A similar trend is observed in the brainstem and cerebellum
(Figure 2.31C, D). In the hippocampus, Gfap positive astrocytes increase in quantity
from 6- to 24-months (Figure 2.31B). Since reactive astrocytes are scored by quantifying
the area of hypertrophy and elongated protractions, we next measured reactive
astrocytes by Gfap “Area Quantitation”. No difference in astrocyte activation is detected
between WT and LKO mice in any region before 12-months (Figures 2.18A, 2.19, 2.20,
2.21, and 2.22). Since no change in astrocyte number or activation is seen for the first
year of life in the LKO mice, the late stage or “middle-aged” emergence of astrocyte
activation may be more related to aging than LD pathology. Interestingly, at 6-months
and after, the laforin heterozygote mice exhibit an increase in Gfap expressing astrocyte
count and area quantitation comparted to WT (Figure 2.32). Why laforin heterozygotes
have increased number and activation of Gfap astrocytes is unclear, however this
finding is in opposition to what is seen in LKO mice, further supporting the hypothesis
that astrocyte reactivity in LKO mice is defective.
Performing a similar analysis on Iba1-immunoreactive microglia, we used “Multiplex
IHC” analysis to measure any change in the number of these cells over time. We find
that the quantity of Iba1 reactive microglia significantly increases in the hippocampus of
LKO mice between 6- and 24-months (Figure 2.31F and Figure 2.23). No difference is
seen in whole brain analysis or in the other ROIs (Figure 2.31E, G-H, 2.24, 2.25, and
2.26). To perform a microglia activation analysis, we used the HALO tissue analysis
software “Microglial Activation” quantification method in which Iba1 positive cells
completely lacking protractions are scored as active. Unlike astrocyte activation, the
morphology of microglia activation is defined by a full retraction of microglia
41

protractions. Using this specified method, we find that LKO microglia activation is 2
times higher than WT within the whole brain, brainstem, and cerebellum and less
prominent in the hippocampus (Figure 2.18B). Importantly, no difference in whole brain
or any ROI is observed in microglia cell count or activation between WT and laforin
heterozygotes (Figure 2.33). These analyses show that microglia, not astrocytes, are
activated throughout the lifespan of the LKO mouse.
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Figure 2.1 Whole brain PAS stain and GCMS analysis of glucose polymers on WT and
LKO mice aged 1-, 3-, 6-, 9-, 12-, and 24-months.
IHC analysis was performed using Indica labs software (HALO) "Area Quantification". A)
Representative IHC images of PAS staining. B) Quantitation of PAS positive inclusions. C)
Quantitation of acid-hydrolyzed glucose polymers by GCMS analysis. D) Quantitation of
PAS+ signal diameters within the hippocampi of 6-, 9-, 12-, and 24-month-old WT and
LKO mice. Black = WT, red = LKO. Pop-out column graphs are WT data. **** = (p <
0.0001) ** = (p = 0.0064)
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Figure 2.2 Whole brain Periodic Acid Schiff (PAS) staining.
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Figure 2.3 Whole brain KM279 and IV58B6 IHC analysis of WT and LKO mice aged 1-, 3, 6-, 9-, 12-, and 24-months.
IHC analysis was performed using Indica labs software (HALO) "Area Quantification". A)
Schematic illustration of IV58B6 and KM279 antibody affinity to healthy and diseased
glycogen. B, D) Representative IHC images of KM279 and IV58B6 quantitated in C and E,
respectively. C, E) Quantitation of KM279 and IV58B6 IHC analysis, respectively. Black =
WT, red = LKO. Pop-out column graphs are WT data.

45

LKO

24 MO

12 MO

9 MO

6 MO

3 MO

1 MO

WT

Figure 2.4 Whole brain KM279 IHC.
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Figure 2.5 Whole brain IV58B6 IHC.
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Figure 2.6 Skeletal muscle and heart PAS stain and KM279 IHC analysis of WT and LKO
mice aged 1-, 3-, 6-, 9-, 12-, 24-months.
IHC analysis was performed using Indica labs tissue analysis software (HALO) "Area
Quantification". A, D) Representative KM279 IHC analysis on skeletal muscle and heart
quantified in B, E, respectively. B, C) Quantitation of KM279 IHC and PAS stain analysis
on skeletal muscle, respectively. E, F) Quantitation of KM279 IHC and PAS stain analysis
on heart, respectively. Black = WT, red = LKO. Pop-out column graphs are WT data.
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Figure 2.7 Skeletal muscle Periodic Acid Schiff (PAS) staining.
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Figure 2.8 Heart Periodic Acid Schiff (PAS) staining.
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Figure 2.9 Skeletal muscle KM279 IHC.
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Figure 2.10 Heart KM279 IHC.
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Figure 2.11 Brain region-of-interest KM279 and IV58B6 IHC analysis of WT and LKO
mice aged 1-, 3-, 6-, 9-, 12-, 24-months.
IHC regional analysis on hippocampus (top row), brainstem (middle row), and
cerebellum (bottom row) was performed using Indica labs software (HALO) "Area
Quantification". A-C) Representative region-of-interest IHC analysis of KM279 (mainly
diseased glycogen) (left) and quantitation (right). D-F) Representative region-of-interest
IHC analysis of IV58B6 (total glycogen, diseased and non-diseased) (left) and
quantitation (right). Black = WT, red = LKO. Pop-out column graphs are WT data.
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Figure 2.12 Hippocampus KM279 IHC.
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Figure 2.13 Brainstem KM279 IHC.
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Figure 2.14 Cerebellum KM279 IHC.
56

LKO

24 MO

12 MO

9 MO

6 MO

3 MO

1 MO

WT

Figure 2.15 Hippocampus IV58B6 IHC.
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Figure 2.16 Brainstem IV58B6 IHC.
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Figure 2.17 Cerebellum IV58B6 IHC.
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Table 2.1 Descriptive statistics of PGB diameters.
PGB diameter measurements were taken from 200 PGBs per hippocampus using Indica
labs software (HALO). Average diameter, 25% percentile, 75% percentile, range, and
coefficient of variation were calculated using Prism 9. Color gradients were produced
using 2 color conditional formatting in Excel.

PAS

6
1.4

LKO
9
12
1.7 2.3

24
3.2

KM279

3.5

3.7

3.6

PAS

1.1
2.7

1.3
3.0

1.7
2.8

PAS

1.7
4.2
4.5

KM279

6
1.6

WT
9
12
1.5 1.4

24
1.5

4.0

2.7

2.7

3.2

3.0

2.3
3.0

1.0
1.8

1.0
1.6

0.9
2.2

1.0
2.1

2.3
4.3
6.0

3.0 4.9 2.0
4.3 4.8 3.7
7.5 14.6 4.4

1.8
3.8
4.0

1.7
4.2
4.0

2.0
3.9
3.5

7.4

5.8

6.0 11.1 52.2 56.6 53.6 47.7

PAS

42

48

49

61

49

25

51

47

KM279

35

26

31

38

52

56

53

47

Age (months)
Average
Diameter
(μm)
25%
Percentile
75%
Percentile

Range (μm)

Coefficient of
variation (%)

KM279
PAS
KM279

60

6

2.3

5.1
45

Figure 18. Whole brain activated astrocyte (GFAP) and microglia (Iba1) analysis of
WT and LKO mice aged 1-, 3-, 6-, 9-, 12-, 24-months. IHC analysis was performed
using the Indica labs tissue analysis software (HALO) "Area Quantification" of GFAP
IHC and “Microglia” activation of Iba1 IHC. A) Representative GFAP IHC (left) and area
quantitation (right). B) Representative Iba1 IHC (left) and area quantitation (right).
Black = WT, red = LKO.
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Figure 2.18 Whole brain GFAP IHC.
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Figure 2.19 Hippocampus GFAP IHC.
63

HET

LKO

24 MO

12 MO

9 MO

6 MO

3 MO

1 MO

WT

Figure 2.20 Brainstem GFAP IHC.
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Figure 2.21 Cerebellum GFAP IHC.
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Figure 2.22 Whole Brain Iba1 IHC.
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Figure 2.23 Whole brain Iba1 IHC.
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Figure 2.24 Brainstem Iba1 IHC.
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Figure 2.25 Cerebellum Iba1 IHC.
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Figure 2.27 Whole brain and region-of-interest KM279 IHC analysis of WT and laforin
heterozygote brains aged 1, 3, 6, 9, 12-months.
IHC analysis was performed using Indica labs software (HALO) "Area Quantification" and
ruler tool. A) Representative IHC images quantitated in B. B) Whole brain quantitation of
KM279 IHC. C) ROI quantitation of KM279 IHC. D) Violin plots of dense dark brown
circular aggregate diameters. E) "Area Quantification" of WT and heterozygote dense
dark brown circular aggregates and light brown uncondensed material. Black = WT, gray
= laforin heterozygotes. Squares and solid line = dense dark brown circular aggregates,
triangles and broken line = light brown uncondensed material. WT data is previously
shown.

70

A

B

C

D

E

F

Figure 2.28 Whole brain IV58B6 IHC and GCMS analysis of glucose polymers on WT
and laforin heterozygote mice aged 1, 3, 6, 9, 12-months.
IHC analysis was performed using Indica labs software (HALO) “Area Quantification”.
A) Representative IHC images quantitated in D. B) Quantitation of acid hydrolyzed
glucose polymers by GCMS. C) Whole brain quantitation of IV58B6. D, E, F) ROI
quantitation of IV58B6 in hippocampus, brainstem, and cerebellum, respectively. Black =
WT, gray = laforin heterozygotes. WT data is previously shown.
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Figure 2.29 Skeletal muscle and heart GCMS analysis of glucose polymers of WT and
LKO mice aged 1-, 3-, 6-, 9-, 12-, and 24-months.
A) Quantitation of GCMS analysis of glucose polymers from skeletal muscle B)
Quantitation of GCMS analysis of glucose polymers from heart. Black = WT, red = LKO.
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Figure 2.26 Quantitative and qualitative analysis of KM279 IHC on WT and LKO
hippocampus of 6, 9, 12, 24-month-old mice. IHC analysis was performed using the
Indica labs tissue analysis software (HALO) "Area Quantification" and ruler tool.
A, B) Qualitative representation of uniform dark brown circular aggregates and
uncondensed light brown material detected by KM279 on WT and LKO brains,
respectively. C) Hippocampus quantitation of WT and LKO uniform and uncondensed
material. Pop-out column graph is WT data. WT = black, LKO = red. Squares and solid
line/bar = uniform material, triangles and broken line/bar = uncondensed material. D)
Representation of "Area Quantification" analysis in C. Red = “uniform” material, yellow
= “uncondensed” material. E) Violin plots of “uniform” material diameters. WT = black,
LKO = red. *** = (p = 0.0002), ** = (p = 0.0021), * = (p = 0.0209)
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Figure 2.27 Whole brain and region-of-interest cell count analysis of GFAP expressing
astrocytes and Iba1 expressing microglia of 1, 3, 6, 9, 12-month-old-mice.
IHC analysis was performed using the Indica labs tissue analysis software (HALO)
”Multiplex IHC". A-D) Quantitation of whole brain and region-of-interest analysis of
GFAP. E-H) Quantitation of whole brain and region-of-interest analysis of Iba1. Black =
WT, red = LKO
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Figure 2.28 Whole brain GFAP IHC analysis on WT and laforin heterozygote brains
aged 1, 3, 6, 9, 12-months. IHC analysis was performed using the Indica labs tissue
analysis software (HALO) ”Multiplex IHC” and “Area Quantification”.
A) Representative GFAP IHC quantitated in B and C. B) Astrocyte cell count. C) GFAP
"Area Quantification". Black = WT, gray = laforin heterozygotes. Black = WT, gray =
laforin heterozygotes. WT data is previously shown.
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Figure 2.29 Whole brain Iba1 IHC analysis on WT and laforin heterozygote brains aged
1, 3, 6, 9, 12-months. IHC analysis was performed using the Indica labs tissue analysis
software (HALO) ”Multiplex IHC” and “Area Quantification”.
A) Representative Iba1 IHC quantitated in B and C. B) Microglia cell count. C) Iba1 "Area
Quantification". Black = WT, gray = laforin heterozygotes. Black = WT, gray = laforin
heterozygotes. WT data is previously shown.
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2.4

Discussion

This study uses four complementary methods and a longitudinal analysis approach
to fill in knowledge gaps regarding normal and diseased glycogen dynamics. This
longitudinal analysis was performed using C57BL/6J WT, LKO, laforin heterozygous mice,
and a digital pathology workflow to produce rigorous and reproducible data that is
supported by GCMS. Our results form a more complete characterization of the LKO
mouse that models LD pathophysiology. These characterizations lead to a model of LD
pathophysiology in which LB accumulation begins in the cerebellum, then the
brainstem, and last the hippocampus, increasing in number to a height that is most
egregious in the hippocampus. Current therapeutic approaches that aim to limit the
production of glycogen or degrade LBs will benefit from the discovery that brain LBs
stop accumulating and begin to form aggregations at 6-months of age. Furthermore, LD
inflammation rescue is widely assessed by reversing the quantity of Gfap expressing
astrocytes in older mice95,215,247,249–252. Our results indicate that microglia, but not
astrocytes, are activated over the entire lifespan of the LKO mouse. Therefore,
microgliosis is the more likely driver of inflammation in LD. These findings among others
discussed below will be highly informative guides for current and future pre-clinical
therapeutic development.
2.4.1 Soluble versus insoluble glycogen in the LKO mouse
The water-soluble quality of glycogen provides cells with carbon and energy105.
Pathogenic buildup of insoluble glycogen defines glycogen storage diseases253. Previous
reports have measured the ratio of soluble to insoluble glycogen in LKO, MKO, and WT
age matched mice. One study on 10-13-month LKO and 15-month MKO mice indicated
that skeletal muscle total glycogen (soluble and insoluble) is 2-times higher in both
genotypes compared to WT106. To uncouple the quantities of soluble glycogen to PGBs,
they used centrifugation to separate the soluble from insoluble glycogen fractions. WT
soluble glycogen levels were the same as in the LKOs and the WT insoluble fraction was
nominal. Since the soluble and insoluble fractions of the LKO mice were approximately
equal, the 2-fold increase in total glycogen in the LKO mice was a result of the insoluble
fraction. The same analysis has been published on the brain tissue from 11-month-old
MKO mice51. These data indicated that total WT glycogen is equal parts soluble and
insoluble. WT and MKO soluble glycogen levels are the same, but MKO insoluble
glycogen is 3-times higher than WT, bringing the total increase in glycogen to ~2.5-times
higher than WT. In both LD models using skeletal muscle or brain tissues, the increase in
total glycogen is driven by LBs while soluble glycogen is unchanged from normal
conditions. These reported findings fall in line with our total glycogen and LB analysis
using IHC.
Using both KM279 IHC and IV58B6 IHC on adjacent tissue sections we were also able
to separate LB accumulation from total glycogen load. Total LKO brain glycogen
measured by IV58B6 IHC is 2-fold higher than WT or laforin heterozygotes. Total LKO
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brain LBs measured by KM279 IHC is half the amount of total glycogen detected by
IV58B6 IHC. Given the preceding studies quantifying soluble and insoluble glycogen in
these mouse models we may infer that the 2-fold increase in IV58B6 detection
compared to WT or laforin heterozygotes is driven by LBs. Importantly, our GCMS
analysis measures total LKO glucose polymers to be 5-fold higher that WT, and 3-times
higher than analyzed by IV58B6 IHC. This result is likely explained by more sugars being
broken down by acid hydrolysis required for GCMS analysis than are detected by the
anti-glycogen antibody IV58B6.
2.4.2 LB aggregation and diverging characteristics of corpora amylacea
Varied sizes of LBs have been previously categorized as type I and II/III80. Type I
refers to smaller dust-like inclusions that are most abundant and type II/III refers to
larger and more rare inclusions254. These characteristics are captured by our
measurements and statistical analyses of PAS+ signal size and variation. The LBs we
categorized in the 25th and 75th percentile represent type I and II/III respectively. Recent
studies have indicated that type I inclusions are exclusive to astrocytes and type II/III to
neurons, even in old age96. Our results show that type I and type II/III, both increase in
size after 6-months of age while total PAS+ signal “Area Quantification” is rises quickly
between 1- and 6-months and is unchanged thereafter. Furthermore, the increased
variation of LB sizes is driven by the appearance of type II/III. Collectively, these analyses
suggest that LBs accumulate and then aggregate. Furthermore, neuronal LBs, not
astrocytic, have been recently suggested to be the main contributors of increased
susceptibility to kainate-induced epilepsy in LD mice98. If so, neuron specific LB (type
II/III) aggregation may be driving epilepsy in LD.
Our diameter measurements and statistical analysis of WT PAS+ signals indicate that
average LB average size and range is larger than corpora amylacea. Furthermore,
corpora amylacea size variation is unchanged with time while LB variation increases and
is driven by the increasing size of type II/III LBs. Thus, these statistics describe innate
differences between corpora amylacea and type II LBs. The same analysis performed on
the uniform material detected by KM279 reveal the opposite, LKO uniform KM279
signals do not increase in variation and the variation of WT uniform KM279 signals is
larger than in LKOs. Collectively, these results suggest innate differences between
corpora amylacea and any type of LB. This is an important distinction considering recent
published data that showcased a common epitope of type I inclusions and corpora
amylacea not shared by type II/III, thus naming the type I inclusions corpora amylacealike bodies (CAL)96. Indeed, CAL and corpora amylacea have structural similarities and
our results contribute to this comparative analysis indicating that corpora amylacea and
CAL are not exactly the same.
KM279 IHC analysis further led to differentiating characterizations between the
detection specificities of KM279 IHC and PAS+ staining. Unlike PAS staining, the anti-PGB
antibody detection signals reveal an uncondensed material encircling a uniform
material. These findings create the impression that the structure of corpora amylacea
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and LBs contains a dense core surrounded by an uncondensed network of particles
made of the same material. These findings are intriguing considering a recently
published model of spontaneous in vitro LB aggregation. In this model, polyglucosan
particles spontaneously aggregate to form networks and active cellular sequestration of
these polyglucosan networks creates tissue specific morphologies20. The uncondensed
material detected by KM279 may be the physiological representation of polyglucosan
networks.
Characterizing the aggregation behavior of LBs is important for informing the
efficacy of the therapeutics in development that aim to decrease LB load by either
reducing and/or breaking down LBs. According to our finding that LBs aggregate in the
brain in combination with the in vitro model of spontaneous LB aggregation, incomplete
destruction or removal of LBs in late-stage LD represented after the 6-month mark in
LKO mice may result in re-aggregation and unsuccessful therapeutic intervention.
2.4.3 Inflammation markers of LD
To assess inflammatory brain damage in LD, two histological markers are widely
used. Gfap for astrogliosis and Iba1 for microgliosis. Previous studies have quantified
Gfap expressing astrocytes in LKO mice at 12-months and 20- to 26-months25,28,221,247,248.
Our longitudinal analysis indicates that before 12-months the number or “Area
Quantification” of reactive Gfap expressing astrocytes does not increase above normal
levels. Therefore, astrogliosis occurs well after the PGBs have infiltrated. Conversely, we
show that activated microglia, the synergistic inflammatory signaling companion of
astrocytes, are significantly higher throughout the lifespan of LKO mice compared to WT
and laforin heterozygotes.
Compared to LKOs, the laforin heterozygote mice show a reverse inflammatory
response in terms of astrocyte and microglia reactivity despite regional increases in
reactive astrocyte levels. This may be accounted for by increased soluble glycogen in the
hippocampus as laforin heterozygotes do not have LBs. Further study is needed to
determine the reason for laforin heterozygous hippocampal glycogen. It may be possible
that there are regional differences in the ability to compensate for laforin expression
that is not accounted for in our whole brain analysis.
Why astrocyte activation is delayed in the LKO mouse model is unclear. One aspect
to consider is that since Gfap is an intermediate filament protein that outlines the
cytoskeletal profile of astrocytes’ somata and main branches, the entire astrocytic
morphology cannot be evaluated by Gfap staining, and thus astrocytic activation may
not be properly captured by “Area Quantification” of Gfap density. On the other hand,
considering the damage inflicted to the brain in LD, the unresponsiveness of astrocytes
may simply be a consequence of their inundation with LBs. CAL is demonstrated to
accumulate in astrocytes and makes up the majority of brain LBs, while only minor
quantities exist in microglia97. Therefore, the possibility that CAL accumulation affects
astrocyte health and compromises the astrocyte’s ability to become activated in LD is
intriguing. The increase in activated Gfap expressing astrocytes seen after 1 year may be
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a delayed response or more related to aging than LD pathology. Taken together,
activated microglia are more likely important to the driving mechanism of inflammation
in LD than activated astrocytes and should be more heavily considered as an important
biomarker for therapeutic development.

2.5

Final conclusions

In this study we confirm and expand on previously published data describing
pathological LD biomarkers. Our analysis of astrogliosis and microgliosis challenges
assumptions about inflammatory drivers. These results redirect the focus of
inflammatory biomarkers and putative therapeutic targets from astrocytes to microglia.
Our longitudinal analysis illustrates the progressive pathology of both LD and WT aging
mice. This thorough analysis will be a highly beneficial benchmark reference for all preclinical therapeutic development approaches to prevent or reverse LD.
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Metabolic changes during aging compared with a neurodegenerative
disease
3.1

Introduction

Aging is a universal human condition that is harmful and likened to disease and the
main risk factor for neurodegenerative disease3. The progressive nature of
neurodegeneration further intertwines neurodegenerative disease with an agedependent dimension5. Central nervous system (CNS) metabolic defects have been
proposed to be an important underlying feature of both aging and neurodegenerative
disease1,3. Thus, it is not only important to understand the metabolism of aging for the
potential to enhance quality of life, but to also establish a metabolic baseline for
studying neurodegenerative disorders. In fact, many aging metabolism studies have
emerged as a consequence of the problem of subtracting the influence of age from
metabolism studies of neurodegenerative diseases144. In aging and neurodegenerative
diseases, a progression of glucose hypometabolism emerges by Fluorodeoxyglucose 18F
Positron Emission Tomography (18F-FDG-PET)10,255. Targeting brain glucose metabolism
has been proposed as one of five ‘brain energy rescue’ strategies to provide significant
symptom relief and disease modification in neurodegenerative disorders7.
Mammalian brain energy consumes 20% of total body energy, and glucose is the
major substrate of brain energy metabolism256. Glycogen can store ~50,000 glucose
molecules that when released can fuel the TCA cycle, making glycogen an important
energy cache257. To form this macromolecule, linear glucose polymers are synthesized
by glycogen synthase (GS) and branched every ~13 residues by glycogen branching
enzyme258. Breakdown is achieved by glycogen debranching enzyme and glycogen
phosphorylase17. Glycogen is well-studied in the liver and muscle where liver glycogen is
catabolized to provide systemic glucose, and muscle glycogen is catabolized to meet
local energy demands during exercise13. The role of glycogen in the heart is suggested to
be an ‘energy buffer’ where glycogen catabolism is titrated relative to glucose uptake
and liberated only during times of ‘anoxaemic emergencies’259.
The role of glycogen in the brain is an emerging field. Historically, glycogen was not
detected in the brain due to issues with euthanasia that triggered glycogen degradation
and lack of sensitivity260,261. Brain glycogen is critical for long-term potentiation and
memory formation, and impairments to these processes characterize neurocognitive
aging45,55. Further, brain glycogen metabolism has been recently linked to proteostasis,
a common feature of aging and neurodegenerative disease262. Additionally, 25% of brain
glycogen is comprised of the sugar monomer glucosamine, which is incorporated into
and released from glycogen by the same enzymes that incorporate and release
glucose16. In two GSD mouse models, brain regions affected by PGBs have impaired
protein N-glycosylation16. If glucosamine sequestration is driven by the formation of
PGBs, thereby limiting the production of UDP-GlcNAc, the fundamental building block of
N-glycans, this would lead to dire consequences of proteostasis and cellular function.
Interestingly, targeted reduction in glycogen synthase improves neuronal function with
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age and extends lifespan in mice99. With reduction in glycogen synthase, an age-related
aberrant glycogen-aggregate known as corpora amylacea is also reduced in mice and
flies99. These data are strong evidence that the development of corpora amylacea
depends on the synthesis of glycogen and that their formation is an evolutionarily
conserved process. The underlying cause of corpora amylacea formation and whether
corpora amylacea is protective, pathological, or both is still under investigation.
Similar cellular origins and morphological characteristics of corpora amylacea have
been reported in the highly pathological glycogen-like aggregates called Lafora bodies
(LBs), found in the childhood dementia Lafora disease (LD)96. LD is a neurodegenerative
glycogen storage disorder, as well as a fatal myoclonic epilepsy and childhood dementia
where seizures and cognitive symptoms emerge around the age of ten and patients
typically die in their early to mid-twenties (OMIM: 254780). LBs are the result of a
molecular deficit in glycogen metabolism and drive the severe clinical course by
depriving the brain of access to its normal glycogen derived glucose cache118. LD is
caused by autosomal recessive mutations in the epilepsy progressive myoclonus type 2a
or 2b (Epm2a or Epm2b) gene46. The proteins encoded by Epm2a and Epm2b are the
glucan phosphatase laforin, and the E3 ubiquitin ligase malin respectively, and each
account for ~50% of cases46. Loss of function of either protein promotes the generation
of the pathogenic, cytoplasmic, LBs throughout the body and most extensively in
skeletal muscle, the heart, and the brain where they are neurotoxic20. Multiple
laboratories utilizing different pre-clinical models have demonstrated that LBs drive
neurodegeneration, synaptic dysfunction, susceptibility to seizure activity, and changes
to long-term potentiation (the process required for memory storage)51,55,92,216,217,263.
To explore the relationship between brain glycogen metabolism and aging, we
utilized the power of metabolomics. Metabolomics has emerged as the latest ‘omics’
technology that is powerful in creating a comprehensive profile of global or systemic
metabolite changes in biological systems at a specific time and condition264. Though the
metabolomics field is new compared to other ‘omics’ fields like, genomics,
transcriptomics, and proteomics, metabolomics has already shown significant potential
for novel biomarker discovery and enhancing our understanding of underlying biological
mechanisms264. Over the last decade, a few global-untargeted metabolomics studies of
the aging murine brain have emerged145,146,265,266. As cross-sectional studies, they are
limited in capturing the real age-related phenomenon. Therefore, there is a need to
incorporate longitudinal measures in aging studies to fill in significant gaps in our
knowledge about metabolite stability over time. This research is important for accurate
identification of age-related biomarkers and biologically relevant metabolic targets.
We designed a unique opportunity to study the effects of aberrant glycogen
metabolism in aging and disease by performing a longitudinal metabolomics analysis on
laforin KO (LKO) and WT mice. The LKO mouse is a monogenetic model of aggressive
neurodegeneration, inflammation, decreased proteostasis, cellular stress response, and
mitochondrial dysregulation caused by aberrant glycogen metabolism267. These
pathologies are also well-established symptoms of aging and aging mice147. An
important common feature of LD and the LKO mouse to aging is the accumulation of
insoluble glycogen-like aggregates (LBs and corpora amylacea, respectively), which both
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depend on glycogen synthase99. One differing characteristic is that LB accumulation is
rapid in comparison to the slowly accumulating corpora amylacea99. To study the
longitudinal metabolic relationship between age and glycogen utilization, we focused
our investigations on central carbon metabolism, hypothesizing that aberrant glycogen
metabolism in the LKO mouse causes changes to TCA cycle metabolism. We performed
this study using LKO and WT C57BL/6J mice aged to be 1-, 3-, 6-, 9-, 12-, and 24-months.
We examined the brain, skeletal muscle, and heart tissues and used an additional
genotype, Epm2a-/+ (laforin heterozygotes), to represent healthy carriers of an LD locus.
We report the TCA metabolite signature of the aging WT mouse and show relative
differences in the metabolic signature in the LKO mouse that are met by the aging WT
mouse in older age. Our data show that defective glycogen metabolism is correlated
with changes to cellular respiration and that with normal aging, similar changes to
cellular respiration are seen. Using a statistical biomarker detection tool, we confirm
recent findings that glucosamine depletion is a likely driving feature of feature of LD and
show a similar pattern in WT aging. Collectively, our findings begin to uncover the
impact of glycogen metabolism on neural energetics and suggest an underlying
metabolic signature common to aging and a mouse model of childhood dementia. These
results have allowed us to form a new hypothesis that glucosamine is depleted by the
formation of corpora amylacea, as it is in LD mice, thereby driving cognitive aging.
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3.2

Methods

3.2.1 Mouse models and tissue preparation
Laforin KO (LKO) mice have been described previously and were generated
by removing the DSPD exon of Epm2a, producing an Epm2a-null mutant217. Male
C57BL/6J WT, and LKO mice were bred to birth laforin heterozygotes. All mice were
housed in a climate-controlled environment with a 14/10 h light/dark cycle (lights on at
0600 h) with water and solid diet provided ad libitum throughout the study. The
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky
approved the animal procedures used in this study as specified by the 1985 revision of
the Animal Welfare Act. WT, LKO, or laforin heterozygous mice were aged to be 1-, 3-, 6, 9-, 12-months. WT and LKO mice were also aged to be 24-months old. Mice were
sacrificed by cervical dislocation and tissues were rapidly dissected. One half of the
heart, half the quantity of dissected skeletal muscle, and one hemisphere of the brain
was flash-frozen in liquid nitrogen and pulverized into powder (5 m particles) using a
liquid nitrogen Freezer/Mill Cryogenic Grinder (SPEX SamplePrep) for glycogen
quantification using gas-chromatography mass spectrometry analysis40. The remaining
halves were formalin fixed and set aside for other experiments.

3.2.2 Gas Chromatography-Mass Spectrometry (GC-MS) analysis
3.2.2.1 Extraction
20 mg of each pulverized tissue was extracted in 1mL of 50% methanol. 250 μL of
the polar fraction was transferred to another eppi-tube and dried at 10-3 mBar using
SpeedVac (Thermo), derivatized, and analyzed by GCMS. The remaining 750 μL was
stored at -80oC for experimental replicates. Derivatization of dried polar samples began
with the addition of 70 μL of 20 mg/mL methoxylamine hydrochloride in pyridine
followed by a 30oC incubation for 1.5 hr. Then, 50 μL was transferred to a V-shaped
amber glass chromatography vial and 80 μL of trimethylsilylating agent N-methyl-Ntrimethylsilyl-trifluoroacetamide (MSTFA) was added. This step was followed by a 30
min incubation at 37oC. After cooling, the derivatized mixture was analyzed by a Triple
Quadrupole GCMS (TQMS) (Agilent 7010). GCMS protocols were similar to those
described previously except for a modified source temperature of 280°C209. Data
processing was performed using MassHunter Unknowns Analysis (B.09.00, Agilent
Technologies, Santa Clara, CA, USA) software matched to the FiehnLib metabolomics
library. Mass spectra were translated to relative metabolite abundance using
MassHunter Quantitative Analysis (TOF) (B08, Agilent Technologies, Santa Clara, CA,
USA). Relative polar metabolite abundances were adjusted to protein input.
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3.2.2.2 Quantification and statistical analysis
Statistical analysis was carried out using GraphPad Prism9. All data are presented as
means ± S.E. One-way ANOVA was used to compare each set of age groups or two
genotypes from the same age group. Up to 5 biological replicates were used for each
age group. Protein normalized metabolites were uploaded to MetaboAnalyst and run
through principal component analysis (PCA) and receiver operating characteristic
analysis (ROC).
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3.3

Results

Glucose derived from glycogen catabolism is used for cellular respiration in a tissue
dependent manner. Thus, we hypothesized that LKO glycogen dysmetabolism promotes
changes to the TCA cycle that are tissue dependent. To test this hypothesis, we
compared the longitudinal TCA signatures of WT mice to LKO mice and laforin
heterozygote mice, which represent a healthy model of a LD caring locus. All mice were
aged 1-, 3-, 6-, 9-, and 12-months, and WT and LKO mice were aged an additional year
to model old-age. These age intervals represent young (1-month), mature adult (3-6months), middle age (9-12-months), and old age (24-months) of the mouse lifespan. We
focused our comparisons on brain, skeletal muscle, and heart, as LBs dominate these
tissues in LKOs. Tissues were rapidly dissected, submerged into liquid nitrogen. Using a
magnetic assisted tissue-grinding mill, tissues were ground into 5 μm while remaining
submerged in liquid nitrogen. Free polar metabolites were removed by the addition of
50% methanol. Each sample set containing 210 polar fractions each and up to 5
biological replicates per age group was derivatized and analyzed by TQMS in a randomly
generated order (Figure 3.1A-B). The 210 pellet fractions containing protein/DNA/RNA
were analyzed simultaneously using GCMS and quantitated protein input was used to
normalize the polar metabolite quantitation (Figure 3.1A, C). Each tissue sample set was
analyzed by the TQMS or GCMS in a single sequence and metabolites were assigned
blindly to decrease the possibility of instrument drift.

3.3.1 TCA metabolite signatures of the aging WT and LKO brain
To establish a TCA cycle signature of the aging brain, we first analyzed WT brain TCA
cycle metabolites that included glucose, fructose, lactate, pyruvate, citrate, glutamate,
succinate, fumarate, and malate. Consistent among each of these metabolites in WT
mice is an increase in metabolite load observed after 1-month that decreases after 6months and increases again between 9- and 24-months (Figure 3.2). Therefore, the
aging brain TCA cycle metabolite load appears dynamic, despite no observable
difference between adult and old-aged mice (3- and 24-months) for glucose, fructose,
lactate, citrate, glutamate, or malate.
We then compared the LKO TCA cycle metabolite signatures to WT. The WT aging
TCA cycle metabolite signature among 1-, 9-, 12-, and 24-month-olds is similar to the
brain TCA cycle signature of LKO mice (Figure 3.3). However, mature adult LKO mice, 36-months, showed a decreased metabolite load for glucose, fructose, lactate, citrate,
glutamate, succinate, fumarate, and malate. The decrease is statistically significant in 6month-olds, where fructose is 3-fold lower than WT, lactate is 2-fold lower than WT,
malate is 2-fold lower than WT, and glutamate is 2-fold lower than WT. Thus, for all
observable TCA cycle metabolites except for pyruvate, LKO TCA cycle metabolite load
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was lower than WT at 3- and 6-months. These results indicate a glycogen metabolism
dependent effect on TCA cycle metabolism in the brain.
3.3.2 TCA metabolite signatures of the aging WT and LKO skeletal muscle and heart
To establish the TCA signature of aging in skeletal muscle, we analyzed TCA cycle
metabolites that included lactate, pyruvate, citrate, succinate, fumarate, and malate. No
change over time is observed in lactate, pyruvate, or citrate levels with WT skeletal
muscle aging (Figure 3.4). A non-significant age dependent trend in WT mice skeletal
muscle can be seen in succinate, fumarate, and malate, where metabolite load
decreases after 1-month, increases after 6-months and decreases again between 9- and
24-months. These results are consistent with previous reports indicating that old age
does not impose significant changes to skeletal muscle TCA cycle metabolite load146,266.
Quantitation of TCA cycle intermediates in LKO skeletal muscle indicates no trend or
significant differences between WT and LKO metabolite load at any age (Figure 3.5).
Therefore, unlike in brain, accumulation of LBs in the skeletal muscle does not appear to
impose changes to TCA cycle metabolite load.
Lastly, we defined the TCA cycle signature of the aging heart. WT heart TCA
metabolite spectra included glucose, lactate, pyruvate, citrate, glutamine, succinate,
fumarate, and malate. Except for glucose, no difference is measured between heart TCA
cycle metabolites of different age groups (Figure 3.6). These data support previous
findings suggesting that unlike glucose, glycogen load in the heart is stable259.
Quantitation of TCA cycle intermediates in LKO heart tissue indicates no trend or
significant differences between WT and LKO metabolite load at any age (Figure 3.7).
Thus, like skeletal muscle, accumulation of LBs in the heart does not appear to create
changes to TCA cycle metabolite load. Our analysis of longitudinal WT and LKO TCA cycle
metabolite loads support our hypothesis that the influence of aberrant glycogen
metabolism on TCA cycle metabolite loads is tissue dependent.
3.3.3

TCA metabolite signatures of laforin heterozygote aging mice

To further determine the influence of LB accumulation on TCA cycle metabolite
signatures, we analyzed these signatures in the laforin heterozygote mice. Using laforin
heterozygote mice to model healthy carriers of an LD locus, we see that no trend or
significant change exists between laforin heterozygotes and WT mice in the brain,
skeletal muscle, or heart (Figures 3.8, 3.9, and 3.10). Thus, the aging trends between WT
are supported by the parallel longitudinal TCA metabolite signatures of the laforin
heterozygotes in all three tissues. These data further suggest that brain TCA metabolism
defects seen in the LKO mice at 3- and 6-months can be corrected with one functional
copy of Epm2a.
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3.3.4 Statistical analysis of TCA metabolite profile variation in aging WT, LKO, and
laforin heterozygotes and biomarker prediction of LD and aging
To examine why TCA metabolite load differs between LKO and WT mice at 3- and 6months but not at older ages, we used principal component analysis (PCA) to describe
metabolite variation at each age interval. Through PCA we see that the brain TCA
metabolite profile of LKO mice increasingly separates from WT and laforin
heterozygotes during 1-, 3- and 6-months of age (Figure 3.11A-C). At 9-months, the
metabolite profile of all three genotypes begins to overlap and by 12-months little
variance exists between any of the metabolite profiles until 24-months (Figure 3.11D-F).
No separation occurs in skeletal muscle or heart except at 24-months (Figure 3.12A-F,
and 3.13A-F). This suggests that natural aging results in similar metabolic pathway
changes as LD. Therefore, we predicted that similar predicted biomarkers of aging and
LD should be observed using a receiver operating characteristic (ROC) curve-based
approach for biomarker prediction. As expected, we identified glucosamine and its
derivative galactosamine as molecular drivers of the LKO metabolic signature in 6-, 9-,
and 12-month-olds (Figure 3.14A-D). Using the same approach to identify biomarkers of
aging, glucosamine also emerged as a metabolite that differentiates young mice from
aging mice (Figure 3.14E-H). These results suggest that glucosamine may be a driver of
both LKO and aging pathology.
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3.4

Discussion

Cognitive decline and neurodegeneration, as well as metabolic changes related to
mitochondrial activity, reactive oxidative stress, proteolytic stress, and hypoxia, are
known phenotypes of normal aging and neurodegenerative diseases of aging3. Glycogen
metabolism has been shown or proposed to underly all of these features, which are
exasperated in the glycogen storage disease and childhood dementia LD267. To explore
our hypothesis that aberrant glycogen metabolism impacts TCA cycle cellular respiration
in LD, we first analyzed a longitudinal model of WT aging TCA cycle metabolism of brain,
skeletal muscle, and heart tissues. We then compared the WT aging signature to LKO
and laforin heterozygote aging to define the age dependent influence progressive LB
accumulation on the TCA cycle.
In the brain of WT mice, there is evidence of a consistent time-dependent trend in
metabolite load that increases after 1-month, decreases after 6-months, and increases
again between 9-and 24-months, such that no observable difference is seen between
the metabolite load of 24- and 3-month-olds. These trends are supported by the laforin
heterozygote mice, as no difference is observed between the laforin heterozygote and
WT mice in any tissue. Our WT aging data is consistent with previously published crosssectional analyses on brain, skeletal muscle, and heart indicating that no TCA cycle
dysregulation is seen in old-aged (24-month-old) mice compared to young adult mice (3month-olds)145,146,266. Consistent with our hypothesis, TCA cycle metabolite load is
decreased in LKOs as adults (3-6-months) which correlates with the time frame in which
significant emergence of LBs is seen. Further, by PCA the LKO brain TCA metabolite
variation diverges from WT, increasing in separation from 1 to 6 months of age.
Interestingly, the TCA metabolome divergence is not seen in older ages, instead the
aged-matched WT TCA metabolome signature increasingly overlaps between 9 and 12months of age. One interpretation of this finding is that the aging TCA metabolome may
be shifting with age such that it progressively resembles the TCA signature of LKO mice.
A similar phenomenon was recently reported in an Alzheimer’s mouse model, wherein
the WT brain metabolome begins to overlap with the AD metabolome at 24-months268.
In support of this interpretation is our predicted biomarker analysis in which we found
that a known biomarker of LD, glucosamine sequestration, is also predicted to be
implicated in WT aging16.
Sequestration of glucosamine in PGBs is a recently published LD phenomenon, which
has been shown to create major downstream infarctions to cellular function largely
involving glycosylation16. Thus, considering the well documented aging and glycogen
dependent progressive accumulation of corpora amylacea, glucosamine sequestration
may be a reasonable target of investigation for the downstream neural dysfunctions of
aging19,138. Further, the lesser degree of glucosamine sequestration by corpora amylacea
may explain the lesser degree of neurocognitive and molecular insults in aging
compared to LD. The overlapping brain cellular respiration signatures between the WT
an LKO mouse models in older age may be further explained by the fact that the LKO
mouse model has a less severe disease progression than LD in humans118. The LD mouse
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model lives until old-age, where LD patients typically die just as they reach adulthood in
their early 20’s215,217–219. As no differences at any age are observed between the LKO
and WT genotype in skeletal muscle or heart tissues, these collective findings contribute
to a growing body of data characterizing unique roles for glycogen that are specific to
the brain. These results suggest that LBs and their metabolic consequences are more
detrimental to the CNS than in the skeletal muscle or heart where they also heavily
accumulate, further supporting previous indications that LBs are neurotoxic78,222.
The extent to which glycogen supports brain energy metabolism requires continued
investigation. Glycogen is required for a healthy cognitive functioning and its
accessibility is critical, as demonstrated in LD118. Glycogen-like aggregations and/or
corpora amylacea hyper-accumulation have been documented in other
neurodegenerative diseases e.g., Alzheimer’s disease, amyotrophic lateral sclerosis
(ALS), temporal lobe epilepsy (TLE), Parkinson’s disease, diabetic neuropathy, peripheral
neuropathy, and motor neuron disease19,138. As compromised energy metabolism is a
known underlying factor of neurodegenerative disease and aging, glycogen
dysmetabolism may be an underlying cause in not only LD and aging, but of many other
neurodegenerative diseases not currently classified as glycogen storage disorders. A
similar analysis of the influence of glycogen on these diseases may be modeled by the
present study. Further, flux analysis on TCA cycle metabolites and glucosamine should
be considered in aging, LD, and other dementias where aberrant glycogen-like
aggregates and glycosylation defects have been reported269,270.
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Figure 3.1 Metabolomics workflow.
A) Polar metabolites from brain, skeletal muscle, and heart tissue were extracted and
separated from the tissue pellet containing protein/DNA/RNA. B) (Top) Polar
metabolites from each tissue were derivatized and analyzed by TQMS. C) (Bottom)
protein in the tissue pellet was analyzed by GCMS.
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Figure 3.2 WT brain TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.3 WT versus LKO brain TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.4 WT skeletal muscle TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.5 WT versus LKO skeletal muscle TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.6 WT heart TCA metabolites
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.7 WT versus LKO heart TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.8 WT versus laforin heterozygote brain TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.9 WT versus laforin heterozygote skeletal muscle TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.10 WT versus laforin heterozygote heart TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used.
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Figure 3.11 PCA plots of brain TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized
metabolites were uploaded to MetaboAnalyst and run through principal component
analysis (PCA).
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Figure 3.12 PCA plots of skeletal muscle TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized
metabolites were uploaded to MetaboAnalyst and run through principal component
analysis (PCA).
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Figure 3.13 PCA plots of heart TCA metabolites.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized
metabolites were uploaded to MetaboAnalyst and run through principal component
analysis (PCA).
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Figure 3.14 Biomarkers of LD and aging.
Mass spectra were translated to relative metabolite abundance normalized to protein
input. Statistical analysis using one-way ANOVA comparing each set of age groups or
genotypes was performed using GraphPad Prism9. All data are presented as means ±
S.E. In each ager group, up to 5 biological replicates were used. Protein normalized
metabolites were uploaded to MetaboAnalyst and run through receiver operating
characteristic analysis (ROC).
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Generation and characterization of a laforin nanobody inhibitor
4.1

Introduction

Glycogen is the storage form of glucose and a highly important substrate for cellular
metabolism271. Nearly all tissues metabolize glycogen and recent work has focused on
the importance of glycogen metabolism in the brain14. Characterization of the enzymes
and mechanisms of glycogen metabolism began over 70 years ago and include:
synthesis by glycogen synthase, branching via glycogen branching enzyme, hydrolysis by
glycogen phosphorylase, and debranching via glycogen debranching enzyme13. Over the
last 20 years, a previously unknown protein called laforin has emerged as an important
contributor to glycogen metabolism homeostasis.
Multiple labs demonstrated that laforin is a glycogen phosphatase and mutations in
the gene encoding laforin cause the formation of aberrant glycogen-like aggregates
called Lafora bodies (LBs)86,89,272. LBs are cytoplasmic, water-insoluble aggregates more
similar to plant starch than human glycogen20,103,104,273. The LBs form in cells from nearly
all tissues and are the pathological agent driving neurodegeneration and death in Lafora
disease (LD) patients25–28. LD is autosomal recessive and classified as both a progressive
myoclonus epilepsy and glycogen storage disease. The direct relationship between
mutated laforin, LB formation, and LB neurotoxicity highlights the importance of
glycogen metabolism in the brain. While laforin removes phosphate from glycogen, how
phosphate impacts normal glycogen homeostasis or how hyper-phosphorylation is
detrimental to glycogen homeostasis and LB formation remains under investigation.
Based on sequence and structural conservation, laforin is classified in the protein
tyrosine phosphatase superfamily and the dual specificity phosphatase clade274. Laforin
is the only known human glycogen phosphatase and is comprised of a dual-specificity
phosphatase (DSP) domain and a carbohydrate binding module (CBM). Like all DSPs,
laforin contains a protein-tyrosine phosphatase catalytic loop that includes a CX5R motif
(CNAGVGR, residues 266–272) at the base of the active site115. The architecture and
depth of this active site allow laforin to dephosphorylate glycogen274–276. The laforin
CBM belongs to CBM family 20 and allows laforin to bind glycogen as well as other
complex carbohydrates in vitro and in vivo, like LBs, amylopectin, and
maltodextrins20,222,276. Key structural aspects of laforin that promote glucan-specific
phosphatase activity are: closely integrated CBM-DSP domains, an anti-parallel
dimerization, and a signature DSP sequence within the active site channel274.
In addition to being a glycogen phosphatase, laforin interacts with several proteins
involved in glycogen metabolism, including the E3 ubiquitin ligase malin84.
Approximately 50% of LD patients have mutations in the gene encoding malin and ~50%
have mutations in the gene encoding laforin. Malin polyubiquitinates a number of
proteins involved in glycogen metabolism, including both laforin and glycogen
phosphorylase84,114,277. The consequences of malin-directed ubiquitination are still being
elucidated. LD mouse models with a mutation in either gene form hyperphosphorylated
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LBs and display neurodegeneration88,89. However, the relationship between
phosphorylation and LD progression remains an unresolved and critical issue78,107,278.
Recombinant antigen-specific, single-domain antibodies, often referred to as
nanobodies (Nb), are increasingly used for modulating protein properties for the
purpose of elucidating function279. While canonical antibodies are comprised of two
heavy chains and two light chains, nanobodies are derived from the antigen binding
domain of heavy-chain antibodies, produced in camelids and select other organisms.
Thus, nanobodies are monomers with a dedicated variable domain, also referred to as
VHH, and are ten times smaller than a canonical IgG, i.e. ~15 kDa. Their small size
promotes their high propensity for binding unique structural features of proteins,
otherwise unreachable by conventional immunoglobulins and capable of manipulating
protein conformation linked to function279–281. Nanobodies contain three
complementary determining regions (CDRs) that are primary determinants of specific
antigen binding. Similar affinities between VHHs and conventional antibodies are
generally attributed to elongated CDR3 loops in VHH domains, which provide a paratope
formed by a single entity282.
In this study, we present the characterization of six laforin nanobodies, consisting of
five unique CDR3 regions. Two llamas were immunized with recombinant human laforin,
74 potential VHH anti-laforin candidates were screened, and six stably binding antilaforin nanobodies were characterized. Epitope mapping of the six laforin nanobodies
established three general epitopes, one that spans both the CBM and DSP on the
opposite side of the DSP active site, one that lies on the CBM, partially covering regions
that bind glycogen, and one that covers the DSP active site. Secondary structure epitope
mapping established that nanobody Nb72 binds the PTP-loop of the laforin DSP domain.
Utilizing three in vitro assays, we demonstrate that Nb72 inhibits the phosphatase
activity of laforin. These laforin nanobodies are a novel set of molecular tools for
defining the role of laforin in glycogen metabolism and disease.
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4.2

Methods

4.2.1 VHH library generation
4.2.1.1 Purification of Laforin
H. sapiens (Hs) Laforin residues 1-328 was expressed from pET28b (Novagen) as an
N-terminal His6 tagged protein, as previously described283. Briefly, laforin was expressed
in BL21 (DE3) (Novagen) E. coli cells grown in 2xYT media at 37oC until OD600 = 0.6,
culture flasks were placed on ice for 20 min, induced with 1 mM (final) isopropyl thio-β D-galactopyranoside (IPTG), grown for an additional 14h at 20oC, and harvested by
centrifugation. Cells were resuspended and lysed in buffer A (20 mM Tris-HCl, 100 mM
NaCl, 10% glycerol, 2 mM DTT, pH 7.5), centrifuged, and the proteins were purified
using a Profinia immobilized metal affinity chromatography (IMAC) column with Ni2+
beads (Bio-Rad) and a Profinia protein purification system (Bio-Rad) using wash (buffer
A) and elution buffer (300mM imidazole, 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2
mM DTT, pH 7.5). The desalted elution fraction was further purified using fast protein
liquid chromatography (FPLC) with a HiLoad 16/60 Superdex 200 size exclusion column
(GE Healthcare). The buffer used for laforin purification for the small-scale pulldowns
described in methods 2.3.2 was (50 mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT,
pH 7.5. For all other experiments, laforin was purified in 20 mM Tris-HCl, 100 mM NaCl,
10% glycerol, 2 mM DTT, pH 7.5.
4.2.1.2 Immunizations
Inoculation, construction of the VHH libraries, panning, and cloning was performed
by the VIB Nanobody Core (Vrije Universiteit Brussel, Brussels). Two llamas were
subcutaneously injected on days 0, 7, 14, 21, 28 and 35 with 250 g/animal of
recombinant laforin emulsified with Gerbu adjuvant P. On day 40, anticoagulated blood
was collected for lymphocyte preparation.

4.2.1.3 Construction of the VHH libraries
A VHH library was constructed from each llama to screen for the presence of laforin
specific nanobodies. First strand cDNA synthesis was achieved using an oligo(dT) primer
and total RNA from peripheral blood lymphocytes as a template. The VHH encoding
cDNA sequences were amplified by PCR, digested with PstI and NotI, and cloned into the
PstI and NotI sites of the phagemid vector pMECS.
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4.2.2 Isolation of laforin specific nanobodies
Each library was panned individually for three rounds on solid-phase coated antigen
(200 µg/mL in 100 mM NaHCO3, pH 9.3). After each round of panning, the enrichment
for laforin-specific phages was assessed by comparing the number of phagemid particles
eluted from antigen-coated wells with the number of phagemid particles eluted from
negative control (uncoated blocked) wells. In total, 950 colonies (475 colonies for each
library: 95 from panning round one, 285 from round two, and 95 from round three)
were randomly selected and analyzed by ELISA for the presence of laforin specific
nanobodies in their periplasmic extracts. The antigen used for panning and ELISA
screening was the same as the one used for immunization, using uncoated blocked wells
as negative control. Out of these 950 colonies, 138 colonies scored positive in this assay.
Based on sequence data of the positive colonies, 74 different full-length nanobody
candidates were distinguished based on complementary determining regions.

4.2.3 Sequence verification, alignment, and evolutionary analysis
Nanobody sequences were verified using the primer: 5’ TTA TGC TTC CGG CTC GTA
TG 3’ and the six direct laforin binding nanobody plasmids will be deposited to
https://www.addgene.org/. All sequence alignments were performed using ClustalOmega available on the European Bioinformatics Institute’s
server(http://www.ebi.ac.uk/.)The evolutionary tree was calculated from the alignment
using neighbor-joining clustering implemented in the Clustal-Omega package284. The
guide tree was displayed with the program iTOL (http://itol.embl.de/)285.

4.2.4 Screening for VHH expression
74 potential VHH candidates were transformed into BL21 (DE3) E. coli cells
(MilliporeSigma) and expression levels were analyzed by Western analysis. Nanobodies
were expressed from pMECS as a C-terminal HA and His6 fusion in 10 mL cultures grown
in 2xYT until OD600 = 0.6. 100 µL of each culture was aliquoted, centrifuged, air dried,
and stored at -20oC while protein expression was induced in the remaining cultures
using 1 mM IPTG (final concentration). Induced cultures grew for 3.5h, 80 µL of the
induced cultures were pelleted, air dried and stored at -20oC. The 100 µL uninduced and
80 µL induced culture pellets were lysed with 75 µL of 50 mM TRIS, 8M urea by
vortexing. Total proteins from the bacteria culture lysate were resolved by stain-free gel
SDS-PAGE (Bio-Rad). Nanobody expression was visualized by Western analysis using an
anti-6xHis antibody (1:1000) (NeuroMab #75-169) and goat anti-mouse secondary
(1:3000) (Invitrogen #62-6520).
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4.2.5 Small scale pulldowns
4.2.5.1 Small scale nanobody purification
Nanobodies screened for expression were purified using the remaining 9.82 mL of
induced culture, which was pelleted and frozen at -20oC. Nanobodies were purified from
the E. coli pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to separate
soluble protein which was incubated with Ni-NTA agarose beads for 1 h at 4oC in 1 mL
bind buffer (20 mM Tris-HCL, 100 mM NaCl, 15 mM Imidazole, pH 8.0). The samples
were washed three times in bind buffer and eluted in 100 µL of 300 mM imidazole, 100
mM NaCl, pH 8.0 and used for small scale pulldowns.

4.2.5.2 Antigen affinity pulldown
Primary screening for nanobody binding was achieved by a small-scale pulldown
method in which Affi-gel 10 affinity resin (Bio-Rad) was bound to laforin and
subsequently to each purified VHH clone286. Expression and purification of laforin was
performed as described above in 50 mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT,
pH 7.5. 50 µL Affi-gel (100 µL slurry) per pulldown was washed and resuspended in cold
PBS per manufacturer’s directions. The washed Affi-gel was saturated with laforin in 50
mM HEPES, 100 mM NaCl, 10% glycerol, 2 mM DTT, (final volume 500 µL) and incubated
with rocking for 1 h at 4o C. The laforin bound Affi-gel resin was spun down at 300 rpm
for 2 min and washed with cold PBS two times. Affi-gel alone was used as a control.
Then, the laforin bound or unbound Affi-gel was blocked with cold 1X TBS for 1 h at 4oC.
The samples were spun down, supernatant was removed, and 75 µL (~4-12 µg) of small
batch Ni2+ purified nanobodies were added. Pulldowns were washed three times with
1X PBS, and the supernatant was removed. Bound proteins were denatured in
Laemmli’s buffer, and ~12 µL of each sample was loaded per well of a stain free SDSPAGE gel and imaged.

4.2.6 Nanobody purification
Larger concentrations of purified nanobodies were achieved by scaling up methods
described in 2.2 and 2.3.1. Nanobodies were expressed in BL21 (DE3) E. coli cells grown
in 2xYT at 37oC to OD600 = 0.9. 15 mL of pre-culture was used per L culture. Cultures
were induced with 1 mM IPTG (final) and incubated for ~16-18 h at 25oC after which,
pellets were harvested by centrifugation. Nanobodies were purified from the E. coli
pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to separate soluble protein
which was incubated with Ni-NTA agarose beads for 1 h at 4oC in 30 mL bind buffer (20
mM Tris-HCL, 100 mM NaCl, 15 mM Imidazole, pH 8.0). The samples were washed three
times in bind buffer and eluted in 300 mM imidazole, 100 mM NaCl, pH 8.0. Eluted
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samples were separated from the Ni-NTA beads by filtering through a 25 mM syringe
filter and then buffer exchanged with 20 mM Tris-Hcl pH 7.5, 100 mM NaCl using FPLC
with a HiLoad 16/60 Superdex 75 column (GE Healthcare).

4.2.7 Size exclusion analysis of VHH-laforin complexes
Laforin and VHH were combined in molar ratio (1:1.1) and resolved by size
exclusion chromatography (SEC) using a HiLoad 10/300 Superdex 200 size exclusion
column and 100 mM NaCl, 20 mM Tris, 10% glycerol, 0.35 mM β-mercaptoethanol
(BME), pH 7.5. WT laforin alone was utilized as a control. Fractions were collected in 500
µL volumes and visualized by loading 20 µL of each fraction onto a stain-free gel SDSPAGE (Bio-Rad) and imaged.

4.2.8 Hydrogen Deuterium Exchange Mass Spectrometry (HDX)
HDX experiments were performed as previously described276,287. The optimal
peptide coverage map of laforin was obtained using a quench solution containing 0.08
M GuHCl, 0.1 M Glycine, 16.6% glycerol, pH 2.4. To initiate HDX experiments, 3 µL of
stock solution (laforin or laforin-nanobody complex at 1 mg/mL) was mixed with 9 µL of
D2O buffer (8.3 mM Tris, 50 mM NaCl, pDREAD 7.2) and incubated at 0oC for 10, 100, 1000
and 10,000 sec. The exchange reaction was quenched by adding 18 µL of the above
quench solution, and the quenched samples were flash frozen with dry ice. All frozen
samples, including un-deuterated and equilibrium-deuterated control samples, were
passed over an immobilized pepsin column (16 µL) at a flow rate of 25 µL/min and
digested peptides were collected on a C18 trap column (Optimize Tech, Opti-trap, 0.2x2
mm) for desalting. The peptide separation was performed on a C18 reverse phase
column (Agilent, Poroshell 120, 0.3x35 mm, 2.7 µL) with a linear gradient of 8-48% B
over 30 min (A: 0.05% TFA in H2O; B: 80% acetonitrile, 0.01% TFA, and 20% (H2O)). Mass
spectrometry (MS) analysis was performed on the Orbitrap Elite mass spectrometer
(Thermo Fisher Sci), which was adjusted for HDX experiments288. The resolution of the
instrument was set at 120,000 at m/z 400. Proteome Discoverer software (v1.3, Thermo
Scientific) was used to identify the sequence of the digested peptide ions from their
MS/MS data. HDXaminer (Sierra Analytics, Modesto, CA) was utilized to confirm the
peptide identification and calculate the centroids of isotopic envelopes of all the
peptides. The level of deuterium incorporation of each peptide was calculated by
applying back-exchange correction289. The ribbon maps were generated from
deuteration level of overlapping peptides to improve the resolution of the HDX data.
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4.2.9 Phosphatase assays
4.2.9.1 Para-Nitrophenyl Phosphate (pNPP) assay
Generic phosphatase activity assays were performed using para-Nitrophenyl
Phosphate (pNPP) as previously described86,290. Assays were performed using 96 well
plates in 50 µL reactions containing 1X phosphatase buffer (0.1 M sodium acetate, 0.05
M Bis-Tris, 0.05 M Tris-HCl, pH 5.0), 2 mM dithiothreitol (DTT), and 50 mM pNPP. To
maintain reactions in the linear phase, 250, 500, or 1000 ng of laforin pre-bound to an
equal molar quantity of nanobody were added to the reaction in triplicates and
incubated in a 37˚C water bath for 10 minutes. The reaction was terminated by the
addition of 200 µL of 0.25 M NaOH and absorbance was measured at 410 nm.

4.2.9.2 Glucan dephosphorylation assays
Glucan phosphatase activity assays were performed as previously described86,290.
Assays were performed using 96 well plates in 100 µL reactions containing 1X
phosphatase buffer (100 mM sodium acetate, 50 mM bis-Tris, 50 mM Tris-HCl, pH 7.0)
and 2 mM DTT, and 10mg/mL rabbit skeletal muscle glycogen or 1 mg/mL potato
amylopectin (MilliporeSigma). To maintain enzymatic activity in the linear phase, every
10 seconds, 250, 500, or 1000 ng of laforin pre-bound to an equal molar quantity of
nanobody were added to the reaction mixture in quadruplicates and incubated for 30
min at RT. The reaction was stopped by the addition of 25 µL of malachite gold reagent
mix added every 10 sec. Once each well was given the malachite gold reagent mix,
stabilizer was added to each well in intervals of 10 seconds. Absorbance was measured
at 635 nm.

4.2.9.3 Statistical analysis
Two-way ANOVA was performed using GraphPad Prism version 9.0.0 for Mac,
GraphPad Software, San Diego, California USA, www.graphpad.com
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4.3

Results

4.3.1 Anti-laforin nanobody primary screen
Two llamas were immunized with purified recombinant human laforin. Lymphocytes
were isolated, and the VHH coding sequences were cloned into a phagemid vector. After
three rounds of panning and ELISA screens using recombinant laforin protein, a total of
74 clones scored positive and were sequenced, revealing 37 different CDR3 groups
(Figure 4.6). A sequence similarity tree reveals the presence of two nanobody groups in
which 35 clones are found in one and 39 are found in the other (Figure 4.1). All 74
clones were transformed into BL21 E. coli cells and VHH expression was determined by
western analysis using an anti-HIS antibody. Approximately 50% of the clones were
eliminated due to lack of expression in BL21 cells (data not shown). The expressing
clones were each purified on a small scale and screened for their capacity to bind laforin
by a pulldown method using affinity resin.
To identify nanobodies that form a stable complex with laforin, the ability of purified
nanobodies to be precipitated by laforin affinity resin was assessed. Laforin coupled
resin was incubated individually with each of the purified VHH clones, the resin was
washed, and bound proteins were eluted and analyzed by SDS-PAGE. This primary
screen identified six clones as having direct antigen binding (Figure 4.2A).
The six identified anti-laforin nanobodies are: Nb40, Nb41, Nb50, Nb57, Nb72, and
Nb73. Based on phylogenetic analysis and sequence alignment (Figures 4.1 and Figure
4.2B), the six identified nanobodies that bind laforin exhibit sequence diversity and
contain five different CDR3 regions. Complete DNA sequences of the six laforin
nanobodies are provided in Table 4.1.
4.3.2 Size-exclusion analysis of anti-laforin nanobodies complexed to laforin
Size-exclusion chromatography (SEC) was utilized to detect and characterize the
laforin-nanobody complexes. Each nanobody was incubated with laforin in ~10% molar
excess, samples were subjected to SEC, fractions were collected, and analyzed by SDSPAGE (Figure 4.3). The laforin-nanobody complexes eluted between 12.11-14.51 mL,
laforin alone eluted at 15.40 mL, and the nanobodies alone eluted between 18.08-19.53
mL. All six laforin-nanobody complexes eluted prior to laforin or the nanobody alone,
indicating a higher molecular weight and supporting the results of the primary screen.
Similarly, SDS-PAGE analyses of the fractions demonstrate co-elution of the laforinnanobody complexes. Nb40 and Nb73 complexed with laforin eluted earlier than others
(Figure 4.3). These supershifted complexes may indicate an increase in nanobody to
laforin stoichiometry. Alternatively, Nb40 and Nb73 may interfere with the laforin CBM
binding to the carbohydrate-based resin. Laforin CBM mutations have been shown to
interrupt this interaction and change the elution time291.
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4.3.3 Nanobody epitope mapping via Hydrogen-Deuterium Exchange Mass
Spectrometry (HDX)
Epitope mapping can be accomplished using hydrogen-deuterium exchange (HDX)
mass spectrometry. HDX quantifies protein surfaces that are solvent accessible. When a
nanobody binds a protein, the surface of the protein becomes less solvent accessible.
This decrease in solvent accessibility can be quantified by HDX.
Each laforin-nanobody complex and laforin alone were incubated in deuterated
buffer for 10, 100, 1,000, and 10,000 seconds (Figures 4.4 and 4.7). A decrease in laforin
deuteration (≥15% decrease in deuteration compared to WT) emerged with Nb40 and
Nb41 (Figures 4.4A and 4.7A), Nb50 and Nb57 (Figures 4.4B and 4.7B), and Nb72 and
Nb73 (Figures 4.4C and 4.7C). Nb40 and Nb41 differ by only one amino acid within
CDR2, with an alanine in Nb40 replaced with a valine in Nb41. Given this high degree of
sequence similarity, their shared epitope was expected. Their epitope partially maps
across the CBM (residues 60-66, 120-124, and 126-129) with the majority spanning
across the recognition domain of the DSP (residues 139-145, 148-161, 163-169, and 171186). The epitope of Nb41 extends further on the DSP (residues 193-197). Sequence
homology between Nb40 and Nb41 is 99.2% (Figure 4.8). Nb50 and Nb57 share a similar
epitope that encompasses most of the CBM (residues 30-33, 35-41, 43-52, 60-66, 120124) and partially across the DSP (residues 287-291). Nb57 extends further on the CBM
(residues 43-56, 58-66, and 126-129). Sequence homology between Nb50 and Nb57 is
66.2% (Figure 4.8). Nb50 and Nb57 share a partial CBM epitope with Nb40 and Nb41.
The DSP epitope of Nb40 and Nb41 partially overlaps with Nb72 and Nb73. The epitopes
of Nb72 and Nb73 are mapped solely on the DSP and overlap with the recognition
domain (residues 139-145, 148-155, 193-197, 236-242). Importantly, Nb72 includes the
PTP-loop (residues 267-275). Intriguingly, the sequence homology between Nb72 and
Nb73 is 70.6% and no sequence homology exists between their CDR3 regions (Figure
4.8).
These results indicate that three general binding regions exist among the six laforin
nanobodies. Nb40 and Nb41 span both the CBM and DSP on the opposite side of the
DSP active site (Figures 4.4D and 4.7D). Nb50 and Nb57 span the CBM, partially covering
regions that bind glycogen (Figures 4.4E and 4.7E). Nb72 and Nb73 bind a region near
the DSP active site and Nb72, but not Nb73, overlaps with the PTP-loop (Figures 4.4F
and 4.7F).
4.3.4 Nb72 inhibits the general phosphatase activity of laforin
Given the binding site of Nb72, we predicted that this nanobody would decrease or
inhibit the phosphatase activity of laforin. To assess laforin’s general phosphatase
activity, we utilized the phosphatase substrate para-nitrophenyl phosphate (pNPP).
Protein tyrosine phosphatases, including laforin, can convert pNPP to para-nitrophenyl
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(pNP) that results in a colorimetric change that can be quantified at OD410. Three
concentrations of recombinant laforin were incubated with a respective and ~1:1 molar
ratio of nanobody Nb72 or Nb23, a nanobody that did not co-precipitate with laforin
(Figure 4.2A) As controls, recombinant laforin was also pre-incubated in buffer lacking a
nanobody, and nanobodies were tested in the absence of laforin. The pNPP substrate
was added to each combination using previously defined optimal conditions, reactions
were quenched with sodium hydroxide, and dephosphorylation levels were quantified
at OD410. Laforin incubated with Nb23 yielded similar levels of pNPP dephosphorylation
as laforin alone, indicating that Nb23 did not inhibit laforin phosphatase activity (Figure
4.5A). Conversely, laforin incubated with Nb72 displayed a dramatic 85% reduction in
pNPP phosphatase activity (Figure 4.5A).
4.3.5 Nb72 inhibits the glycogen phosphatase activity of laforin
The small molecule pNPP is a readout for general phosphatase activity. However,
pNPP can integrate into the DSP active site independent of the laforin CBM to be
converted into pNP. In cells, laforin binds glycogen via its CBM and engages the
phospho-glucose substrate with its DSP active site to dephosphorylate the substrate.
Therefore, we sought to determine if Nb72 binding to laforin inhibits its specific glucan
phosphatase activity.
Glycogen dephosphorylation can be assessed by quantifying phosphate release using
a malachite gold colorimetric assay. Three concentrations of recombinant laforin were
incubated with nanobody Nb72 or the negative control nanobody Nb23 in a respective
and ~1:1 molar ratio. As a control, recombinant laforin was also pre-incubated in buffer
lacking a nanobody. Then, rabbit skeletal muscle glycogen was added as the substrate
using previously defined optimal conditions. Reactions were incubated at 20˚ C for 30
min and then quenched with the phosphatase inhibitor N-ethylmaleimide. Malachite
gold solutions were added, and dephosphorylation levels were quantified at OD635.
Laforin incubated with Nb72 yielded a dramatic 95% reduction in laforin’s glycogen
phosphatase activity while Nb23 did not reduce the activity (Figure 4.5B). No other
nanobody showed a robust inhibitory effect on laforin’s phosphatase activity towards
amylopectin (Figure 4.9).
Laforin’s endogenous substrate is glycogen86,272,292. However, laforin has a higher
binding affinity for LBs222,293. While glycogen is water-soluble, the glucose chains of LBs
are longer and predicted to form helical structures making LBs more waterinsoluble20,104,273. Plant amylopectin is also a water-insoluble glucan that has covalently
attached phosphate and has been utilized as a LB proxy20,86,292,294. Therefore, we
performed a similar assay as above utilizing malachite gold, laforin, and the nanobodies
with amylopectin as the substrate. Overall, laforin released ~10-fold more phosphate
from amylopectin than glycogen, which is as expected given the higher level of
phosphate in amylopectin105,295. Nb72 was observed to significantly inhibit laforin
phosphatase activity by 55% against amylopectin (Figure 4.5C). These data further
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strengthen a growing body of results suggesting that laforin has a higher degree of
binding and/or activity towards insoluble substrates.
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4.4

Discussion

The glycogen phosphatase laforin is critical for brain glycogen metabolism.
Mutations in the laforin gene promote the formation of cytoplasmic, insoluble glycogenlike aggregates that are the pathological agent of LD46,49,118,272 . The mechanism by
which laforin influences the solubility of glycogen is still unknown, and progress in this
discovery could be accelerated with additional tools. The current study showcases the
generation of six laforin nanobodies, mapping of the nanobody epitopes by HDX, and
three in vitro assays demonstrating that nanobody Nb72 inhibits laforin’s phosphatase
activity.
HDX nanobody epitope mapping revealed that one nanobody, Nb72, decreased
deuterium exchange within the laforin PTP-loop, implying that Nb72 could inhibit the
laforin phosphatase activity. Three in vitro phosphatase activity assays established that
binding Nb72 to laforin markedly reduces the phosphatase activity of laforin. The first
assay employed a non-specific substrate, para-nitrophenyl phosphate (pNPP), to assess
the inhibitory activity of Nb72. The pNPP assay quantifies laforin phosphatase activity
independent of glycogen binding. Nb72 decreased laforin phosphatase activity by 85%.
Using more biologically relevant substrates, we discovered that Nb72 diminishes laforin
phosphatase activity against skeletal muscle glycogen by 95%, and amylopectin by 55%.
Thus, Nb72 is more effective at inhibiting laforin’s phosphatase activity directed towards
glycogen. These data are consistent with published reports demonstrating that laforin
preferentially binds more water-insoluble substrates like amylopectin and LBs222,296. The
reason for this preference has been proposed to be that the CBM domain has an
enhanced contribution to phosphatase activity as the carbohydrate increases in
complexity and/or insolubility294. Laforin is dramatically stabilized in the presence of a
longer chain length oligosaccharide compared to a shorter chain length oligosaccharide.
Further, the presence of the longer chain length oligosaccharide promotes cooperativity
in binding between the dimers of laforin that is not observed with a shorter chain length
sugar substrate276. These data are further supported by our findings that more
phosphate is released from amylopectin than glycogen in the presence of laforin. The
~10-fold difference in phosphate release can be accounted for by the ~10-fold
difference in total phosphate contained in amylopectin versus glycogen. Glycogen
contains 1 phosphate per 1,000-10,000 glucose residues and amylopectin contains 1
phosphate per ~300 glucose residues89,106,258,294,297,298.
Nanobodies are a rapidly growing technology that are being utilized in novel ways to
refine a wide variety of traditional techniques such as crystallization chaperoning,
affinity purification, immunoprecipitation, super-resolution microscopy, confocal
microscopy, flow cytometry, cell delivery, radiolabeling, and modulating protein
function and interactions in cells299,300. An immediate opportunity to utilize the laforin
nanobodies is with respect to modulating laforin’s phosphatase activity, glycogen
binding, and interactions. Nb72 clearly inhibits the glycogen phosphatase activity of
laforin in vitro. Nb50 and Nb57, CBM-binding nanobodies, may modulate laforin’s
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catalytic activity (Figure 4.9) by altering carbohydrate binding in cell culture. These
nanobodies could be expressed in cells as intrabodies to probe the relationship between
glycogen phosphate with glycogen metabolism, central carbon metabolism, and
metabolic signaling events without imposing structural mutations to laforin.
Another opportunity to use the laforin nanobodies is protein crystallography. The
only full-length laforin structure to date is the catalytically inactive human LaforinC266S276. While this structure has provided key insights, as described above, a structure
of the wildtype and patient mutations is needed to fully define the catalytic cycle and
resolve why laforin mutations cause LD. This work has been hampered due to the
extensive conformational dynamics of laforin. Crystallizing laforin with the nanobodies
could permit capturing additional conformational states299 that are important for its
biological function. Additional panning of the nanobody library using either laforin
mutants with distinct conformational states or laforin bound to substrate or partner
protein could allow identification of additional unique conformation-specific
nanobodies.
Multiple groups have demonstrated that laforin and malin physically interact and
form a complex301. Additionally, the in vivo function of laforin likely includes a
sophisticated scaffolding and/or signaling role because multiple studies have found that
laforin interacts with several glycogen metabolism related proteins86,116,117. In fact, many
laforin protein interactions are both involved in glycogen metabolism and are putative
substrates of malin, including the protein phosphatase 1 regulatory subunits GL, R5 and
R6/PTG; glycogen synthase, the pyruvate kinase isoforms PKM1 and PKM2; and AMPactivated protein kinase  subunits49,111,301,302. Due to these interactions, the laforinmalin complex has been suggested to participate in protein degradation, oxidative
stress, and the unfolded protein response117. Therefore, LD pathology could arise from
mutations that affect the specific activity of laforin and/or malin, and also from
mutations that impair the interaction of both proteins to form a complex.
Moreover, laforin has potentially pleiotropic roles associated with dynamic cellular
localization changes303,304. Laforin has been shown to translocate to the nucleus under
nutrient or heat stress and can return to the cytoplasm once the stress conditions
cease50. Interestingly, malin has recently been shown to ubiquitinate glycogen
phosphorylase and translocate it to the nucleus thereby promoting nuclear glycogen
catabolism. The released glucose 1-phosphate is utilized for histone acetylation to
regulate transcriptional profiles114. Therefore, the nuclear localization of malin and,
under certain conditions, of laforin suggests a regulatory function of both proteins in the
nucleus. Furthermore, a natural mutation in laforin causes it to lose ER localization303.
Fluorescent nanobody fusions, sometimes called chromobodies, are useful markers to
track and visualize dynamic changes without disturbing other cellular functions279,305–307.
To date, most assays detecting laforin localization have probed for a tagged version of
laforin that is often over-expressed50. Anti-laforin nanobodies as intrabodies and/or
chromobodies could be useful tools for defining both laforin dynamic localization and
physical interactions. Overall, these nanobodies represent an important set of tools that
will open new avenues to illuminate the mechanism of laforin’s role in normal glycogen
metabolism and LD.
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Figure 4.1 Anti-laforin nanobody guide tree.
A binary tree was generated from a sequence alignment and subsequent tree
generation of the 74 generated laforin nanobody clones using Clustal-Omega.
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Figure 4.2 Direct antigen binding nanobodies and comparison of their sequences.
(A) Primary screening for nanobody binding was achieved by incubating laforin with
affinity resin, washing the resin, blocking the resin with TBS, incubating the laforin
bound affinity resin with a nanobody, and washing the resin before the laforinnanobody complex was eluted. Free (wash) and bead bound laforin and/or nanobody
was loaded onto an SDS-PAGE stain-free gel and imaged (top). As a control, affinity resin
without bound laforin was blocked and then incubated with nanobody (bottom). (B)
Sequence alignment of nanobodies in A. Sequence homology is 55.9% identical.
Complementary determining regions are highlighted in red and framework regions are
highlighted in gray (Kabat).
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Figure 4.3 Size-exclusion (SEC) analysis of anti-laforin nanobodies complexed to
laforin.
For each SEC analysis of the laforin-nanobody complex, the respective fractions are
visualized by an SDS-PAGE stain-free gel shown to the right. A-F) SEC analysis of the
laforin dimer alone is shown in black (15.4mL). A) Nb40 (18.45mL) complexed to laforin
in light teal (12.65mL). B) Nb41 (18.58mL) complexed to laforin in dark teal
(14.51mL). C) Nb50 (18.08mL) complexed to laforin in light orange (14.28mL). D) Nb57
(18.19mL) complexed to laforin in dark orange (14.3mL). E) Nb72 (18.89mL) complexed
to laforin in light green (14.12mL). F) Nb73 (19.53mL) complexed to laforin in dark green
(12.11mL).
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Figure 4.4 HDX analysis of anti-laforin nanobody binding of Nb41, Nb57, and Nb72.
Fractions of each nanobody bound to laforin (Figure 4.3) were analyzed by hydrogen
deuterium exchange mass-spectrometry (HDX) and the deuteration level was compared
to laforin alone. The percent difference in deuteration between the nanobody complex
versus laforin alone is represented with a negative percent change in blue to a positive
percent change in red. Each colored bar below the primary sequence represents percent
change in deuteration at one of four time points. Secondary structure elements are
depicted above the primary sequence with the CBM and DSP motifs labeled. Regions
where the nanobody caused a ≥15% change in deuteration are highlighted with a
colored line. A) The Nb41 epitope on laforin spans β3, β7 and β8 sheets, ⍺4, ⍺5, and
partially ⍺6 helices. Highlighted with a dark teal line. B) The Nb57 epitope on laforin
includes the β3 sheet and partially covers the ⍺10 helix. Highlighted with a dark orange
line. C) The Nb72 epitope on laforin covers the ⍺4 helix, and partially spans the ⍺6, ⍺8,
and ⍺9 helices. Highlighted with a light green line. D-F) The identified epitope for each
nanobody was modeled onto the surface map of the laforin structure (PDB: 4RKK). Nb41
(dark teal), Nb57 (dark orange), and Nb72 (light green) respectively mapped on laforin.
The CBM and DSP of laforin are colored dark gray and light gray respectively.
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Figure 4.5 Laforin activity in the presence of Nb72.
A) The specific activity of laforin against pNPP in the presence and absence of
nanobodies. B) The specific activity of laforin against rabbit skeletal muscle glycogen in
the presence and absence of nanobodies. C) The specific activity of laforin against
potato amylopectin in the presence and absence of nanobodies. Each bar is the mean
±SEM of 4 replicates. * p < 0.0301, *** p = 0.0007, **** p < 0.0001.

124

Table 4.1 DNA sequences of the six laforin binding nanobodies.

Nb40

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGT
CTCTGGAAGCATCGTCAGTACGAATACTATGAGCTGGTACCGCCAGGCTCCAGGGAAACAGCGCGAGTTGG
TCGCACTTATTTCGCCTGGTGGTAGGACAGACTATGCAGACTCCGCGAAGGGCCGATTCACCATCTCCAGA
GACAACACCAAGAACACGATTTATCTCCAAATGAACAGCCTGAAGCCTGAGGACACGGCCGTCTATTACTG
TAATACTAATCCTAACGGCTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCATACCCGT
ACGACGTTCCGGACTACGGTTCCCACCACCATCACCATCACTAG

Nb41

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGTTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGT
CTCTGGAAGCATCGTCAGTACGAATACTATGAGCTGGTACCGCCAGGCTCCAGGGAAACAGCGCGAGTTGG
TCGCACTTATTTCGCCTGGTGGTAGGACAGATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGA
GACAACACCAAGAACACGATTTATCTCCAAATGAACAGCCTGAAGCCTGAGGACACGGCCGTCTATTACTG
TAATACTAATCCTAACGGCTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCATACCCGT
ACGACGTTCCGGACTACGGTTCCCACCACCATCACCATCACTAG

Nb50

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGCGCAGGGTGGGGACTCTCTGAGACTCTCCTGTGCAGC
CTCTGGACGCACCTTAAGTACGTATGTCATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGTGAATTTG
TAGCAGCTATTGACTGGAGTGATAGCACATATTATGCAGACTCCGTGGCGGGCCGATTCAGCATCTCCAGG
GACAACGCCAAGAACACGGTGGATCTGCAAATGAACAGCCTGAAACCTGGGGACACGGCCGTTTATGTCTG
TGCAGCAGCTTTAGGGTCTGTACTAACGAAGAATCAAGCCCTGTATTACTACTGGGGCCAAGGGACCCAGG
TCACCGTCTCCTCAGCGGCCGCATACCCGTACGACGTTCCGGACTACGGTTCCCACCACCATCACCATCAC
TAG

Nb57

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGGCTGGGGGGTCTCTAGGACTCTCCTGTGCAGG
CTCTAACGTACTCTTCAGTCGCTTTACCACGGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAATTGG
TCTCAACGATTACTCGTGCGGGTAGTATAACGTATGCAGACTCCGTGAAGAGCCGATTCACCATCTCACGA
GACAGCGCCAAGAACACGATTTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTCTATTACTG
TAATGTGGATATATTAGGCCGGAACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCAT
ACCCGTACGACGTTCCGGACTACGGTTCCCACCACCATCACCATCACTAG

Nb72

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTTTGAGACTTTCCTGTGCAGC
CTCTGGAAATATCTTCAGTATCAATGCCATGGCCTGGTACCGACAGGCTCCAGGGAAACTGCGCGAGTATG
TCGCACATATTTCTAGTGATAACACAAACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAAAC
AACGTCGGGAATATGGCGTATCTGCAAATGAACAGCCTGAAACCTGAAGACACAGCCGTCTATTATTGTAC
ATCTGTCGCAACCTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCATACCCGTACGACGTTC
CGGACTACGGTTCCCACCACCATCACCATCACTAG

Nb73

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGACTCTCTAAGAGTTTCCTGTGGAGC
CTCTGGACGCACCTTCAGTAAATATGCTTGGTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTTGCAG
CTATTTACTGGAGTGGTGCTATTACGAACTATGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAAAGAC
AACGCCAAGAACACGGTGTATCTGCAGATGAACAGCCTGAAACCTGAGGACACGGCCGTTTATTACTGTGC
AGCCGGCCGATACTATGGTAGTGCTACCTTCGCGGATGCATATGACTATTGGGGCCAGGGGACCCAGGTCA
CCGTCTCCTCAGCGGCCGCATACCCGTACGACGTTCCGGACTACGGTTCCCACCACCATCACCATCACTAG
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Figure 4.6 Nanobody sequence alignment.
37 CDR3 groups are represented among the 74 generated laforin nanobodies
(highlighted in red). Sequence homology of the 74 nanobodies is 33.1% (Clustal-Omega).
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Figure 4.7 HDX analysis of anti-laforin nanobody binding of Nb40, Nb50, and Nb73.
Fractions of each nanobody bound to laforin (Figure 4.3) were analyzed by hydrogen
deuterium exchange mass-spectrometry (HDX) and the deuteration level was compared
to laforin alone. The percent difference in deuteration between the nanobody complex
versus laforin alone is represented with a negative percent change in blue to a positive
percent change in red. Each colored bar below the primary sequence represents percent
change in deuteration at one of four time points. Secondary structure elements are
depicted above the primary sequence with the CBM and DSP motifs labeled. Regions
where the nanobody caused a ≥15% change in deuteration are highlighted with a
colored line. A) Laforin-Nb40 epitope spans β3, β7 and β8 pleated sheets and ⍺4 and ⍺5
helices. Highlighted with a light teal line. B) Laforin-Nb50 epitope includes the β3
pleated sheet and partially covers the ⍺10 helix. Highlighted with a light orange line. C)
Laforin-Nb73 epitope covers the ⍺4 helix, and partially covers the ⍺6 and ⍺8 helices.
Highlighted with a dark green line. D-F) The identified epitope for each nanobody was
modeled onto the surface map of the laforin structure (PDB: 4RKK). Nb40 (light teal),
Nb50 (light orange), and Nb73 (dark green) respectively mapped on laforin. The CBM
and DSP of laforin are colored dark gray and light gray respectively.
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Figure 4.8 Anti-laforin nanobody sequence alignments.
Sequence homology between Nb40 and Nb41 is 99.2%, Nb50 and Nb57 is 66.2%, and
Nb72 and Nb73 is 70.6% (Clustal-Omega). CDRs highlighted in red, framework
highlighted in gray.
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Figure 4.9 Laforin-nanobody activity assays.
The specific activity of laforin against potato amylopectin in the presence and absence
of nanobodies. Only Nb72 inhibits laforin’s phosphatase activity. Each bar is the mean
±SEM of 4 replicates. **** p < 0.0001.
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A nanobody-based ELISA screen for PTC readthrough of Epm2a
5.1

Introduction

Over 8,000 rare genetic diseases have been described and most are without
therapeutic options308. Underlying ~12% of rare genetic disease mutations are nonsense
mutations/STOP mutations/premature termination codons (PTCs)309. PTC mutations
transcribed in frame into mRNA result in truncated protein translation310. Excitingly,
repurposed small molecules have shown promising results in correcting PTC mutations
to generate full-length proteins311,312.
The first pharmaceutical agents tested to suppress PTC mutations therapeutically
were aminoglycosides (AGs)313. AGs are primarily used as antibacterial agents that
inhibit bacterial protein synthesis314. Translational inhibition occurs because AGs
prevent ribosome mRNA translocation by binding the 50S ribosomal subunit and the
bacterial aminoacyl site of the 16S ribosomal mRNA. In eukaryote cells, AGs do not
inhibit translation and can promote misincorporation of near-cognate aminoacyl-tRNA
at the site of the PTC mutation310,315. Therefore, AGs can promote full length translation
of PTC mutated mRNA. The precise mechanism of PTC readthrough is not yet well
understood. However, a recent study indicated that geneticin (G418), the best
characterized PTC readthrough AG, may interfere with tRNA due to tight binding of the
ribosome’s decoding center, like that observed for bacterial ribosomes316.
AGs have been tested for their ability to promote readthrough in over 100 tissueculture and mouse models for multiple diseases, including Duchenne Muscular
Dystrophy (DMD) and Cystic Fibrosis (CF)317. These studies demonstrated that AGs like
G418 and gentamicin can promote readthrough of the PTC mutations, however, their
clinical application is limited due to ototoxicity and contribution to superbug evolution.
Therefore, the application of AGs is better suited for proof-of-concept experiments in
vitro.
The search for non-toxic, well-characterized compounds that safely confer
readthrough activity in humans led to the first bench to bedside translation of a PTC
readthrough therapy. The non-aminoglycoside molecule ataluren (PTC124) produced
full readthrough of the most common PTC mutation found in patients with DMD and is
approved for clinical use by the European Commission318. However, The Food and Drug
Administration denied approval for PTC124 in the United States because the provided
data, including a safety evaluation, was inadequate319. Interestingly, the mechanism of
action for PTC124 is suggested to diverge from G418 and is derived exclusively from its
ability to inhibit release factor activity316. Unfortunately, a recent meta-analysis of
PTC124 clinical trials in DMD patients determined that PTC124 provided only a mild
slowing of DMD disease progression compared with placebo320. Furthermore, PTC124
has not yet proven to be an effective readthrough drug for any other genetic disease.
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These outcomes have been attributed to the repeated finding that nucleotide
sequence regulates suppression of PTCs and no one drug suppresses two PTCs to the
same extent321. Further, no algorithms can predict how the genetic context influences
the readthrough ability of a given PTC. The CF field recently discovered the readthrough
properties of escin, a non-toxic herbal supplement, by using an enzymatic assay to
screen 1600 small molecules311. Therefore, the development of a high throughput drug
screening approach designed for discovering PTC specific readthrough compounds
among clinically approved drug libraries may be required to achieve therapeutic and
translational potential.
An ideal disease to develop a PTC readthrough high throughput screening assay is
one that is monogenetic where mutations result in aberrant protein function that drive
disease. Lafora disease (LD) is an autosomal recessive childhood dementia resulting
from mutations in the Epm2a gene322,323. Epm2a mutations, of which 15% are PTCs,
result in the loss-of-function of laforin, the glycogen phosphatase324. Sequence and
structural conservation classifies laforin in the protein tyrosine phosphatase superfamily
and the dual specificity phosphatase clade274. Laforin is the only known human glycogen
phosphatase and is comprised of a dual-specificity phosphatase (DSP) domain and a
carbohydrate binding module (CBM)274. Laforin loss-of-function results in the production
of aberrant glycogen-like aggregates in the cytoplasm called Lafora bodies (LBs)81,324.
The LBs are found in the cytoplasm of cells from most tissues, including patient skin
biopsies and post-mortem brain tissue80. Using multiple mouse and fly models,
independent investigators have determined that LBs drive pathophysiology25,26,28,81. No
treatment exists for this fatal disease, but recent pre-clinical work suggests that rescuing
normal laforin expression leads to the ablation of LBs325,326. Thus, rescuing laforin
expression may be an attractive avenue for therapeutic development.
In this study, we explored three cell culture approaches for screening the
readthrough efficiencies of small molecules against the 12 clinically known Epm2a PTC
mutations. We generated a Western blot assay, an enzymatic assay, and a laforin
nanobody-based ELISA to test readthrough. Using these assays, we tested gentamicin,
G418, and escin for readthrough. PTC124 was excluded from this study as prior work
determined that it was unsuccessful at promoting readthrough of Epm2a PTC
mutations. The Western blot and enzymatic assay are widely used low-throughput
approaches for PTC readthrough screening that we modified for Epm2a309–312,322,323. The
results of these screens proved that gentamicin and G418 can induce readthrough of
Epm2a PTC mutations in vitro. However, they are limited in their potential to be
adapted for high throughput screening due to demanding technical requirements.
For a third screening approach with potential for scale, we designed a novel
nanobody based sandwich ELISA. Nanobodies are antibodies naturally produced the
camelid family327. Nanobodies consist of a single monomeric variable domain (VHH)
with a complete antigen binding site. Nanobodies can be readily selected and
produced in E. coli, ensuring their supply and consistent quality328. In contrast to
conventional antibodies, nanobodies are exceptionally stable, withstanding
fluctuations in temperature and pH281,282. These advantages make nanobodies ideal
for high throughput use and clinical environments. Using alpaca (Vicugna pacos)
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generated nanobodies raised against human recombinant laforin, we developed
highly specific monoclonal antibodies to replace the polyclonal anti-laforin
antibodies currently used to isolate laforin329. Our nanobody based ELISA system is a
unique readthrough screening system in which full-length laforin, but not truncated
laforin, can be detected by a CBM binding anti-laforin nanobody. This same system can
be used to determine phosphatase activity by interchanging the addition of the
CBM binding detection nanobody with the phosphorylated substrate para-nitryl
phenyl phosphate. Therefore, the nanobody based ELISA readthrough screening
system has two possible outputs, quantitation of laforin full length translation and
resulting phosphatase activity. The laforin nanobody ELISA may be a scalable option
for high throughput analysis of Epm2a readthrough drugs.
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5.2

Methods

5.2.1 cDNA generation and sequencing
Primary fibroblasts were grown using Fibrolife S2 Cell Culture Medium
supplemented with Fibrolife S2 Lifefactors LS-1038 (Lifeline Cell Technology). 1%
Penstrep was substituted for gentamicin for suppression of bacterial growth. To extract
genomic DNA, 20 μl of ThermoPol Buffer (New England Biolabs) was added to the
samples, boiled for 5 min and digested with Proteinase K (10 mg/mL) for 2 h at 55°C.
Then, Proteinase K was inactivated by boiling for 10 min. Total RNA was isolated using
PureZOL/Aurum Total RNA Isolation Kit (Bio-Rad) according to the manufacturer’s
instructions. The RNA quality for RNA-seq was tested using an Agilent Bioanalyzer 2100.
Quantitative RT-PCR was performed using SoAdvanced SYBR® Green supermix. The
cDNA and a 207 bp sequence of the genomic DNA was amplified using PCR. PCR was
carried out in a 25 μl reaction solution containing 1 μl of 10 mm dNTP, 1 μl of 10 mm
forward and reverse primer, 2.5 μl of 1× ThermoPol Buffer (New England Biolabs), and
0.5 units of Pfu Polymerase (New England Biolabs). Amplicons were purified and
subcloned into a pJET1.2/blunt vector using the CloneJET PCR Cloning Kit (ThermoFisher
Scientific). Plasmids were transformed into E. coli and the DNA was sequenced.
5.2.2 Reporter plasmid cloning
Three sets of reporter plasmids were generated for this study. For the enzyme
assays, complementary oligonucleotides were generated, annealed, and ligated into a
pAC99 reporter plasmid, as previously described323. This plasmid contains a unique
Msc1 cloning site between lacZ and luc genes coding for β-galactosidase and luciferase,
respectively. β-galactosidase and luciferase coding sequences are separated by an inframe stop codon corresponding to the mutation found in a patient, flanked by four
codons in 5’ and 3’, respectively.
The reporter plasmids generated for the Western blots were generated using site
directed mutagenesis to insert an Epm2a PTC mutation into WT laforin cDNA flanked by
a 5’ Flag tag and 3’ Myc tag. Each mutated amplicon was inserted into a pcDNA 3.1+
Amp/Zeocin cloning plasmid (ThermoFisher Scientific) using the BamHI and NotI
restriction sites. Because the Flag and Myc tags could interfere with laforin nanobody
capture and detection in the ELISA screening system, a similar set of plasmids without
tags was created. PCR amplification of the previously generated PTC mutated laforin
cDNA was inserted into a pcDNA 3.1+ Amp/Zeocin (ThermoFisher Scientific) cloning
plasmid using the BamHI and NotI restriction sites.
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5.2.3 Cell culture transfections and drug treatments
HEK293 cells were grown in DMEM (ThermoFisher Scientific) containing 10% fetal
bovine serum. Reporter plasmids were transfected for 24 h using FuGene according to
the manufacturer’s instructions. For drug treatments, 2 mL of multiple concentrations of
Geneticin (G418), Gentamicin, or 0.04% DMSO in media was added per well of a 6-well
plate and left to incubate overnight (~24 h). Cells were harvested using trypsin,
prepared for Western blots or ELISAs, and flash frozen. Cells harvested for Western blots
were lysed in RIPA buffer (0.5% deoxycholate, 1% IGEPAL-CA630, 0.1% sodium dodecyl
sulfate, 150 mM NaCl, 50 mM Tris-8.1). Cells harvested for ELISAs were lysed in PLC-lysis
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP-40, 1 mM
EGTA, 10 mM NaPPi, 100 mM NaFl, supplemented with protease inhibitor cocktail).
For the enzymatic assays, HeLa cells were seeded in the wells of 6 well plates and
left to grow overnight (~24 h). Then, 3 h before transfection, the cell medium was
removed, and 2 mL of fresh medium was added. During the 3 h incubation, the
transfections were prepared using 18 μL at 1 μg/μL of DNA in 600 μL of NaCl and
vortexed. In a separate tube, 36 μL of JetPei in 600 μL of NaCl was mixed by vortexing.
Then, the JetPei mixture was added to the DNA mixture and incubated for 30 min at RT.
Next, 200 μL of the transfection mixture was added to each well of the 6-well plate.
Because the precipitate can be toxic to these cells, transfections were performed close
to the end of the day and cell treatment was performed in the morning ~16 h later. Drug
treatment consisted of aspirating the media from the 6-well plates and adding 2 mL of
either 2.5 mM Gentamicin, 2.5 mM Geneticin, 10 μM Escin, or 0.4% DMSO in media and
incubating overnight (~24 h). Finally, the cells were harvested by trypsin and added to
respective epi-tubes for enzyme assay preparation.
5.2.4 SDS-PAGE and Western Blot
Protein concentrations were determined using the Pierce BCA Protein Assay Kit
(Thermo Scientific 2327) according to the manufacturer’s protocol. Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blots were run using
TGX stain free pre-case 12% gels (Bio-Rad). Western transfers were performed using a
semidry turbo-transfer system onto PVDF membranes (Bio-Rad). The membranes were
blocked with 5% nonfat milk and probed with primary antibodies [mouse anti-FLAG M2
(Sigma-Aldrich) and rabbit anti-MYC (Origene)] at a 1:1000 dilution. The membranes
were incubated with the secondary antibodies [goat anti-rabbit IgG, HRP-linked
antibody and goat anti-mouse IgG, HRP-linked antibody (Invitrogen)] at a 1:3000
dilution. The membranes were developed using chemiluminescence followed by
fluorescence. Gels and membranes were imaged on a ChemiDoc MP imaging system
(BioRad).
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5.2.5 Enzyme assays
Luciferase was assayed by following the protocol of Nguyen, with a Berthold LUMAT
LB 95501 luminometer for light detection330. Chloramphenicol acetyltransferase (CAT)
activity was determined in accordance with the two-phase partition method331. βgalactosidase was assayed in accordance with the classical method of Miller332.
5.2.6 Laforin purification
H. sapiens (Hs) laforin residues 1–328 was expressed from pET28b (Novagen) as an
N-terminal His6 tagged protein, as previously described329. Briefly, laforin was expressed
in BL21 (DE3) (Novagen) E. coli cells grown in 2xYT media at 37oC until OD600 = 0.6,
culture flasks were placed on ice for 20 min, induced with 1 mM (final) isopropyl thio-ßD-galactopyranoside (IPTG), grown for an additional 14 h at 20oC, and harvested by
centrifugation. Cells were resuspended and lysed in buffer A (20 mM Tris-HCl, 100 mM
NaCl, 10% glycerol, 2 mM DTT, pH 7.5), centrifuged, and the proteins were purified
using a Profinia immobilized metal affinity chromatography (IMAC) column with Ni2+
beads (Bio- Rad) and a Profinia protein purification system (Bio-Rad) using wash (buffer
A) and elution buffer (300 mM imidazole, 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2
mM DTT, pH 7.5). The desalted elution fraction was further purified using fast protein
liquid chromatography (FPLC) with a HiLoad 16/60 Superdex 200 size exclusion column
(GE Healthcare). Laforin was purified in 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 2
mM DTT, pH 7.5).
5.2.7 Nanobody purification and HRP-conjugation
Nanobodies were purified as previously described329. Nanobodies were expressed in
BL21 (DE3) E. coli cells grown in 2xYT at 37oC to OD600 = 0.9. 15 mL of pre-culture was
used per L culture. Cultures were induced with 1 mM IPTG (final) and incubated for ~16–
18 h at 25oC after which, pellets were harvested by centrifugation. Nanobodies were
purified from the E. coli pellets with Ni-NTA resin. E. coli cell lysates were centrifuged to
separate soluble protein which was incubated with Ni- NTA agarose beads for 1 h at 4oC
in 30 mL bind buffer (20 mM Tris- Hcl, 100 mM NaCl, 15 mM imidazole, pH 8.0). The
samples were washed three times in bind buffer and eluted in 300 mM imidazole, 100
mM NaCl, pH 8.0. Eluted samples were separated from the Ni-NTA beads by filtering
through a 25 mM syringe filter and then buffer exchanged with 20 mM Tris-Hcl pH 7.5,
100 mM NaCl using FPLC with a HiLoad 16/60 Superdex 75 column (GE Healthcare).
Nanobodies being screened for their use as detection nanobodies were conjugated to
HRP (Abcam) according to the manufacturer’s protocol.
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5.2.8 Enzyme-Linked Immunosorbent Assay (ELISA)
Wells of a Corning 9018 96-well plate were incubated with 100 μL of capture
nanobody (Nb41) overnight (~16 h) at a final concentration of 0.18 μL/mL in 1X Trisbuffered saline (TBS) at 4 oC with a plate cover. Wells were then rinsed three times with
200 μL 1X TBS followed by incubation for 1 h with 200 μL of blocking solution (1% BSA in
1X TBS) at RT followed by wells being rinsed three times with 200 μL 1X TBS. The sample
(100 μL; recombinant H. sapiens (Hs) laforin 329X or whole cell lysate diluted to 100 μL
in 1X TBS, 1mM DTT) was added and incubated for 1 h a RT, the wells were rinsed three
times with 200 μL of 1X TBS, and 100 μL of primary HRP-conjugated nanobody was
added in 1X PBS in 1% BSA, 1mM DTT and incubated for 1 h at RT. The wells were then
washed three times with 200 μL TBS and 100 of TMB substrate (Thermo Fisher) was
added and developed according to the manufacturer’s instructions. The reaction was
terminated by adding 100 of stopping solution (0.18 M H2SO4). Absorbance was
quantified at 450 nm using a BioTek Ephoch2 microplate reader. To quantify the
saturation curves for putative capture nanobodies bound to the plate, the anti-Camelid
IgG, HRP-linked antibody was used at a 1:5000 dilution and developed using TMB
substrate (Thermo Fisher).
5.2.9 para-Nitrophenyl phosphate (pNPP) assay
Generic phosphatase activity assays were performed using para-nitrophenyl
phosphatase (pNPP) as previously described329. Assays were performed using 96 well
plates in 50 μL containing 1X phosphatase buffer (0.1 M sodium acetate, 0.05 M Bis-Tris,
0.05 M Tris- HCl, pH 5.0), 2 mM dithiothreitol (DTT), and 50 mM pNPP). Wells of a 96well plate were incubated capture nanobody (Nb41) overnight (~16 h), rinsed three
times with 1X TBS, by incubating with blocking solution (1% BSA in 1X TBS) at RT,
followed by wells being rinsed three times with 200 μL 1X TBS. 100 μL recombinant
laforin in 1X TBS, 1mM DTT was added and incubated for 1 h at RT, the wells were
rinsed three times with 200 μL of 1X TBS, and 100 μL of 1X phosphatase buffer
containing 50mM pNPP was added to the wells and incubated in a 30oC water bath for
10 min. The reaction was terminated by the addition of 100 μL of 1 M NaOH.
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5.3

5.3.1

Results

PTC mutations in Epm2a

An important consideration before developing PTC readthrough screening assays is
whether the PTC in question is transcribed in frame into mRNA. PTC mutations located
near splice sites may not be transcribed in frame and instead result in alternatively
spliced mRNA or trigger nonsense mediated decay of the pre-mRNA transcript333. These
PTC mutations are not candidates for readthrough therapy.
Twelve Epm2a LD PTC mutations have been reported with R241X being the most
common mutation in LD (Figure 5.1A and Table 5.1)81,296,334–339. The point mutation
underlying R241X is a g.113165 C>T mutation that results in a premature TGA stop
codon (Figure 5.1A and Table 5.1). The C>T point mutation is located three nucleotides
from the 5’ end of the fourth exon and not predicted to trigger nonsense mediated
decay, which typically requires a PTC to be at least 50-55 nucleotides upstream of an
exon-exon junction (Figure 5.1A)333. However, the C>T placement could induce variance
in pre-mRNA splicing. To assess whether the g.113165 C>T mutation is transcribed in
frame, we obtained primary skin fibroblasts from a patient homozygous for g.113165
C>T. After confirming the genetic mutation by gene sequencing, we performed an RNA
prep from the same primary fibroblasts followed by RT-PCR to determine in frame
transcription (Figure 5.1B-C). The cDNA was isolated and sequenced to determine that
the R241X mutation is not alternatively spliced and results in the c.721 C>T point
mutation (Figure 5.1C). This result implies that the resulting translated protein will be
truncated at R241 and the R241X Epm2a PTC mutation is a candidate for readthrough
therapy.

5.3.2 A Western blot assay for screening PTCs
A traditional approach for determining readthrough expression involves
overexpressing PTC mutated cDNA in HEK293 cells, incubating the cells with a
readthrough drug, and determining total expression levels via Western blot analysis. To
adapt this system for Epm2a R241X, we utilized the MeCP2 R294X PTC mutation
implicated in Rett syndrome as an experimental control. Readthrough expression of
MeCP2 R294X has been previously shown using gentamicin340. Thus, two similar
plasmids were made, one containing MeCP2 R294X cDNA and the other containing
Epm2a R241X cDNA, each joined to a 5’ Flag-tag sequence. A third construct was made
in the same way, except it contained the WT Epm2a cDNA. The WT cDNA allowed us to
control for change in translation levels independent of readthrough. After incubating
the HEK293 cells with increasing concentrations of gentamicin (0-3.5 mM), cells were
harvested, total protein extracts were generated, and WBs were performed to detect
the Flag-tag. We determined that readthrough expression of both Epm2a and MeCP2
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increases in concentration, while WT laforin levels do not change (Figure 5.2A). These
are encouraging results, but not definitive results of readthrough as they do not
normalize for basal levels of readthrough. Additionally, aminoglycosides have been
shown to stabilize PTC mutated mRNA, potentially promoting variation in mRNA stability
between the WT and PTC targets analyzed310.
Therefore, we generated a dual reporter system also detectable by Western blot.
The benefit of a dual gene reporter system is that both reporter proteins are expressed
from the same mRNA, eliminating potential variation in mRNA stability between the
different targets. We developed this system by flanking the PTC mutated Epm2a cDNA
by a 5’ Flag-tag and a 3’ Myc-tag. HEK293 cells were transfected with 2 μg/mL of DNA
and incubated with 0-2 mM G418 for 24 hr. Cells were harvested, total protein extracts
were generated, and WBs were performed to detect the Flag- or Myc-tag. After
overexpression of the test plasmid in HEK293 cells and incubation with G418, we ran a
Western blot and detected the Flag-tag with a fluorescent secondary antibody, and the
Myc-tag with a chemiluminescent secondary antibody (Figure 5.2B). Thus, translation
levels of the truncated laforin peptide are detected by the anti-Flag antibody and
readthrough is measured by the anti-Myc antibody on the same blot. As expected,
Western blot analysis indicated that WT expression levels as detected by either anti-Flag
or anti-Myc are not changed with increasing concentrations of G418. Conversely,
increased expression of the R241X mutated cDNA is detected by the anti-Myc antibody
at 1 mM G418 indicating readthrough. Using the anti-Flag antibody, we also observed
increased expression of laforin at 1 mM G418. Furthermore, we detected a protein with
at 29 kD upon G418 addition. This protein may be the result of expression of the
truncated form of laforin R241X, which is calculated to have a molecular weight of 29
kD. Interestingly, higher concentrations of G418 did not result in readthrough. This
result is likely explained by the fact that G418 is often used as a cell selection reagent
and high concentrations of G418 can compromise cell vitality. This result supports the
notion that the toxicity of G418 limits its use to preliminary pre-clinical studies in low
doses. These data suggest that the Flag/Myc reporter system is useful as a readthrough
screening system. However, due to Western blot limitations, like technical demand,
time, and off-target antibody detection, this screening assay is not practical for a quick
and streamlined analysis of readthrough compound libraries.
5.3.3 An enzymatic assay for screening PTCs
To examine readthrough across the 12 Epm2a PTC mutations, we employed a widely
cited cell culture-based assay optimized for higher throughput compared to Western
blot analysis309–312,322,323. The basic mechanics of this assay involve the overexpression of
a plasmid containing two enzyme reporter genes, LacZ and Luc, that flank a 9-codon
sequence containing a PTC mutation at codon 5 (Figure 5.3). This plasmid is transfected
into HeLa cells, optimal for their fast growth, that are then incubated with a
readthrough drug. When partial protein expression is generated in the cells, the 5’
reporter gene, LacZ, will express β-galactosidase attached to the partial protein
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sequence. If readthrough of the PTC mutation occurs, then the full dual reporter fusion
protein will be expressed containing an N-terminal β-galactosidase and the C-terminal
luciferase (expressed from luc), linked together by the 9 amino acid protein sequence.
Therefore, readthrough efficiency is estimated by normalizing luciferase activity to βgalactosidase activity.
HeLa cells were transfected with 1 μg/μL of DNA and incubated with each 0.04%
DMSO, 2.5 mM gentamicin, 2.5 mM G418, or 10 μM escin for 24 hours. Cells were
harvested and added to respective epi-tubes for enzyme assay preparation. Using the
enzymatic assay, we first determined the readthrough expression of each of the 12
Epm2a PTC mutations, grouped by PTC codon, using 2.5 mM gentamicin versus DMSO.
There was an increase in expression for all of the mutants with W165X, R241X, and
E158X expression being statistically significant with gentamicin versus DMSO. These
results indicated that gentamicin could produce readthrough of each Epm2a PTC
mutations to varying degrees above the DMSO control with a 2-6-fold increase observed
(Figure 5.4A-B). Interestingly, there was some level of readthrough for each of the
mutants in the presence of DMSO, indicating basal readthrough, with R241X exhibiting
the highest level of basal readthrough in this system (Figure 5.4A). This result is
encouraging because basal readthrough levels are suggested in the literature to be an
indicator of best responders to drug induced readthrough323. Additionally, R241X is the
most common LD mutation. Next, we tested G418 to establish its usefulness as a
positive control, and escin as a possible clinically relevant drug candidate. G418 typically
produced readthrough expression levels higher than that of gentamicin (Figure 5.5A).
Like gentamicin, G418 yielded statistically significant readthrough in W165X, R241X, and
E158X as well as two additional PTCs, W287X, E138X. These results demonstrate that
G418 is a more potent readthrough compound than gentamicin for the Epm2a
mutations and align with published reports testing G418 on other genes316. For both
AGs, Epm2a TAG mutations yielded the highest level of readthrough and TGA the lowest
(Figure 5.4A, 5.5A). In contrast, escin did not produce readthrough expression above
basal DMSO-treated levels (Figure 5.5B). Therefore, gentamicin and G418, but not escin,
can be used to promote readthrough of Epm2a PTCs in cell culture.
Commercial gentamicin is not a pure compound and is majorly composed of
gentamicins C1, C1a, C2, and C2a constituting 92–99% of the mixture. Of the minor
components, gentamicin B constitutes 0.8–5.3%, and C2b between 1.3–2.1%.
Occasionally, sisomisin is found, comprising only 0.4–0.6%. Additionally, gentamicin A
and X2 (also known as gentamicin X) together comprise between 1.1–7.8%. Other
components in the complex include gentamicin B1 and garamine. Recent work showed
that despite gentamicin X2 and B1 being minor components they are potent
readthrough inducers341,342. Since their levels can vary by lot, this variation may impact
readthrough expression. To determine the effect of drug batch on readthrough
variability we tested 9 batches of gentamicin on the R241X mutation. HeLa cells were
transfected with 1 μg/μL of DNA and incubated with each 0.04% DMSO, 2.5 mM G418,
or 2.5 mM gentamicin from 9 different batches for 24 hours. Cells were harvested and
added to respective epi-tubes for enzyme assay preparation. While there was some
minor readthrough variation, there was no significant differences of induced
140

readthrough between batches (Figure 5.6). Thus, despite some variability, lot should not
greatly affect the accuracy of readthrough measurements.
Lastly, we considered the role of cell type on readthrough expression variability.
While HeLa cells are more optimal for higher throughput screening than slower growing
cells like NIH3T3 or HEK293, HeLa cells may not necessarily be optimal for highest
expression of readthrough. HeLa, NIH3T3, or HEK293 cells were transfected with 1
μg/μL of DNA and incubated with each 0.04% DMSO, or 2.5 mM gentamicin. Cells were
harvested and added to respective epi-tubes for enzyme assay preparation.
Interestingly, gentamicin promoted statistically significant readthrough of R241X in HeLa
and NIH3T3 cells but the increased readthrough in HEK293 cells was not statistically
significant (Figure 5.7A-C). These results suggest that HeLa cells in comparison to
NIH3T3 or HEK293 are an optimal cell line because they grow faster and can yield
statistically significant effects of readthrough. The enzymatic assay established in vitro
proof that readthrough of all 12 Epm2a PTC mutations is possible. However, the
technical requirements, though easier than Western blot analysis, are still too time
consuming and prone to human error for efficient screening of large drug libraries.
5.3.4 A nanobody based ELISA screening approach
We recently developed six laforin nanobodies and characterized their binding
affinity and the laforin epitope. The six laforin nanobodies were categorized into three
groups that shared epitopes. One epitope spans both the CBM and DSP on the opposite
side of the DSP active site and is bound by nanobodies 40 and 41 (Nb40 and Nb41). The
second epitope spans the CBM, partially covering regions that bind glycogen and is
bound by nanobodies 50 and 57 (Nb50 and Nb57). The third epitope overlaps with a
region near the laforin DSP active site, and is bound by nanobodies 72 and 73 (Nb72 and
Nb73), but only Nb72 inhibits laforin phosphatase activity329. Based on these known
epitopes, we hypothesized that a pair of nanobodies could be used to generate a
sandwich ELISA for detecting and quantifying laforin readthrough.
We first determined the optimal plate saturation concentrations of the nanobodies
that primarily bind the DSP. We excluded the use of Nb72 since it inhibits laforin
enzymatic activity and we wanted to use phosphatase activity as a potential readout.
Therefore, we examined Nb40, Nb41, and Nb73. We first plated 100 μL per well of
increasing concentrations of Nb40 (0–30 μg/mL), Nb41 (0–70 μg/mL), and Nb73 (0–150
μg/mL) and detected the saturation curves with an HRP conjugated anti-Camelid
antibody, developed using TMB substrate and read at OD450 using a microplate reader.
The results indicated that Nb40, Nb41, and Nb73 each displayed a different presaturating concentration of 3 μg/mL, 8 μg/mL, and 11 μg/mL, respectively (Figure 5.8AC). To determine which of these nanobodies was useful as a capture nanobody, we
tested each nanobody by plating the respective pre-saturating concentration and
subsequently binding 100 μL of increasing concentrations (0–20 μg/mL) of purified
recombinant human laforin. As a readout of laforin phosphatase activity, we incubated
laforin with the generic phosphatase substrate, para-nitrophenyl phosphate and
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performed pNPP assays. Protein tyrosine phosphatases, including laforin, can covert
pNPP to para-nitrophenyl (pNP) and the colorimetric change is quantified at OD410. By
performing pNPP assays, Nb41 was identified as a useful capture antibody that allows
the DSP of laforin to remain active (Figure 5.8D, data not shown for Nb40, and Nb73)).
The linear range of captured laforin was within the known linear range of detection by
the pNPP assay. Based on the pNPP assay results, the saturation concentration of
recombinant laforin is 20 μg/mL.
We then determined which CBM binding nanobody was most optimal for laforin
detection. In each well, we plated 100 μL of Nb41 at 8 μg/mL and bound 100 μL purified
recombinant human laforin at 20 μg/mL. After washing, capture nanobody saturation
curves were generated using increasing concentrations of Nb50, or Nb57, at 0–2 μg/mL
each conjugated to HRP (Figure 5.8E-F). Wells were then washed and developed using
TMB substrate and read at OD450 using a microplate reader. Nb57-HRP exhibited a
robust saturation curve with a higher specificity than Nb50-HRP (Figure 5.8E-F). Presaturating concentrations were indicated to be 0.18 μg/mL for Nb57-HRP and 1 μg/mL
for #113.
Currently, the polyclonal anti-laforin antibody #113 is utilized to immunoprecipitate
laforin as it demonstrated the most robust ability to capture laforin from cell lysate290.
We sought to determine whether Nb57-HRP provided higher specificity than polyclonal
anti-laforin antibody #113. To generate and compare the saturation curves using Nb57HRP and #113, we plated 100 μL of Nb41 at 8 μg/mL and bound 100 μL purified
recombinant human laforin at 20 μg/mL. After washing, we bound of 100 μL of Nb57HRP at 0.18 μg/mL, or 100 μL of #113 at 1 μg/mL (Figure 5.9A-B)343. Bound #113 was
subsequently washed and bound with a secondary antibody. A
After washing the Nb57-HRP bound and #113 and secondary bound plates, the
assays were developed using TMB substrate and read at OD450 using a microplate
reader. Comparing the standard curves generated by Nb57-HRP or #113, Nb-57-HRP
signals appeared in closer alignment with the four-parameter logistic (FPL) model. Thus,
the monoclonal Nb57-HRP detected laforin with higher specificity than the polyclonal
anti-laforin antibody.
To determine the assay efficiency, the percent recovery of Nb57-HRP was
determined by generating a 22-point standard curve of recombinant laforin and
analyzing the linear range using a four-parameter logistic (FPL) model (Figure 5.10A-B).
100 μL of Nb41 at 8 μg/mL was plated and bound 100 μL purified recombinant human
laforin at 20 μg/mL. After washing, 100 μL of Nb57-HRP at 0.18 μg/mL was bound. A
second wash performed before the assays was developed using TMB substrate and read
at OD450 using a microplate reader. The FPL model was selected because it provides a
better fit (percent recovery) to all of the data compared to linear models, even under
circumstances where the linear model lack-of-fit value (R2) is equal or greater than
0.99344.
bottom − top
Y = top +
𝑥 slope
1+(
)
EC50
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In the FPL mode, Y is the output value, absorbance in this case, which is 450 nm for
the pNPP assay. “Top” is the upper asymptote and “bottom” is the lower asymptote. X is
the concentration of recombinant laforin in the well, EC50 is the concentration with 50%
maximum response, and slope is the Hill coefficient. Evaluation of the percent recovery
of each point with the concentration calculated by the FPL curve established that the
lowest concentration measured within 20% of the FPL curve and that is significantly
higher than background, which is 2 μg/mL recombinant laforin (Figure 5.10A-B). The
upper limit is 10 μg/mL, indicating that the range for accurate quantification of laforin is
between 20-1000 ng (Figure 5.10A).
A final experiment concluded preliminary development of the nanobody-based
laforin ELISA for the purpose of screening laforin PTC readthrough. Plasmids containing
WT Epm2a, R241X Epm2a or an empty vector were transfected into HEK293 cells. After
transfection, whole cell lysates were then prepared using native PLC-lysis buffer.
Increasing concentrations of whole cell lysates were incubated in the wells of a 96-well
plate saturated with Nb41. Subsequent detection of laforin was performed using 0.18
μg/mL of Nb57-HRP (Figure 5.11). The signal of WT laforin detection exceeded the signal
produced in the wells containing laforin R241X or empty vector by 10-fold. Therefore,
these data indicate that this nanobody based ELISA may be used to screen readthrough
of R241X Epm2a.
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5.4

Discussion

To date, more than 100 studies have shown that the stimulation of PTC readthrough
may result in the partial restoration of the expression of deficient proteins that underlie
~40 different genetic diseases317. However, no study has demonstrated a remarkable
improvement in patient health or a significant alleviation of the disease phenotype. The
establishment of a truly efficient PTC readthrough based therapy requires new, more
potent compounds with less toxicity. This goal may be achieved by scanning drug
libraries to repurpose and/or modify compounds to achieve efficient nonsense
suppression. To effectively implement this strategy, high throughput testing is needed
to screen drugs against specific PTC mutations.
LD is an ideal disease to model a high throughput screening approach for PTC
readthrough as PTC mutations in a single gene result in loss-of-function at the protein
level that directly causes LD pathophysiology25,26,28,81. Furthermore, a simple and costeffective in vitro assay has been previously developed to establish the presence or
absence of glucan phosphatase activity290. To explore high throughput assay
development for Epm2a PTCs we first adapted two traditional low-throughput screening
approaches, a Western blot assay and an enzymatic assay, to test two AGs and the nontoxic herbal anti-inflammatory compound escin, that had been reported to promote
readthrough in some systems, to establish a proof-of-concept for Epm2a readthrough.
Using these dual gene reporter assays we determined that readthrough is possible for
all 12 Epm2a PTC mutations using gentamicin. Gentamicin and G418 are the most
commonly used pre-clinical aminoglycosides in PTC readthrough studies, with G418
promoting readthrough at lower concentrations and higher efficiencies than gentamicin
and other aminoglycosides such as amikacin, paromomycin, and tobramycin321. As
expected, G418 proved to be a more potent readthrough compound for Epm2a PTCs
than gentamicin and may serve as a robust positive control for future studies.
A known factor of readthrough efficiency variation is the PTC mutation and
surrounding nucleotide sequence321. Though there is no absolute rule to predict PTC
mutation readthrough efficiencies, TAA are often reported as the PTC mutations most
recalcitrant to readthrough, followed by TGA with TAG exhibiting the highest level of
readthrough315,323. For the Epm2a PTC mutations, TAG mutations yielded the highest
level of readthrough and TAA the lowest. Interestingly, Epm2a PTC readthrough in TGA
and TAA PTCs using either gentamicin or G418 was more frequent. Therefore, the
surrounding Epm2a nucleotide context may be uniquely modulating ease of
readthrough. TGA and TAA PTC mutations exhibited higher readthrough by gentamicin
than TAG. These results are inconsistent with other disease models and suggest that the
surrounding nucleotides may be a more important factor in modulating PTC
readthrough. Encouragingly, the TGA mutation R241X, the most common mutation in
LD, shows a significant amount of basal readthrough, which has predive value for its
potential to be readthrough by small molecules.
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Using the dual reporter enzymatic assay, all 12 PTC mutations were screened for
readthrough with three compounds and a control and analyzed within the span of 15
days. Therefore, this enzymatic assay proved to be higher throughput than the Western
blot assay. As a dual reporter assay, the enzymatic assay provides similar benefits as the
Western blot but is a much more quantitative approach. The fluorescent nature of the
internal control (β-galactosidase) permits accurate calibration of individual experiments
for the overall expression level of each construct (vector stability, transfection
efficiency, transcriptional and translation rates). However, limitations still exist in this
assay as luciferase was shown to have off-target interactions with small molecules.
Thus, the possibility of readthrough drug interaction and attenuation of excitation or
emission light is an important consideration with this assay. A more ideal screening
method would include the benefits of a fast-growing cell culture system, a dual reporter
system, and an absence of off target drug interaction.
To generate the proof-of-concept for a such an approach, we generated a novel
nanobody based ELISA. We used previously generated anti-laforin nanobodies to
construct an ELISA that can capture laforin without inhibiting its phosphatase activity
and subsequently detect the full-length product. With nanobody epitopes previously
defined, we chose a pair of nanobodies with different binding sites, such that the
capture nanobody (Nb41) binds the DSP, and the detection nanobody (Nb57) binds the
CBM329. We first developed a recombinant laforin standard curve by capturing with
Nb41 and detecting with Nb57-HRP. We also determined that the generic phosphatase
activity of recombinant laforin captured by Nb41 can be tested using para-nitrophenyl
phosphate in a pNPP assay. These results provided the proof-of-concept that laforin
recovered from cell lysate or human tissue may be quantified and assessed for
phosphatase activity in parallel assays. To test the laforin nanobody ELISA using whole
cell lysate, we used Nb41 to capture laforin from cell culture previously overexpressed
with WT laforin, laforin R241X, or EV. We discovered the encouraging results that Nb57HRP can detect WT laforin at 10-times the concentration found in the cell lysates
compared to empty vector. Importantly, Nb57-HRP does not detect the truncated
laforin peptide generated from transcribing laforin R241X in the absence of readthrough
compounds. These data suggest that the overexpressed truncated form has competed
for binding to Nb41 but is not subsequently detected by Nb57-HRP because it lacks a
CBM. These results suggest that the nanobody based ELISA using Nb41 and Nb57-HRP
can be used to detect readthrough of R241X.
Continued development of our nanobody based ELISA screening strategy is needed
to verify this hypothesis. Theoretically, the combination of Nb41 and Nb57-HRP should
be able to detect the full readthrough products of any laforin PTC mutation. However,
detection of basal readthrough for internal control may be limited depending on the
PTC mutation or require different sets of nanobodies. Of note, the pre-clinical
development for therapy aiming to recover laforin protein expression, like adenoassociated viral vector (AAV) therapy, may use the laforin nanobody ELISA to quantitate
and assess the quality of laforin phosphatase activity326. Moreover, the long shelf life of
nanobodies, low technical requirements, and ease of reproducibility when performing
an ELISA provide the possibility of using the laforin nanobody ELISA in clinical settings.
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Further development of the nanobody based ELISA for PTC readthrough may act as a
blue-print for creating similar assays for screening PTCs specific to other diseases,
helping to alleviate the bottleneck of bench-to-bedside translation of PTC readthrough
therapy.
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Figure 5.1 12 PTC mutations in Epm2a cause Lafora disease.
A) Location of LD PTCs mapped to Epm2a. Blue = Carbohydrate Binding Module, Green =
Dual Specificity Phosphatase Domain. Arrow is pointing to R241X, the most common
mutation in LD. B) Gene sequencing of patient fibroblasts C) cDNA was generated from
patient fibroblasts and sequenced. The g.113165 C > T and corresponding c.721 C > T
C>T point mutation is found, indicating that the R241X PTC mutation is transcribed in
frame from gene to mRNA.
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Table 5.1 Epm2a PTC mutations and corresponding nucleotide changes at the mRNA
and gene level.
Underscored nucleotides indicate the position in the gene codon that is mutated and
results in a PTC.
Protein

mRNA

Gene

p.Q55X

c.163 C > T

g.5520 C > T; CAG

p.W60X

c.179 G > A

g.5536 G > A; TGG

p.Y86X

c.258 C > G

g.5615 C > G; TAC

p.Y87X

c.259 A > T

g.5616 A > T; AAG

p.Y112X

c.336 C > A

g.54594 C > A; TAC

p.E138X

c.412 G > T

g.54670 G > T; GAA

p.S158X

c.473 C > G

g.54731 C > G; TCA

p.W165X

c.495 G > A

g.105388 G > A; TGG

p.R241X

c.721 C > T

g.113165 C > T; CGA

p.Q247X

c.739 C > T

g.113183 C > T; CAG

p.C278X

c.834 C > A

g.113278 C > A; TGC

p.W287X

c.861 G > A

g.113305 G > A; TGG
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Figure 5.2 Western blot screening of aminoglycoside induced readthrough of R241X.
A) HEK293 cells were transfected with MeCP2 R241X, R241X, or WT NT-Flag construct
and treated with increasing concentrations of gentamicin for 48 h. Laforin or MeCP2
levels were assessed by western analysis with anti-Flag antibody. B) HEK293 cells were
transfected with R241X, or WT NT-Flag and CT-Myc construct, treated with increasing
concentrations of G418 for 48h. Laforin levels were assessed by western analysis using
anti-Flag and anti-Myc antibodies.

149

Figure 5.3 Description of the dual gene reporter system.
For quantification in HeLa cells, β-galactosidase and firefly luciferase coding sequences,
flanked an oligonucleotide that included a PTC mutation. Their expression is driven by
the SV40 promoter (pAC99 vectors). The construction of the oligonucleotides was
performed by surrounding the PTC mutation of interest by four codons and cloned inframe between β-galactosidase and firefly luciferase coding sequences. Readthrough
was determined by normalizing the expression of firefly luciferase to the expression of
β-galactosidase obtained for each nonsense mutation.
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Figure 5.4. Enzymatic screening for identifying nonsense mutations responsive to
aminoglycoside treatment.
A) Readthrough of 12 PTC mutations in Epm2a was measured in HeLa cells with and
without gentamicin (2.5 mM) treatment for 24 h. B) Foldchange of readthrough from
gentamicin treatment compared to DMSO. Mean values are presented together with
the standard error of the mean (SEM) (n=5).
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Figure 5.5 Enzymatic screening for identifying nonsense mutations responsive to G418
or escin treatment.
A) Readthrough of 8 PTC mutations in Epm2a was measured in HeLa cells with and
without G418 (2.5 mM) compared to gentamicin (2.5 mM) treatment for 24 h.
Gentamicin and DMSO data is previously shown. B) Readthrough efficiencies of 10 PTC
mutations in Epm2a were measured in HeLa cells with and without escin (10 μM) for 24
h. DMSO data is previously shown. Mean values are presented together with the
standard error of the mean (SEM) (n=5).
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Figure 5.6 Enzymatic screening for variability in gentamicin induced readthrough.
A) Readthrough of the R241X PTC mutations in Epm2a was measured in HeLa cells with
and without gentamicin (2.5 mM) or G418 (2.5 mM) treatment for 24 h. A different lot
of gentamicin was used in each trial.

153

Figure 5.7 Enzymatic screening of Epm2a R241X readthrough in NIH3T3 and HEK293
cells.
Readthrough of the R241X PTC mutation in Epm2a was measured in A) HeLa (data is
previously shown) B) NIH3T3, and C) HEK293 cells with and without gentamicin (lot 3)
(2.5 mM) or escin (10 μM) treatment for 24 h. *** = p = 0.0003, **** = p < 0.0001
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Figure 5.8 Optimizing capture and detection nanobodies.
A-C) Each putative capture nanobody was plated in a 96-well plate at increasing
concentrations overnight. Saturation curves were determined by detecting each
nanobody with an HRP-conjugated anti-camelid antibody. A) Nb40 B) Nb41 C) Nb73
D) To determine the working range of recombinant laforin, a standard curve using a
pNPP assay was performed to detect laforin phosphatase activity. Nb41 was plated at 8
μg/mL overnight. Increasing concentrations of recombinant laforin were incubated with
pre-bound Nb41. E-F) To determine the saturation curves of putative detection
nanobodies, Nb41 was plated at 8 μg/mL overnight. 2000 ng per well of recombinant
laforin was captured by Nb41. E) Increasing concentrations of Nb50-HRP detected
recombinant laforin. F) Increasing concentrations of Nb57-HRP detected recombinant
laforin.
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Figure 5.9 Saturation curves of laforin detection antibodies, Nb57-HRP and polyclonal
anti-laforin antibody #113.
Nb41 was plated at 8 μg/mL overnight. Increasing concentrations of recombinant laforin
was captured by Nb41. A) Nb57-HRP at 0.18 μg/mL was used to detect laforin. B)
Polyclonal anti-laforin antibody #113 at 1 μg/mL was used to detect laforin.
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Figure 5.10 Working range of recombinant laforin at optimized antibody
concentrations.
A) An absorbance versus concentration curve was generated for multiple concentrations
to determine the working range of the laforin ELISA. The minimum detection is 2 μg/mL
and signal saturation is reached above 10 μg/mL. The curve is fit with an FPL best fit
curve and R2 = 0.9153. The experiment uses n = 3 replicates. B) Using the FPL model,
percent recovery was determined by comparing concentration loaded vs the
concentration as determined by the curve.
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Figure 5.11 Laforin nanobody ELISA detection from whole cell lysates.
WT laforin, empty vector (EV), or R241X was overexpressed in HEK293 cells. Whole cell
lysates were prepared using PLC-lysis buffer and flash frozen. 8 μg/mL Nb41 was plated
in a 96-well plate overnight, increasing concentrations of whole cell lysate were
incubated with Nb41, wells were washed, and laforin was detected using 0.18 μg/mL
Nb57-HRP.
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Concluding remarks
6.1.1 Summary and future directions

The pathophysiology of Lafora disease (LD) is centered around the overaccumulation
of aberrantly structured glycogen called polyglucosan bodies (PGBs)81,324. Aberrant
metabolism is a cause and consequence of LD PGBs resulting in early onset, rapid
progression, and exacerbated symptomology common to many neurodegenerative
diseases (Chapter 1)322,323. LD is one of 17 glycogen storage diseases (GSDs) that are
defined by aberrant accumulation of glycogen/PGBs, where the contribution of PGBs to
neuropathology is the most well studied in LD models17. From the atomic to pathological
levels, the fundamentals of LD are understood. Several in vitro biochemical and
structural techniques, in situ cell culture models, and in vivo mouse models have been
generated to determine: 1. Mutations in laforin or malin result in LD PGBs that are
hyperphosphorylated and aberrantly branched compared to normal glycogen78,222. 2.
Laforin binds and dephosphorylates glycogen115. 3. The accumulation of LD PGBs causes
disruptions to neuronal energetics resulting in defects in memory and cognition, and
neurodegeneration25,26,28,81.
As the field tests putative therapeutics for LD in pre-clinical settings, our cellular,
structural, biochemical, and physiological understanding of LD is being put to the
ultimate test of translatability. In this work, we have scrutinized assumptions of the
laforin knockout (LKO) model. We have confirmed and expanded on time dependent
physiological aspects and challenged assumptions about the relationship of PGB
accumulation to inflammation, a widely used marker of LD recovery (Chapter 2). Now
that we have clarified benchmarks of pre-clinical therapeutic testing for LD, these
references may act as guides for future studies. Additionally, the finding that microglia
(not astrocytes) are activated throughout the lifespan of the LKO mouse indicate that
they are possible therapeutic targets for neuroinflammation and should be examined
further. The absence of astrocyte activation during the most acute time frame of LD PGB
accumulation is curious, and future studies should explore whether astrocytic PGB
accumulation is driving deleterious metabolic defects that influence their expected
neuroinflammatory behavior. Furthermore, the coordination of activity between
astrocytes and microglia may be disrupted and investigation of this matter in the LKO
mouse model may reveal clues about the pathological cascade effect that is initiated by
LD PGBs.
In the LKO mouse we utilized cutting edge metabolomics techniques to begin to
understand the consequences of aberrant glycogen metabolism to cellular respiration
(Chapter 3). This study opened an avenue for discovering metabolic therapeutic targets
in LD and proposed a direct link between PGB accumulation and downstream metabolic
defects in LD and normal aging. Although our insights into citric acid cycle metabolite
load in LKO mice compared to WT have revealed clear respiratory consequences of PGB
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accumulation, their biological impact should be thoroughly investigated (Chapter 3).
This area of investigation will also lead to filling in the ripple effect events that link PGBs
to downstream brain dysmetabolism. Moreover, our methods for characterizing LD
pathophysiology should be used as a model for similar investigations of other
neurodegenerative diseases that are also affected by aberrant glycogen/PGB
accumulation. Of the 17 GSDs, only a handful have been discovered to have
glycogen/PGB accumulation that is neurotoxic. Most GSDs are clinically classified as
myopathies or cardiopathies. However, in several GSDs, secondary CNS symptomology
has been documented but understudied, for example, patients with GSD0 are often
afflicted by seizures. Furthermore, the contribution of peripheral and/or motor neuron
glycogen/PGB accumulation to GSDs should be re-examined as its contribution to
defects in muscular and cardiac failure may be significant.
One major gap in our understanding of biochemical aspects of LD is the mechanism
of laforin’s phosphatase activity on glycogen, and moreover, the biological relevance of
glycogen phosphate. To tackle these important questions about glycogen metabolism,
we have made significant advancements in generating tools. The generation of six antilaforin nanobodies and their defined epitopes opens the doors for discovering the role
of laforin interactions and mechanisms (Chapter 4).
Although LD is a very rare disease, this body of work has shown that studying LD
offers a unique window into understanding issues that are universal among mammals
including glycogen metabolism, neurodegenerative disease, and aging. Our last study
again aimed to use the in-depth genetic and biochemical understanding of LD to
generate a translatable drug screening system for all other genetic diseases (Chapter 5).
Though more work is required to realize the potential of these assays, these
explorations have set up the tools and framework for pre-clinical testing of laforin
rescue. The laforin nanobody enzyme linked immunosorbent assay (ELISA) can be
immediately useful for current efforts to development an AAV therapy for LD.
Although this work and the hypotheses generated herein are directly applicable to
LD, future findings may impact other neurodegenerative diseases and epilepsies. LD
shares key cellular processes with many diseases and developments in our
understanding of their translation to treatments will provide similar valuable insight for
others. Additionally, these findings may assist in resolving some of the questions and
controversies surrounding the significance of glycogen to brain energy metabolism.
6.1.2 Final conclusions

This work has contributed to the advancements of biomarkers, tools, and
therapeutics for LD. These studies have also laid a model for the investigation of
aberrant glycogen and aberrant glycogen metabolism in other neurodegenerative
diseases, paving the way for novel therapeutic target discovery.
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